n790 Endocrinology PDF

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"
CLINICAL ENDOCRINOLOGY, METABOLISM AND NUTRITION

Thesis Program of the Curriculum N790
Doctor of Applied Medical Science
Coordinator
Thomas M. Stulnig, Associate Professor, Clinical Division of Endocrinology and Metabolism,
Department of Internal Medicine III, Medical University of Vienna, Whringer Grtel 18-20,
1090 Vienna, Austria; phone: +43 1 40400 4368; fax: +43 1 40400 7790;
E-mail: thomas.stulnig@meduniwien.ac.at
General Description and Aims

Endocrinology and metabolism are traditionally linked to each other not only in clinical
settings. Due to the importance of hormones to regulate metabolism of individual cells,
tissues and whole organisms, regulatory mechanisms in metabolism and endocrine axes often
follow common mechanisms. Following the elucidation of endocrine regulatory mechanisms
and principal metabolic pathways in the midst of the 20th century, recent developments in
methods of molecular biology and in vivo investigations have now paved the way for further
significant progress in the field of endocrinology and metabolism. Beginning with the
molecular identification of transcription factors for genes implicated in metabolic and
endocrine regulations up to in vivo NMR spectroscopy for analysis of metabolic regulation in
humans these novel methods will facilitate essential contributions for the elucidation of
endocrine and metabolic regulations and enable the development of novel therapeutic
approaches. A prerequisite for this progress to occur in research and clinics is the availability
of trained researchers and clinicians.
The clinical approach to patients suffering from disorders in hormone and metabolic
homeostasis has changed in parallel with basic scientific progress, e.g., by the advancements
in molecular genetics and their application for diagnosis of a multitude of disorders.
Moreover, the prevalence of endocrine and metabolic diseases has shifted, e.g., due to the
increased frequency of obesity and the increasing age in our population. Hence it is expected
that the field of endocrinology and metabolism will be subject to further exciting
developments in the near future.
It is the aim of the Doctoral Program of Applied Medical Science on "Endocrinology
and Metabolism" to train young scientists and professionals practising Endocrinology and
Metabolism in its broadest sense for independent scientific work in medical and associated
professions. The symbiosis of science and practice will be accomplished by combining
scientific experience and guidance with practical seminars. As a result, graduates will be
prepared to apply scientific and practical methods in his/her profession in order to
continuously improve professional practice and effectivity, to take responsibility for changing
situations and to address modern issues of Endocrinolgy and Metabolism by independent
application-oriented research projects. In addition, graduates will be trained in presenting
results to other specialists in the field and to educate laypersons likewise.
Principles of endocrinology and metabolism are not only scientifically and clinically
present in the specialty of internal medicine, but also in gynecology, pediatrics, surgery and
page 1 of 168
nutritional medicine. The lecturers and principal investigators of this doctoral study program
work in diverse areas from basic sciences up to various clinical disciplines and provide
opportunities for scientific research in diverse aspects of the field of endocrinology and
metabolism including nutrition. Thematically, the program comprises mainly applicationoriented theses from translational research up to diagnostics and therapeutic approaches.
Methodologically, the spectrum comprises a broad array of biochemistry and molecular
biology up to in vivo investigations and clinical trials.
In the framework of this doctoral study, the student will scientifically work in a welldefined thematic segment under supervision of an experienced principal investigator. Aim of
the scientific work is the compilation of a doctoral thesis. In addition, the student will have
the possibilities to gain theoretical knowledge in endocrinology and metabolism in its
broadest sense and in various methods for its investigation, e.g. in basic seminars. Own
scientific works will be accompanied by critical discussion of scientific results from other
groups in journal clubs. Current research projects of involved groups will be discussed in
thesis seminars. Practical seminars are specific to the Applied Doctoral Study Program.
Practical seminars will give guidance to professional application of modern achievements and
prepare for dissemination of current knowledge to laypersons. These instruments will put own
scientific work into the context of other scientific and practical achievements to promote
skilled independent work and application of scientific methods. Furthermore, practical and
thesis seminars advance students presentation skills.
The Medical University of Vienna has established a research focus concentrating
scientific resources on various aspects of metabolism including efforts on the investigation of
type 2 diabetes mellitus and the metabolic syndrome, diabetic complications, high-field NMR
spectroscopy of metabolic intermediates, mechanisms of metabolic regulation, interference of
metabolism with immunological and inflammatory mechanisms, inherited metabolic
disorders, and (neuro)endocrine regulation. The Applied Doctoral Study program
"Endocrinology and Metabolism" strengthens these efforts and provides a unique opportunity
for students to promote their graduation while interacting with a critical mass of expert
principal investigators and clinicians.
The participating university teachers belong to three groups according to their roles in
the Applied Doctoral Study Program Endocrinology and Metabolism:
1. Supervisors (S) possess remarkable scientific output and are experienced professionally
and in training doctoral students. They give lectures and supervise students in their thesis
projects.
2. Young supervisors (YS) comprise particularly ambitious principal investigators who are
on the way but have not yet achieved a venia docendi (Habilitation). Young
supervisors are supported by experienced supervisors. Students guided by young
supervisors meet more often with the thesis committee, i.e. every 6 months, instead of the
usual yearly meetings to guarantee the highest level of education. Young supervisors
contribute to the courses as do other teachers and students benefit by obtaining insight into
more technical details.
3. Lecturers (L) comprise teachers who currently do not fulfill all criteria or abstain from
supervising students but have considerable knowledge and experience in a given area.
Lecturers contribute to the courses often by presenting a particularly practical approach.
Last but not least it is emphasized that the current version of the program with its
contributing principal investigators and lecturers is regarded as a preliminary nucleus. The
program is designed to integrate more teachers and institutions in order to cover the field of
endocrinology and metabolism and related disciplines in all theoretical and practical aspects.
page 2 of 168
Recommended Literature
The Metabolic and Molecular Bases of Inherited Disease / Charles R. Scriver (Editor),
William S. Sly (Editor), Barton Childs, Arthur L. Beaudet, David Valle, Kenneth W.
Kinzler, Bert Vogelstein; McGraw-Hill Professional; 8th edition (2000) - 4 volume set,
6338 pages.
Williams Textbook of Endocrinology / P. Reed Larsen et al.; Saunders, Philadelphia, Pa.
[u.a.], 10th ed., 2003. - XXIII, 1927 pages.
Textbook of Endocrine Physiology / ed. by James E. Griffin.; Oxford Univ. Press ,
Oxford, 4th ed., 2000. - X, 479 pages.
Neuroendocrinology in Physiology and Medicine / ed. P.Michael Conn, Marc E. Freeman;
Humana Press, Totowa, NJ, 2000.
page 3 of 168
Courses
Propedeutics
The propedeutics will be an obligatory part of the Applied Medical Science doctoral study.
Six semester hours (SHrs) have to be completed with emphasis on natural science or medical
courses for graduates from medical and non-medical studies, respectively. Please follow
general regulations for the Applied Doctoral Science study as posted.
Basic Seminar
The Basic Seminar is held in winter semsters only (2 semester hours) comprising two
different sets of themes (I and II). In total 4 SHrs must be completed for the thesis program.
The Basic Seminar will provide a broad overview of the field of Endocrinology and
Metabolism including nutritional aspects.
VO Basic Seminar "Endocrinology and
Metabolism [I/II]";
2 SHrs (compulsory course); English; personal
registration by email to Prof. Th. Stulnig
(thomas.stulnig@meduniwien.ac.at)
Sabina Baumgartner-Parzer, Christian

Bieglmayer, Martin Bischof, Olaf
Bodamer, Wilfred Druml, Manuela
Fdinger, Clemens Frnsinn, Gabriele
Husler, Jrg Michael Hiesmayr,
Alexandra Kautzky-Willer, Michael
Krebs, Bernhard Ludvik, Anton Luger,
Wolfgang Marktl, Bruno Niederle, Peter
Pietschmann, Gerhard Prager, Erich
Roth,
Thomas
Stulnig,
Walter
Tschugguel, Nicole Unger-Manhart,
Heinrich Vierhapper, Ludwig Wagner,
Kurt Widhalm
BASIC SEMINAR I
Title
Teacher
Congenital adrenal hyperplasia
S. Baumgartner-Parzer
Modern methods of clinical laboratory analysis
C. Bieglmayer
In vivo studies on hepatic glycogen metabolism
M. Bischof
Stable isotope techniques-basics and applications
O. Bodamer
Clinical Nutrition and Infusion Therapy 1
W. Druml
Molecular methods in research and diagnostics of

metabolic diseases 1
M. Fdinger
Basics for working with experimental animals
C. Frnsinn
Physiology and pathophysiology of growth
G. Husler
Epidemiology of malnutrition
M. Hiesmayr
page 4 of 168
Gestational diabetes
A. Kautzky-Willer
Insulin resistance
M. Krebs
Obesity
B. Ludvik
Physiology of the hypothalamic-pituitary regulation
A. Luger
Physiology of nutrition and pathophysiology of

macronutrients
W. Marktl
Endocrine surgery 1
B. Niederle
Bone biology
P. Pietschmann
Bariatric surgery 1
G. Prager
Protein catabolism, post-aggression phase,

immunonutrition 1
E. Roth
Lipid metabolism and hyperlipidemia
Th. Stulnig
Pathophysiology of estrogen-dependent diseases
W. Tschugguel
D-A-CH Reference values for food intake
N. Unger-Manhart
Adrenal glands
H. Vierhapper
Genes relevant in endocrine tumorigenesis
L. Wagner
Familial hypercholesterolemia in childhood and

adolescence
K. Widhalm
BASIC SEMINAR II
Title
Teacher
Multiple Endocrine Neoplasia 2
S. Baumgartner-Parzer
Interpretation of endocrinological lab results
C. Bieglmayer
Hypoglycemia counterregulation in type 1 diabetes
M. Bischof
Analytical techniques for quantification of small molecules O. Bodamer

Clinical Nutrition and Infusion Therapy 2
W. Druml
Molecular methods in research and diagnostics of

metabolic diseases 2
M. Fdinger
From cell culture to the whole organism: experimental

approaches
C. Frnsinn
Basic scientific aspects of growth
G. Husler
Stresshyperglycemia, nutritive intervention in hospitalized

patients
M. Hiesmayr
Pregnancy in patients with type 1 and type 2 diabetes

mellitus
A. Kautzky-Willer
Direct and indirect effects of nutrients on glucose

metabolism
M. Krebs
Metabolic syndrome
B. Ludvik
page 5 of 168
New developments in the regulation of appetite and body

weight
A. Luger
Physiology of nutrition and pathophysiology of vitamins

and trace elements
W. Marktl
Endocrine surgery 2
B. Niederle
Bariatric surgery 2
G. Prager
Pathogenesis and treatment of osteoporosis
P. Pietschmann
Protein catabolism, post-aggression phase,

immunonutrition 2
E. Roth
Dyslipidemias and polyunsaturated fatty acids
Th. Stulnig
Pathophysiology of endometriosis
W. Tschugguel
Polyphenols: anitoxidants and signalling molecules?
N. Unger-Manhart
Thyroid gland
H. Vierhapper
The beta cell and insulin transcription
L. Wagner
Principles and evidence for a preventive nutrition
K. Widhalm
Journal Club
The Journal Clubs (critical paper reviews) are held on a weekly basis by the programs
teachers. Currently, a single Journal Club is established each term. In total 12 SHrs must be
completed for the thesis program.
Title
Lecturer(s)
SE Journal Club "Endocrinology and Metabolism

[Semester]";
2 SHrs (compulsory course); English; personal
registration by email to Prof. Th. Stulnig
(thomas.stulnig@meduniwien.ac.at)
Contents: presentation and critical discusssion of
published papers

Husler, Jrg Michael Hiesmayr,
Alexandra Kautzky-Willer, Michael
Pietschmann, Gerhard Prager, Erich
Roth,
Thomas
Stulnig,
Walter
Tschugguel, Nicole Unger-Manhart,
Ludwig Wagner, Kurt Widhalm
Compulsory Optional Courses

According to the curriculum, each student must attend a total of 12 SHrs of Thesis Seminars
and 4 SHrs of Practical Seminars, i.e. a total of 16 SHrs. More elective courses are to be
announced in the future. Please see the current index of courses of the Medical University of
Vienna for details
page 6 of 168
Title
Lecturer(s)
SE Thesis Seminar "Endocrinology and

Metabolism [Semester]"
2 SHrs; English; personal registration by email to
Prof. T. Stulnig (thomas.stulnig@meduniwien.ac.at)
Contents: presentation and critical discussion of
thesis projects

Husler,
Jrg
Michael
Hiesmayr,
Alexandra
Kautzky-Willer,
Michael
Pietschmann, Gerhard Prager, Erich Roth,
Thomas Stulnig, Walter Tschugguel,
Nicole Unger-Manhart, Ludwig Wagner,
Kurt Widhalm
SE Practical Seminar "Endocrinology and

Metabolism [Semester]"
2 SHrs; English; personal registration by email to
Prof. T. Stulnig (thomas.stulnig@meduniwien.ac.at)
Contents: Case studies in endocrinology and
metabolism will be presented in an interactive
manner in order to promote analytical thinking and
practical problem solving; depending on the
teaching faculty member, clinical cases or
laboratory problems will be addressed; ethical and
societal issues are to be discussed; another focus
will be made on presentation techniques in order to
teach students to communicate clinical issues and
scientific results in an easy to understand language

Husler,
Jrg
Michael
Hiesmayr,
Alexandra
Kautzky-Willer,
Michael
Pietschmann, Gerhard Prager, Erich Roth,
Thomas Stulnig, Walter Tschugguel,
Nicole Unger-Manhart, Ludwig Wagner,
Kurt Widhalm
Elective Courses
Please see the current index of courses of the Medical University of Vienna for details on
elective courses for doctoral study programs.
page 7 of 168
Experimental Techniques
Methods
Working groups
in vitro methods
apoptosis / proliferation assays
Baumgartner-Parzer, Unger-Manhart, Roth
bone histomorphometry
Pietschmann
cell culture, cell lines
Stulnig, Luger, Wagner, Bodamer, UngerManhart
cell culture, perfusion model
Luger
cell culture, primary
Stulnig, Baumgartner-Parzer, Pietschmann,

Luger, Wagner, Bodamer, Husler
enzymatics
Bodamer
FACS - dynamic measurements (calcium etc.)
Stulnig
FACS - immunofluorescence
Stulnig, Baumgartner-Parzer, Pietschmann,

Wagner, Unger-Manhart
fatty acid analysis (GC)
Stulnig
fluorescence microscopy
Stulnig, Wagner
gas chromatography
Stulnig, Bodamer
gene expression profiling (microarrays)
Stulnig, Fdinger
HPLC, FPLC and other chromatographic analyses Wagner, Bodamer, Roth

immunohistochemistry
Baumgartner-Parzer, Husler
immunoassays (ELISA, FIA, RIA etc.)
Pietschmann, Bodamer
immunoblotting
Stulnig, Baumgartner-Parzer, Frnsinn,

Krebs, Husler
immunoprecipitation
Stulnig, Wagner
isolated muscle incubation
Frnsinn
lipoprotein ultracentrifugation
Stulnig
magnetic cell sorting
Stulnig
mass spektrometry
Bodamer
metabolic labeling
Stulnig, Wagner
metabolic rates with radioactive tracers
Frnsinn
mikronukleation in lymphocytes
Bodamer
northern blotting
Stulnig, Baumgartner-Parzer, Frnsinn,

Wagner, Bodamer, Fdinger
PCR, genomic
Baumgartner-Parzer, Fdinger
PCR, on chip
Bodamer
page 8 of 168
PCR, real-time (quantitativ, SNP)
Stulnig, Pietschmann, Wagner, Fdinger,

Husler
PCR, reverse transciptase (RT-PCR)
Stulnig, Pietschmann, Wagner, Fdinger
protein expression
Wagner
protein sequencing
Bodamer
reporter gen assay
Stulnig, Baumgartner-Parzer, Wagner
RFLP
sequencing
southern blotting
spectrophotometric enzyme analyses
Frnsinn
SSCP
Bodamer
subcellular fractionation
Stulnig, Wagner
tissue explants (adipose)
Stulnig
transfection, gene expression
Stulnig, Wagner
in vivo methods - animal experiments

effects of antidiabetic drugs in rats
Frnsinn
mouse models
Stulnig, Pietschmann, Bodamer, UngerManhart
rat models
Pietschmann
stabile isotope application
Bodamer
in vivo methods - experiments in humans

body composition measurement
Widhalm
epidemiology of malnutrition
Hiesmayr
indirect calorimetry
Hiesmayr
magnetic resonance spectroscopy, multi-nuclear
Roden, Bischof, Krebs, Bodamer
muscle biopsy
Krebs
nutritional training, assessment of nutritional

status
Widhalm, Roth, Unger-Manhart, Druml,

Hiesmayr
positron emission spectroscopy
Bischof, Krebs
stabile isotope technique (protein turnover,

glucose turnover, gluconeogenesis,
methionine-homocysteine metabolism)
Roden, Bischof, Krebs, Bodamer
tests of endocrine function
Luger
tests of insulin secretion and insulin sensitivity
Roden, Bischof, Kautzky-Willer, Krebs
page 9 of 168
Faculty
incl. contact information and role in the program
Principal investigator
E-mail
Ao.Univ.Prof.DI.Dr. Sabina BaumgartnerParzer
sabina.baumgartner-parzer@meduniwien.ac.at
Ao.Univ.-Prof. Dr. Christian Bieglmayer
christian.bieglmayer@akhwien.at
Ao.Univ.-Prof. Dr. Martin Bischof
martin.bischof@meduniwien.ac.at
Ao.Univ.-Prof. Dr. Olaf Bodamer
olaf.bodamer@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Wilfred Druml
wilfred.druml@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Manuela Fdinger
manuela.foedinger@meduniwien.ac.at
YS
Ao. Univ.-Prof. Dr. Clemens Frnsinn
clemens.fuernsinn@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Gabriele Husler
gabriele.haeusler@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Michael Hiesmayr
michael.hiesmayr@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Alexandra KautzkyWiller
alexandra.kautzky-willer@meduniwien.ac.at
Ao. Univ.-Prof. Dr. Michael Krebs
michael.krebs@meduniwien.ac.at
Ao.Univ.-Prof. Dr. Bernhard Ludvik
bernhard.ludvik@meduniwien.ac.at
Ao.Univ.Prof. Dr. Anton Luger
anton.luger@meduniwien.ac.at
Ao.Univ.-Prof. Dr. Wolfgang Marktl
wolfgang.marktl@meduniwien.ac.at
Ao.Univ.-Prof. Dr. Bruno Niederle
bruno.niederle@meduniwien.ac.at
Ao. Univ.Prof. Dr. Peter Pietschmann
peter.pietschmann@meduniwien.ac.at
Univ.-Doz. Dr. Gerhard Prager
gerhard.prager@meduniwien.ac.at
Prim. ao.Univ.-Prof. Dr. Michael Roden
michael.roden@wgkk.sozvers.at
ao.Univ.-Prof. DI. Dr. Erich Roth
erich.roth@meduniwien.ac.at
Ao.Univ. Prof. Dr. Thomas Stulnig
thomas.stulnig@meduniwien.ac.at
Ao.Univ.Prof. Dr. Walter Tschugguel
walter.tschugguel@meduniwien.ac.at
Univ.-Doz. Mag. Dr. Nicole Unger-Manhart nicole.unger-manhart@meduniwien.ac.at
Role*
Ao.Univ.Prof. Dr. Heinrich Vierhapper
heinrich.vierhapper@meduniwien.ac.at
Ao.Univ.Prof. Dr. Ludwig Wagner
ludwig.wagner@meduniwien.ac.at
Univ. Prof. Dr. Kurt Widhalm
kurt.widhalm@meduniwien.ac.at
* currently assigned roles: S, supervisor; YS, young supervisor; L, lecturer.

page 10 of 168
Description of thesis projects and CVs of supervisors & lecturers:
Sabina BAUMGARTNER-PARZER ...................................................................................... 12

Christian BIEGLMAYER ........................................................................................................ 19
Martin BISCHOF ..................................................................................................................... 21
Olaf A. BODAMER................................................................................................................. 26
Wilfred DRUML ...................................................................................................................... 34
Manuela FDINGER............................................................................................................... 35
Clemens FRNSINN............................................................................................................... 44
Gabriele HUSLER................................................................................................................. 50
Michael J. HIESMAYR ........................................................................................................... 53
Alexandra KAUTZKY-WILLER ............................................................................................ 57
Michael KREBS....................................................................................................................... 63
Bernhard LUDVIK................................................................................................................... 70
Anton LUGER.......................................................................................................................... 77
Wolfgang MARKTL ................................................................................................................ 84
Bruno NIEDERLE ................................................................................................................... 86
Peter PIETSCHMANN .......................................................................................................... 102
Gerhard PRAGER .................................................................................................................. 111
Michael RODEN .................................................................................................................... 116
Erich ROTH ........................................................................................................................... 126
Thomas M. STULNIG ........................................................................................................... 134
Walter TSCHUGGUEL ......................................................................................................... 142
Nicole UNGER-MANHART................................................................................................. 148
Heinrich VIERHAPPER ........................................................................................................ 153
Ludwig WAGNER................................................................................................................. 154
Kurt M. WIDHALM .............................................................................................................. 161
page 11 of 168
Sabina BAUMGARTNER-PARZER
Department of Internal Medicine III, Clin. Div. Endocrinology and Metabolism
sabina.baumgartner-parzer@meduniwien.ac.at
Diabetes associated micro- and macrovascular dysfunction. Analysis of

cellular and molecular mechanisms.
Abstract
Long standing diabetes is characterized by diabetic microangiopathy (diabetic retinopathy and
nephropathy) and by premature atherosclerosis. The latter represents the major cause of
morbidity and mortality in patients with diabetes mellitus, whereas diabetic retinopathy is the
leading cause for blindness in Europe.
Recent data suggest that loss of retinal endothelial cells and pericytes due to apoptosis results
in acellular capillaries and ischemia, providing the basis for the progression of diabetic
retinopathy to the proliferative form of this disease. Accelerated apoptosis of endothelial cells
and vascular smooth muscle cells in atherosclerotic regions is assumed to result in plaque
erosion and plaque rupture and thus to favor atherothrombosis. It was only recently that bone
marrow derived endothelial progenitor cells (EPCs) have been found to contribute to vascular
repair and angiogenesis. In diabetic patients, however, numbers of EPCs circulating in the
blood are reduced when compared to healthy control subjects. Such reduction of EPCs may
contribute to diabetes associated endothelial dysfunction and to the clinical manifestation of
atherosclerosis and cardiovascular disease. Therefore, it is of importance to evaluate the
hypothesis that diabetes associated metabolic abnormalities (hyperglycemia, dyslipidemia and
chronic elevation of free (non-esterified) fatty acids (FFA), elevated levels of
proinflammatory cytokines and adhesion molecules) cause depletion of EPCs in diabetic
patients.
We have previously shown that vasoprotective factors (antioxidants, leptin) prevent, whereas
atherosclerotic risk factors (oxidized/glycated LDL, hyperglycemia, proinflammatory
cytokines, elevated free fatty acids) trigger apoptosis in cultured vascular cells, depending on
stimulus and cell type. Using inhibitors of caspases, of protein kinases and of transcription
factors, we could identify the respective target molecules and signal transduction pathways.
Due to our extensive experience in this field of research, in future studies we want to test the
hypothesis that function (apoptosis, proliferation and secretory profile) of human endothelial
progenitor cells is directly affected by diabetes associated metabolic factors. It will be
evaluated, whether EPCs functional alterations can be modulated by vasoprotective agents
and the respective target molecules and signaling pathways will be characterized.
Thesis Subjects
Modulation of human endothelial progenitor cell function by metabolic factors.
Techniques and infrastructure
Isolation and culture of primary cultures of human vascular cells and of endothelial progenitor
cells, apoptosis and proliferation assays, FACS analysis, Western and Northern blots,
immunocytochemistry, transfection experiments.
page 12 of 168
Curriculum Vitae
Sabina M. Baumgartner-Parzer
Address: Department of Medicine III, Division of Endocrinology & Metabolism, Medical
University of Vienna, Waehringer Grtel 18-20, A-1090 Vienna, Austria; Phone +43 1 40400
4368; Fax +43 1 404007790; Email sabina.baumgartner-parzer@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
5.11.1962
Bad Ischl, Austria
Austria
Education
1985-1989
1981-1985
Doctoral thesis
Study of biotechnology
1973-1981
Career History
1998-present
11/1997
1990-1997
1993 and 1994

1989
1985-1989
1985
Secondary school: Gymnasium der Kreuzschwestern

Gmunden-Orth
Associate Professor of Biochemistry at the Department of

Internal Medicine III, Div. Endocrinology & Metabolism,
Medical University of Vienna
Head of the working groups of vascular biology and of
molecular genetics of hereditary endocrine diseases
Habilitation at the University of Vienna
Post-Doc at the Research Laboratories of Department of
Medicine III, Division of Endocrinology & Metabolism,
Medical University of Vienna (former Division of
Endocrinology & Diabetes Mellitus, 1st Medical
Department, University of Vienna)
2 months Visiting Fellow at the Havard Medical School,
Boston
Promotion (Dr. rer.nat.techn)
Thesis at the 1.Dept. of Medicine (Prof. Mannhalter / Prof.
Deutsch), University of Vienna
Graduation (Dipl.-Ing) at the University of Bodenkultur
Career-related Activities
page 13 of 168
2003 -present
Editorial board of the journal Metabolic Syndrome and

Related Disorders
Assistent Editor of the journal Diabetologia
Organization of the EASD Satellite Symposium:"Role of
adhesion molecules in Diabetes Mellitus"
1998-2003
1996
Awards
2005
Poster-Prize - Austrian Society of

Endocrinology&Metabolism
Science award of Upper Austria
Dr. Karl Schleinzer-Award (University of Bodenkultur)
1997
1985
1984/85
Award for gifted students
Memberships
Austrian Diabetes Association (DG),
Austrian Association for Endocrinology and Metabolism (GES),
European Association for the Study of Diabetes (EASD)
Gesellschaft fr gute Labor und Analysenpraxis (GALP)
Sources of funding since 2000
Period
Organization
Role
Title
kE
2005-2006
Eurasia Pacific
Network (Grant to
Erdenekhuu
Nansalma)
FWF(CharlotteBhler-Program to
coworker)
Supervisor
Vascular dysfunction in diabetes
10
Supervisor
Nutritional free fatty acids and

diabetic vascular dysfunction.
Analysis of cellular and
molecular mechanisms and
interactions.
Freie Fettsuren und Diabetes
assoziierte Geferkrankungen
80
2005-2007
2004-2005
Jubilumsfonds der Costerr. Nationalbank investigator
1997-1999
Jubilumsfonds der Principal

sterr. Nationalbank investigator
1997-1999
FWF
1993-1995
Herzfeldersche
60
20
Principal
investigator
Principal
Bedeutung von LDLGlykierungsprodukten bei der

Entstehung von Gefkomplikationen im Rahmen des
Diabetes Mellitus
Hyperglykmie und Apoptose
Einflu von Glukose auf ET-1
page 14 of 168
Familienstiftung
investigator
und EDRF Produktion in

kultivierten humanen
Endothelzellen verschiedener
Stromgebiete
Supervision of doctoral and diploma students (since 2000)

Diploma students: Andrea Lindenmayer, Kathrin Malits, Ursula Schauer, Magdalena Reithner
PhD students:
Name
Title of thesis
Karin Tobler
Function of endothelial progenitor cells in

gestational diabetes
Heterogeneous regulation by hyperglycemic /
hyperlipidemic states as well as by an adjuvans
in colon cancer therapy (levamisole) of
apoptosis, proliferation and associated
gene/protein expression in vascular endothelial
cells.
Michaela
Artwohl
Period
(expected)
2005(2008)
1997-2000
Acadaemic
title
(PhD)
Dr. rer.
nat.techn
Teaching
- Biochemische, molekularbiologische Arbeitsmethoden in der Endokrinologie (fr
Wahlfachausbildung gem 13 Studiengesetz Medizin, fr Diplomanden und Dissertanten.
- Experimentelle Arbeiten in Endokrinologie und Stoffwechsel (fr Wahlfachausbildung
gem 13 Studiengesetz Medizin, fr Diplomanden und Dissertanten).
- Molekulare Endokrinologie, gemeinsam mit H Cross (Pathophysiologie)
- Eukaryonten - Biogenese von Zellorganellen (Wahlfachvorlesung gem. mit
Prof. Gll) - Externer Lehrauftrag an der Univ. f. Bodenkultur
- Biochemische, molekularbiologische Aspekte der Endokrinologie (Dozentenvorlesung)
- Ringvorlesung - ICP (Interdiscinplinary Cooperation Project of Molecular Medicine) im
SS 1999
Publications
44 peer reviewed publications and 3 reviews in scientific journals, 8 invited lectures
Peer reviewed manuscripts since 2000 (original research and reviews)
First, last or corresponding author manuscripts:
M Artwohl, T Hlzenbein, L Wagner, A Freudenthaler, W Waldhusl, SM BaumgartnerParzer. Levamisole induced apoptosis in cultured vascular endothelial cells. Brit J
Pharmacol 131:1577-1583, 2000
SM Baumgartner-Parzer, E Schulze, S Pauschenwein, S Rondot, P Nowotny, W Waldhusl, H
page 15 of 168
Vierhapper: Mutational spectrum of the steroid 21-hydroxylase gene in Austria

Identification of a novel missense mutation. J Clin Endocrinol Metabol 86:4771-4775,
2001
SM Baumgartner-Parzer, WK Waldhusl. The endothelium as a metabolic and endocrine
organ: its relation with insulin resistance. Exp Clin Endocrinol Diabetes 109 Suppl: 166179, 2001
SM Baumgartner-Parzer, S Pauschenwein, W Waldhusl, K Plzler, P Nowotny, H
Vierhapper. Increased prevalence of heterozygous 21-OH germ line mutations in patients
with adrenal incidentalomas. Clin Endocrinol 56, 811-816, 2002
M Artwohl, M Roden, T Hlzenbein, A Freudenthaler, W Waldhusl, SM BaumgartnerParzer. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells.
Int J Obesity 26:577-580, 2002
SM Baumgartner-Parzer, P Nowotny, W Waldhusl, H Vierhapper. A rare duplicated 21-OH
haplotype and a de novo mutation a family analysis. J Clin Endocrinol Metabol 88:
2794-2796, 2003
M Artwohl, WF Graier, M Roden, M Bischof, A Freudenthaler, W Waldhusl, SM
Baumgartner-Parzer. Diabetic low-density lipoprotein triggers apoptosis in vasular
endothelial cells. Diabetes 52:1240-1247, 2003
M Artwohl, M Roden, W Waldhusl, A Freudenthaler, SM Baumgartner-Parzer. Free fatty
acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial
cells. FASEB J 18: 146-148, 2004
H Vierhapper, C Bieglmayer, G Heinze, SM Baumgartner-Parzer. Frequency of RETprotooncogene mutations in patients with normal and with moderately elevated (50-100
pg/ml) pentagastrin-stimulated serum concentrations of calcitonin. Thyroid 14:580-583,
2004
SM Baumgartner- Parzer, P Nowotny, W Waldhusl, H Vierhapper. Carrier frequency of
Congenital Adrenal Hyperplasia (21-OH-deficiency) in a Middle European population. J
Clin Endocrinol Metab 90: 775-778, 2004
M Artwohl, C Frnsinn, W.Waldhusl, T Hlzenbein, G Rainer, M Roden, A Freudenthaler,
SM Baumgartner-Parzer. Thiazolidinediones inhibit proliferation of micro- and
macrovascular cells. Evidence for a PPAR-independent mitochondrial mechanism.
Diabetologia, 48:586-594, 2005
M Artwohl, T Hlzenbein, C Frnsinn, A Freudenthaler, N Huttery, W. Waldhusl and SM
Baumgartner-Parzer. Thiazolidinediones inhibit apoptosis and heat shock protein 60
expression in human vascular endothelial cells. Thromb Haemost 93:810-815, 2005
SM Baumgartner-Parzer, R Lang, G Heinze, B Niederle, K Kaserer, W Waldhusl and H
Vierhapper. Polymorphisms in exon 13 and intron 14 of the RET-protooncogene: Genetic
modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90: 6232-6236,
2005
page 16 of 168
H Vierhapper, L Wagner, S Hanslik, B Niederle, S Rondot, E Schulze, C Bieglmayer, K

Kaserer and S Baumgartner-Parzer. Primary hyperparathyroidism in a patient with a
seemingly homozygous Y719F RET mutation. Thyroid 15: 1303-1308, 2005
H Vierhapper, B Niederle, C Bieglmayer, K Kaserer and S Baumgartner-Parzer. Early
diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of
serum calcitonin in patients with thyroid disorders. Thyroid 15: 1267-1272, 2005
SM Baumgartner-Parzer, G Fischer, H Vierhapper. Predisposition for de novo gene
aberrations in the offspring of mothers with a duplicated CYP21A2 gene. J Clin
Endocrinol Metab 90:1164-1167, 2007
M Artwohl, K Muth, Kosulin K, R de Martin, T Hlzenbein, G Rainer, A Freudenthaler, N
Huttary, L Schmetterer, WK Waldhusl, SM Baumgartner-Parzer. R(+)-alpha-lipoic acid
inhibits endothelial apoptosis and proliferation involvement of Akt and Retinoblastoma
protein / E2F. Am J Physiol Endocrinol Metab Jun 2007 (epub ahead of print)
Co-author manuscripts:
H Frisch, T Battelino, E Schober, SM Baumgartner-Parzer, P Nowotny, H Vierhapper. Salt
wasting in simple virilizing congenital adrenal hyperplasia. J Pediatr Endocrinol Metab
14:1649-1655, 2001
AP Szremska, R Stoxreither, L Kenner, M Artwohl, HC Theussl, SM Baumgartner-Parzer, E.
Passegue, EF Wagner, V. Sexl. Jun B inhibits proliferation and transformation in B
lymphoid cells. Blood 102:4159-4165, 2003
W Gartner, T Daneva, I Mineva, SM Baumgartner-Parzer, H Vierhapper, M Weissel, B
Niederle, L Wagner. Identification of a novel SNP within intron 19 of the RET gene by
comparative RFLP analysis of benign and neoplastic endocrine tissue. ncbi.nlm.nih
GenBank Accession AY615726; 2004
W Gartner, T Daneva, I Mineva, S Baumgartner-Parzer, B Niederle, H Vierhapper, M
Weissel, L Wagner. A new identified RET proto-oncogene polymorphism is found in a
high number of endocrine tumor patients. Human Genetics 117:143-153, 2005
D Stoiber, B Kovacic, C Schuster, C Schellack, M Karaghiosoff, R Kreibich, E Weisz,
Artwohl M, OC Kleine, M Mller, S Baumgartner-Parzer, J Ghysdael, M Freissmuth, V
Sexl. Tyk2 is a key regulator for the tumor surveillance of B lymphoid tumors. JCI 114
(11):1650-1658, 2004
F Votava, D Trk, J Kovacs, D Mslinger, SM Baumgartner-Parzer, et al. Estimation of the
false negative rate in the newborn screening for congenital adrenal hyperplasia. Eur J
Endocrinol 152:869-874, 2005
V Dolzan, J Solyom, G Fekete, J Kovacs, V Rakosnikova, F Votava, J Lebl, Z Pribilincova, S
Baumgartner-Parzer, S Riedl, F Waldhauser, H Frisch, M Stopar-Obreza, C Krzisnik, T
Battelino. Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype
association in Middle European patients with congenital adrenal hyperplasia. Eur J
page 17 of 168
Endocrinol 153:99-106, 2005

K Namiranian, F Mittermayer, M Artwohl, J Pleiner, G Schaller, BX Mayer, M Bayerle-Eder,
M Roden, SM Baumgartner-Parzer, M Wolzt. Free fatty acids do not acutely increase
asymmetrical dimmethylarginine concentrations. Horm Metabol Res 37: 768-772
DG Haider, F Mittermayer, G Schaller, M Artwohl, SM Baumgartner-Parzer, G Prager, M
Roden, M Wolzt. Free fatty acids normalize a rosiglitazone-induced vasfatin release. Am
J Physiol Endocrinol Metab 291:E885-890, 2006
Invited Talks:
Hyperglycemia and endothelial cells. XIII. International Donausymposium on Diabetes
mellitus. Vienna 5.-7.10.1995
Apoptose - der programmierte Zelltod. sterr. Biochemische Ges, Biochemisches Institut,
Universitt Graz, 29.6.1996
Role and mechanisms of apoptosis in endothelial cells: Zellkultur-Workshop - European
Tissue Culture Society, Wien 21/02/1997
Effect of tri-iodothyronine on cultured endothelial cells. The Vascular System in Thyroid
Disease. Heidelberg 6.10.1999
Hyperglycemia and endothelial dysfunktion. Donau-Symposium, Zrich 16.10.1999
Molekulargenetische Diagnostik des AGS. Jahrestagung der sterr. Gesellschaft fr
Endokrinologie und Stoffwechsel. St. Wolfgang, 19.-21. April 2001
Molekularbiologische Diagnostik bei Nebennierentumoren. Jahrestagung der sterr.
Gesellschaft fr Endokrinologie und Stoffwechsel. St. Wolfgang, 25.-27.April 2002
Mechanismen des endothelialen Re-Modeling durch metabolische Faktoren. Potsdamer
Expertengesprche Diabetes. Berlin 26.02.2005
page 18 of 168
Christian BIEGLMAYER
Clinical Institute for Medical and Chemical Laboratory Diagnostics
christian.bieglmayer@akhwien.at
Curriculum Vitae
Personal data:
Born 09/15/1947, living in Vienna, married, one son.
Education:
1965-1974: Study of chemistry at the University of Vienna. Thesis: Function of the
glyoxysomal membrane in the metabolism of growing fat storing plants", PhD graduation and
basic military service.
Profession:
1972-1974: Half-day employee at the Institute of General Biochemistry, afterwards full-time
university assistant.
1976-1981: Hormone-Laboratory of the 1st Dept. Obstetrics and Gynaecology (General
Hospital of Vienna).
1981-1991: Entrusted with the organisation and direction of the Endocrine Laboratory of the
2nd Dept. Obstetrics and Gynaecology.
1987 "Venia docendi for Biochemistry". 1988 assistant professor and since 1990 tit.a.o. Univ.
Prof.
1991 till now: manager of the domain Endocrinology at the Clinical Institute for Medical
and Chemical Laboratory Diagnostics (KIMCL)
Consultant of WHO in Pyongyang, North-Korea in 1988. QUASTA ring-trial leader for
quality assurance of Fertility Hormones.
Award: "Theodor Krner Award" for "Secretion of gonadotropins by pituitary cell culture" in
1978.
Membership: Austrian Biochemical Society (member of the board from 1986 to 1988),
Austrian Society for Clinical Chemistry, Austrian Society for Endocrinology and Metabolism
(founder-member and member of the board since 1995) and New York Academy of Science.
Grants: "Fonds zur Frderung der wissenschaftlichen Forschung" (1989: "Eicosanoids in
menstrual blood"), "Brgermeisterfonds der Bundeshauptstadt Wien" (1991: "Influence of
cytotoxic drugs on tumor - mucin synthesis" and 1997: "Effects of 5-reductase inhibitors on
androgen metabolism in skin cells").
Scientific work: About 250 articles in scientific periodicals and books: carbohydrate
metabolism in plants, steroid hormone receptors, autoimmune-reactions in pre-eclampsia,
clinical and experimental endocrinology and oncology, bone marker.
Lectures: Fertility Hormones, Bone metabolism, Hormones of the adrenal gland,
Hormones, function tests and tumor markers in gynecology. Modern methods of hormone
analysis, Interpretation of hormone reports. Outside lectures: Principles of radiation
protection and work with radioisotopes in medical laboratories, Biotechnology in diagnostic
laboratories.
page 19 of 168
Guidance of 35 students during their diploma work or thesis and final examinations. Guidance
of MDs during their special training in laboratory medicine.
page 20 of 168
Martin BISCHOF
Dept. Internal Medicine III, Clin Div. Endocrinology and Metabolism
martin.bischof@meduniwien.ac.at
Effect of Continuous Subcutaneous Glucose Monitoring and Insulin

Infusion on the Incidence of Hypoglycemia in Type 1 Diabetic Patients
Abstract
Hypoglycemia is a frequent complication in long-term type 1 diabetes, especially in patients
with low HbA1c-levels. On average, one type 1 diabetic patient attempting to maintain nearnormoglycaemia suffers two episodes of symptomatic hypoglycemia per week and one
episode of severe, at least temporarily disabling, hypoglycemia approximately once a year.
Long-term type 1 diabetic patients often develop hypoglycemia unawareness leading to a
greater risk of severe hypoglycemia since symptom recognition and accurate detection of
extreme blood glucose values are crucial for management of type 1 diabetes.
With subcutaneous glucose sensors continuous blood glucose monitoring is possible. Even
with older systems where glucose levels are not visible for the patient, the increased amount
of blood glucose measurements allowed the physician to optimize insulin therapy resulting in
reduced incidence of hypoglycemia. Only recently an improved system for continuous blood
glucose measurements became available. Glucose levels are visible for the patient and alarm
limits can be set. A randomized study demonstrated that this system reduces the duration of
hypoglycemic episodes by 45%.
The latest innovation in hypoglycemia therapy is the combination of continuous insulin
supply with continuous blood glucose monitoring. This concept was implemented by the
Paradigm Real Time - System which recently became available in Europe. The long-term
effects of this therapeutic option on the incidence of hypoglycemia and the quality of life in
type 1 diabetic patients has not yet been studied.
Thesis Subjects
This study plans to evaluate the hypothesis is that a combination of optimal insulin therapy by
CSII combined with continuous blood glucose monitoring reduces hypoglycemia frequency
and duration in type 1 diabetic patients with frequent hypoglycemia under functional insulin
therapy. Furthermore we hypothesize that this therapy will improve quality of life and reduce
the fear of hypoglycemia.
Continous subcutaneous insulin infusion, Continous glucose monitoring systems
page 21 of 168
Curriculum Vitae
Martin BISCHOF, MD
Division of Endocrinology & Metabolism, Department of Internal Medicine III, Medical
University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; Phone +43 1
40400 7257 Fax +43 1 40400 7257 email martin.bischof@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
01.04.1969
Vienna, Austria
Austria
Education
2003
1987 1996
1979 1987
Certification Internal Medicine

studies of Human Medicine
secondary school
Career History
2005-present
2004 present
2004
1998 2004
1996-1998
1996
1992-1995
2005-present
Clinical responsibility for the Metabolic Research Unit

Associate Professor of Medicine at the Medical University
of Vienna
Attending Physician at the Div. of Endocrinology &
Metabolism
venia docendi for Internal Medicine
Clinical training and lecturer at the Division of
Endocrinology & Metabolism, Medical University of
Vienna
Postdoctoral fellow
Department of General and Experimental Pathology,
University of Vienna Medical School
Fellowship Brown University, Rhode Island, USA
Scientific coworker of the group Tumorpathology
Management Training for Medical Leaders at the

University of Krems
page 22 of 168
Awards
2002
1996
Aventis-Preis, University of Vienna Medical Faculty

Legacy Hirtl-Buss, University of Vienna Medical Faculty
(research grant)
Memberships
Austrian Diabetes Society
European Society for the Study of Diabetes
Austrian Society for Endocrinology and Metabolism
Austrian Society for Internal Medicine
Sources of funding (since 2000)
Period
Organization
Short Title
K/yr
2005
2007
FWF (F17980-B11)
Brain metabolism during hypoglycemia in

type 1 DM
70
2004
2006
Austrian National
Bank Project #10892
Glucose metabolism in GSD 1
26
Supervision of doctoral students (since 2000)

Name
Title of thesis
Period (expected)
Martina Mandl
Measurement of unidirectional
2005 2008
fluxes to ATP in human occipital
lobe using 31PMR saturation
transfer
Acad.Title
PhD
Publications
27 peer reviewed publications in scientific journals
Bischof-M, Ludwig-C, Hofer-A, Kletter-K, Krebs-M, Stingl-H, Nowotny-P, Waldhusl-W,
Roden-M. Hormonal and Metabolic Counterregulation During and After High-Dose InsulinInduced Hypoglycemia in Diabetes Mellitus Type 2. Hormone and Metabolic Research (2000)
32:417-423
Bischof-MG, Bernroider-E, Ludwig-C, Kurzemann-S, Kletter-K, Waldhusl-W, Roden-M.
Effect of Near Physiologic Insulin Therapy on Hypoglycemia Counterregulation in Type 1
Diabetes. Hormone Research (2001) 56:151-158.
Bischof-MG, Krssak-M, Krebs-M, Bernroider-E, Stingl-H, Waldhusl-W, Roden-M. Effects
page 23 of 168
of Short-Term Improvement of Insulin Treatment and Glycemia on Hepatic Glycogen

Metabolism in Type 1 Diabetes Mellitus. Diabetes (2001) 50: 392-398
Bischof-MG, Bernroider-E, Krssak-M, Krebs-M, Stingl-H, Nowotny-P, Yu-C, Shulman-GI,
Waldhusl-W, Roden-M. Hepatic Glycogen Metabolism in Type 1 Diabetes After Long-Term
Near Normoglycemia. Diabetes (2002) 51: 49-54
Bischof-MG, Mlynarik-V, Brehm-A, Bernroider E, Krssak-M, Bauer-E, Madl-C, Waldhusl
W, Roden-M. Brain Energy Metabolism During Hypoglycemia in Healthy and Type 1
Diabetic Humans. Diabetologia (2004) 47: 648-651
Bischof-MG, Brehm-A, Bernroider-E, Krssak-M, Mlynarik-V, Krebs-M, Roden-M. Cerebral
glutamate metabolism during hypoglycemia in healthy and type 1 diabetic humans. European
Journal of Clinical Investigation (2006) 36:164-169
Bischof-MG, Heize-G, Vierhapper-H. Vitamin D Status in a Healthy Population and its
Relation to Age and BMI. Hormone Research (2006) 66: 211-215
Gessl-A, Bischof-M. Thyroid disorders and the Kidney. Nephro-News (2006) 8: 1-12
Krebs-M, Stingl-H, Nowotny-P, Weghuber-D, Bischof-M, Waldhusl-W, Roden-M.
Prevention of in Vitro Lipolysis by Tetrahydrolipstatin. Clinical Chemistry (2000) 46: 950954
Raber-W, Raffesberg-W, Bischof-M, Scheuba-C, Niederle-B, Gasic-S, Waldhusl-W, RodenM. Diagnostic Efficacy of Unconjugated Plasma Metanephrines for the Detection of
Pheochromocytoma. Archives of Internal Medicine (2000) 160: 2957-2963
Cross-HS, Bareis-P, Hofer-H, Bischof-MG, Bajna-E, Kriwanek-S, Bonner-E, Peterlik-M. 25Hydroxyvitamin D3-1-Hydroxylase and Vitamin D Receptor Gene Expression in Human
Colonic Mucosa is Elevated During Early Cancerogenesis. Steroids (2001) 66:287-292
Bareis-P, Bises-G, Bischof-MG, Cross-HS, Peterlik-M. 25-Hydroxy-Vitamin D Metabolism
in Human Colon Cancer Cells During Tumor Progression. Biochemical Biophysical Research
Communications (2001) 285: 1012-1017
Stingl-H, Krssak-M, Krebs-M, Bischof-MG, Nowotny-P, Frnsinn-C, Shulman-GI,
Waldhusl-W, Roden-M. Lipid-Dependent Control of Hepatic Glycogen Stores in Healthy
Man. Diabetologia (2001) 44: 48-54
Krebs-M, Krssak-M, Nowotny-P, Weghuber-D, Gruber-S, Mlynarik-V, Bischof-M, Stingl-H,
Frnsinn-C, Waldhusl-W, Roden-M. Free Fatty Acids Inhibit the Glucose-Stimulated
Increase of Intramuscular Glucose-6-Phosphate Concentration in Humans. Journal of
Clinincal Endocrinology and Metabolism (2001) 86: 2153-2160
Bayerle-Eder-M, Fuchsjager-Mayrl-G, Sieder-A, Polska-E, Roden-M, Stulnig-T, BischofMG, Waldhusl-W, Schmetterer-L, Wolzt-M. Effect of Pravastatin on Responsiveness to Nmonomethyl-L-Arginine in Patients With Hypercholesterolaemia. Atherosclerosis (2002) 160:
177-184
Bareis-P, Kallay-E, Bischof-MG, Bises-G, Hofer-H, Ptzi-C, Manhardt-T, Bland-R, CrossHS. Clonal Differences in Expression of 25-Hydroxyvitamin D3-1-hydroxylase, of 25Hydroxyvitamin D3-24-hydroxylase, and of the Vitamin D Receptor in Human Colon
Carcinoma Cells: Effects of Epidermal Growth Factor and 1,25-Dihydroxyvitamin D3.
Experimental Cell Research (2002) 276:320-327
page 24 of 168
Stingl-H, Schnedl-WJ, Krssak-M, Bernroider-E, Bischof-MG, Lahousen-T, Pacini-G, RodenM. Reduction of Hepatic Glycogen Synthesis and Breakdown in Patients with Agenesis of the
Dorsal Pancreas. Journal of Clinincal Endocrinology and Metabolism (2002) 87: 4678-4685
Anderwald-C, Bernroider-E, Krssak-M, Stingl-H, Brehm-A, Bischof-MG, Nowotny-P,
Roden-M, Waldhusl-W. Effects of Insulin Treatment in Type 2 Diabetec Patients on
Intracellular Lipid Content in Liver and Skeletal Muscle. Diabetes (2002) 51: 3025-3032
Artwohl-M, Graier-W, Roden-M, Bischof-M, Freudenthaler-A, Waldhusl-W, BaumgartnerParzer-S. Diabetic Low-densitiy Lipoprotein Triggers Apoptosis in Vascular Endothelial
Cells. Diabetes (2003) 52:1240-1247
Cauza-E, Hanusch-Enserer U, Bischof M, Spak-M, Kostner-K, Dunky-A, Ferenci-P.
Increased C282Y Heterozygosity in Gestational Diabetes. Fetal Diagnosis and Therapy (2005)
20:349-354
Weghuber-D, Roden-M, Franz-C, Chmelik-M, Torabia-S, Nowotny-P, Gruber-S, WaldhuslW, Klingler-A, Bischof-M, Widhalm-K. Insulin resistance, but not obesity determines fatty
liver in obese children. Submitted for publication.
Zauner-A, Nimmerrichter-P, Anderwald-C, Bischof-M, Schiefermeier-M, Ratheiser-K,
Schneeweiss-B, Zauner-C. Severity of insulin resistance in critically ill medical patients.
Submitted for publication.
page 25 of 168
Olaf A. BODAMER
Dept. General Paediatrics
olaf.bodamer@meduniwien.ac.at
Mechanisms of prematurity - the potential role of genetic and metabolic

factors
Abstract
Preterm delivery is the worldwide leading cause of infant mortality and morbidity. In the
United States of America between 7 and 8% of live born newborn infants have a birth weight
of 2500 g. About 20% of these weigh 1500 g or less and are mostly born prematurely. The
causes for premature birth and intrauterine growth retardation are closely related and are
multifactorial in origin; many social, environmental, medical and genetic factors have been
suggested. Genetic factors from both mother and fetus probably play a role in determining
gestational length and could confer a possible genetic predisposition towards preterm birth.
Since infections seem to be most prevalent among the identifiable causes of preterm birth, it is
conceivable that genetic factors that predispose to infections may play an important role. A
candidate genetic study focusing on genes that encode cytokines, mediators of apoptosis and
host defense found associations with allelic variants in the genes for interleukin 4 and 10 (IL4,
IL10), the tumor necrosis factor alpha (TNF), and the mannose-binding lectin gene (MBL2).
The possible genetic context between infection, inflammation and preterm delivery is also
supported by other findings, in particular for IL4 and TNF. In addition, genetic and dietary
factors conferring metabolic perturbations, such as low cholesterol during early pregnancy
have been associated with adverse outcome including prematurity.
The objectives of our research are twofold: First to identify novel genetic and metabolic
factors that are associated with prematurity and, secondly, to identify and test appropriate
mouse models of prematurity with respect to novel therapeutic approaches.
Thesis Subjects)
Arginine:glycine amidinotransferase (AGAT) knock-out mice - a model for prematurity and
perinatal asphyxia?
The role of genetic factors for the pathophysiology of prematurity - prospective multi-center,
multi-national study.

Mouse model of AGAT deficiency; phenotypic characterization of mice; primary tissue
cultures; enzymatic analysis; molecular analyses (PCR, dHPLC, sequencing); chip arrays; all
required equipment available.
page 26 of 168
Curriculum Vitae
Olaf BODAMER
Division of Biochemical and Paediatric Genetics, Department of General Paediatrics, Medical
University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria Phone +43 1 40400
3210; Fax +43 1 4063484; Email olaf.bodamer@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
25.03.1963
Stuttgart, Germany
Germany
Education
2005
Specialist in Human Genetics (Medizinische Biologie)
2001 present
1999
1999
1997-1999
1997
1994 - 1997
1989 1992
1982 1989
1974 1982
Career History
2004 present
2004 present
2002 present
2002
Specialist in Inborn Errors of Metabolism

Specialist in Paediatrics
American Board Certification in Medical Genetics
Fellowship Medical Genetics, Baylor College of Medicine,
Houston, USA
Educational Commission for Foreign Medical Graduates
(ECFMG) test passed
PhD Studies at the University College London, UK
Doctoral thesis MD at the University Medical School
Heidelberg and Saarland
Studies of Human Medicine at the University of
Heidelberg, Germany
secondary school in Stuttgart, Germany
Director of the Austrian National Screening Program

Director of Biochemical and Paediatric Genetics at the
Department of General Paediatrics, Medical University of
Vienna.
Associate Professor at the Department of General
Paediatrics, Medical University of Vienna. Consultant at
the Childrens Hospital Mdling and Prayer Childrens
Hospital Vienna
venia docendi for Paediatrics
page 27 of 168
2001-present
Elected Fellow of the American College of Medical

Genetics
1999-2001
Assistant Professor at the Department of Human and

Molecular Genetics, Baylor College of Medicine, Houston,
USA
1997 1999
Fellow at the Department of Human and Molecular Genetics,

Baylor College of Medicine, Houston, USA
1994 1999
1992 1993
Senior Research Associate at the Institute of Child Health,

London, UK
University Assistant at the Division of Paediatric Oncology
and Haematology, Univ.-Childrens Hospital Erlangen,
Germany
1989 1992
Doctoral thesis at the University Medical School Heidelberg and

Saarland
1989 1992
Assistant Childrens Hospital Ludwigshafen, Germany and

different private practices
2001 present
Director of quality management at the Division of Biochemical

and Paediatric Genetics, Medical University Vienna
2003 present
2003 present
Awards
2005
2001
1988
Director of the interdisciplinary working group at the

University Childrens Hospital Vienna
Director of the National Metabolic Registry
Wissenschaftspreis sterreichische Gesellschaft fr

Kinder- und Jugendheilkunde
Travel award Society of Inbron Errors of Metabolism USA
Stipend of the DAAD (Deutscher Akademischer
Auslandsdienst)
Memberships
Deutsche Gesellschaft fr Kinderheilkunde
Society for the Study of Inborn Errors of Metabolism
British Inherited Metabolic Group, England
American Society of Human Genetics
American College of Medical Genetics
sterreichische Gesellschaft fr Humangenetik
International Society for Neonatal Screening
page 28 of 168

Period
Organization
Short Title
K/yr
2007
2009
Navi Mumbai Institue Incidence of Inborn Errors of Metabolism in

of Research in Mental India
and Neurological
Handicap
7,5
2007
2009
Ministry of Science
67
2006
2010
Ministry of Health
Neonatal Screening for Lysosomal storage

disorders
2006
2007
Cytonet
Hepatocytes and ureacycle function
16
Threonine Metabolism in individuals with
18
Diagnostic strategies for the molecular diagnosis

of Lysosomal storage disorders
2006 - 2007 Milupa
207
phenylketonuria
2004 - 2009 Genzyme
42
Morbus Fabry, Development of a novel method

for neonatal screening for lysosomal
2004 - 2008 SHS GmbH
Development of analytical techniques
46
2002
2004
Neonatal screening for disorders of steroid
63
Austrian National
Bank (#9572)
genesis

Name
Title of thesis
Period (expected)
Karin Tuschl therapeutic effects of oral
Acad.
Title
2001 - 2004
MD
Haploid Protein Expression Test
2001 - 2004
MD
Homocysteine and Methionine

Metabolism using stable isotopes
2004 - 2007
MD
Tetrahydrobiopterin in patients with

classical phenylketonuria-a stable
isotope study
Rene
Ratschmann
Yvonne
Sommer
Karin Tuschl Stipend Metabolicum ( 15.000)
2004
Denise
Rauter
Maternal PKU
2002 - 2003
Mag.
Manuela
Epigenetics and Methylation
2004 2006
MD
Hiess
page 29 of 168
Dimitri
Tandem MS Screening
2005 - 2007
MD
CDGIK a novel disorder of

glykosylation
2005 -
PhD
2006 -
PhD
2007 -
PhD
Saliabis
Julia
Vodopiutz
Furhan Iqbal AGAT Mousemodel

Ana Ki
Genetics of prematurity
Publications
61 and 10 peer reviewed publications and reviews, resp., in scientific journals,
53 invited lectures,
Y. Estrov, F. Scaglia, O.A.F. Bodamer. Psychiatric symptoms in inborn errors of metabolism.
J Inher Met Dis 2000; 23:2-6. (Review)
O.A.F. Bodamer, A.Vellodi. Protein, glucose and energy metabolism in Gaucher disease type
I. J Inher Met Dis 2000; 23:86-87.
F. Feillet, O.A.F. Bodamer, S. Sequeira, M. Dixon, J.V.Leonard. Resting energy expenditure
in disorders of propionate metabolism. J. Ped 2000; 136:659-663.
O.A.F. Bodamer, D.Halliday, J.V. Leonard. The effects of L-alanine supplementation in lateonset glycogen storage disease type II. Neurology 2000; 55:710-712.
O.A.F Bodamer, D. Halliday. Uses of stable isotopes in clinical diagnosis and research in the
pediatric population. Arch Dis Child 2001; 84:444-448. (Review)
O.A.F. Bodamer, D.S. Rosenblatt, S.H. Appel, A.L. Beaudet. Late-onset combined
homocystinuria and methylmalonic aciduria (cblC). Neurology 2001; 56:1113.
O.A.F. Bodamer, E.J. Popek, C.A. Bacino. Atypical presentation of amniotic band syndrome.
Am J Med Gen 2001; 100:100-102.
O.A.F. Bodamer, R.M. Bravermann, W.J. Craigen. Diagnosis of autosomal recessive
osteopetrosis: presence of fractures in a 3-month old female. J Paed Child Health
2001; 37:520-522.
O.A.F. Bodamer, S.M. Bloesch, A. Gregg, S. Stckler-Ipsiroglu, W.E. OBrien. Analysis of
guanidinoacetate and creatine by isotope dilution electrospray tandem mass-spectrometry.
Clin Chim Acta 2001; 308:173-178.
O.A.F. Bodamer, E. Wraith, CR Scott, F. Scaglia. A New Variant Type III (Type IIID)
Gaucher Disease Characterized by Dysmorphic Features, Absence of Cardiovascular
Involvement, and Compound Heterozygosity for a Novel Mutation (D409H/C16S) Am J
Med Genet 2002; 109:328-31.
D.L. Smith, O.A.F. Bodamer. Practical management of combined MMA / homocystinuria
(cblC).
J
Child
Neurol.
2002;
17:353-6.
(Review)
O.A.F. Bodamer, D. Mslinger, A. Mhl und S. Stckler-Ipsiroglu. Neugeborenen-screening
in sterreich: Bestandsaufnahme, Neuentwicklungen und Zukunftsperspektiven. Pdiat
Prax 2002; 61:539-549.
O.A.F. Bodamer, D. Haas, M.M.P. Hermans, A.J.J. Reuser, J.V. Leonard, G.F. Hoffmann.
Long-term management of childhood/non-classical infantile Glycogen Storage Disease
Type II (GSD-II) with oral L-alanine supplementation. Ped Neurol 2002; 27:145-147.
page 30 of 168
O.A.F. Bodamer, F. Feillet, R.E. Lane, P.J. Lee, M.A. Dixon, D. Halliday, J.V. Leonard.
Utilisation of cornstarch in glycogen storage disease type Ia. Europ J Gastroenterol
Hepatol 2002; 14:1251-1256.
O.A.F. Bodamer, D. Bercovich, M. Schlabach, C. Ballantyne, D. Zoch, A.L. Beaudet. Use of
Denaturing HPLC to provide efficient detection of mutations causing familial
hypercholesterolemia. Clin Chem 2002; 48:1913-1918.
K. Hussein*, O.A.F. Bodamer*, F.J. Cameron, C. Camacho-Hubner, M.A. Soos, J. Jones, F.
Taylor, S. ORahilly, A. Aynsley-Green. A new syndrome of hemihypertrophy and severe
non-ketotic hypoglycaemia without hyperinsulinism in childhood. Hormone Research
2004; 61:222-227. *joint first author
O.A.F. Bodamer, R. Ratschmann, E. Paschke, T. Voigtlnder, S. Stckler-Ipsiroglu
Recurrent acroparesthesia during febrile infections in a 9 year-old male. Lancet
2004; 363:1698.
O.A.F. Bodamer, S. Gruber, S. Stckler-Ipsiroglu. Nuclear magnetic resonance spectroscopy
in GCDH deficiency. JIMD 2004; 27:877-883.
K. Tuschl, O.A.F. Bodamer, W. Erwa, A.Mhl. Novel Method for Rapid Analysis of Total
Plasma Homocysteine by Tandem Mass Spectrometry. Clin Chim Acta 2005; 351:139-41.
K. Tuschl, A. Gal, E. Paschke, S. Kircher, S., O.A.F. Bodamer. Mucopolysaccharidosis type
II in females case report and review of literature. Ped Neurol 2005; 32:270-272.
M. Holub, L. Potocki, O.A.F. Bodamer. Oral-Facial-Digital Syndrome Type 1: Review of
Cerebral Malformations. Am J Med Genet 2005; 136:218? (Review).
O.A.F. Bodamer, A. Mhl. Analysis of acylcarnitine ester for the diagnosis of inborn errors of
metabolism using tandem mass-spectrometry. Chem Month 2005; 136:1293-1297.
O.A.F. Bodamer. Genetische Polymorphismen und Prdisposition. Pdiatrie Pdiologie 2005;
1:27-31. (Review).
O.A.F. Bodamer, T Sahoo, A Beaudet, W OBrien, L Sweetman, T Bottiglieri, C Wagner, F
Scaglia. Evidence for impaired creatine synthesis in patients with combined
methylmalonic aciduria and homocystinuria (cblC) new pathomechanism and rationale
for treatment of disorders of remethylation? Annals of Neurol 2005; 57:557-560.
R. Ratschmann, O.A.F. Bodamer. Genetische Polymorphismen und Prdisposition. Pd. Prax
2005; 66:659-664. (Review).
CB. Item, S. Stckler-Ipsiroglu, C. Willheim, A. Mhl, O.A.F. Bodamer. Use of Denaturing
HPLC to provide efficient detection of mutations causing guanidinoacetate
methyltransferase deficiency. Mol Genet Metab 2005; 86:328-334.
O.A.F. Bodamer, M. Beck, M. Weigl. MPS-I. Iatros Pdiatrie 2005. (Review)
O.A.F. Bodamer, K Hussein, AA Morris, C-D Langhans, D Rating, E Mayatepek, JV
Leonard. Glucose and leucine kinetics in children with idiopathic ketotic hypoinsulinaemic
hypoglycaemia. Arch Dis Child 2006;91:483-6
O.A.F. Bodamer, W. Maurer, G. Mitterer, M.W. Mueller, A. Pollak, W.M. Schmidt.
Mannose-binding lectin (MBL2) polymorphisms and the risk of preterm birth. Genetics in
Medicine 2006;8:518-524
M. Holub, K. Tuschl, R. Ratschmann, K. Strnadova, W. Sperl, A. Mhl, G. Heinze, O.A.F.
Bodamer. Influence of hematokrit and localisation of punch in dried blood spots on levels
of amino acids and acylcarnitines measured by tandem mass spectrometry. Clin Chim Acta
2006;373:27-31
K. Strnadova, M. Holub, A. Mhl, K. Tuschl, F. Waldhauser, O.A.F. Bodamer. Long-term
stability of amino acids and acylcarnitines in dried blood spots used for neonatal screening
by tandem mass spectrometry. Clin Chem 2007;53:717-722
page 31 of 168
K. Tuschl, M. Holub, M. Herle, B. Fritz, R. Stindl, C. Fonatsch, O.A.F. Bodamer. Trisomy

1q42.3-qter and monosomy 21q22.3-qter associated with ear anomaly, facial dysmorphism,
psychomotor retardation and epilepsy. Am J Med Genet 2007 (accepted).
M. Freilinger, D. Kalisch, A. Mhl, O. Haas, A. Moritz, O.A.F. Bodamer. Methylation status
in females with Rett syndrome. J Child Neurol 2007(accepted).
J. Vodopiutz, C.B. Item, M. Husler, H. Korall, O.A.F. Bodamer. Severe speech delay as
presenting symptom of guanidinoacetate methyltransferase deficiency. J Child Neurol
2007 (accepted).
O.A. Bodamer, G.F. Hoffmann, M. Lindner. Expanded Newborn Screening in Europe in
2007. JIMD 2007 (accepted).
F. Scaglia, V.R. Sutton, O.A.F. Bodamer, S.K. Shapira. Mitochondrial DNA depletion. J
Child Neurol 2001; 16:136-138.
S.A. Berend, O.A.F. Bodamer, S.K. Shapira, L.G. Shaffer, C.A. Bacino. A familial complex
chromosomal rearrangement resulting in a recombinant chromosome. Am J Med Genet
2002; 109:311-7.
C.B. Item, C. Stromberger, A. Muhl, C. Edlinger, O.A.F. Bodamer, A. Schulze, R. Surtees, V.
Leuzzi, G.S. Salomons, C. Jakobs, S. Stckler-Ipsiroglu. Denaturing gradient gel
electrophoresis for the molecular characterization of six patients with guanidinoacetate
methyltransferase deficiency. Clin Chem 2002; 48:767-9.
C. Stromberger, O.A.F. Bodamer, S. Stckler-Ipsiroglu. Clinical characteristics and
diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis. 2003;26:299308. (Review).
J. Crone, D. Moslinger, O.A.F. Bodamer, W. Schima, WD Huber, E Holme, S. Stockler
Ipsiroglu. Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a
child with tyrosinaemia type I. Acta Paediatr. 2003; 92:625-8.
M. Orendac, J. Zeman, S.P. Stabler, R.H. Allen, J.P. Kraus, O.A.F. Bodamer, S. StcklerIpsiroglu, V. Kozich. Homocystinuria due to cystathionine -synthase deficiency: novel
biochemical findings and treatment efficacy JIMD 2003; 26:761-773.
C.B. Item, S. Mercimek-Mahmutoglu, R. Battini, C. Edlinger-Horvat, C. Stromberger, O.A.F.
Bodamer, A. Mhl, M.A. Vilaseca, H. Korall, S. Stckler-Ipsiroglu. Characterisation of 7
novel mutations in seven patients with GAMT deficiency. Hum Mut 2004; 23:524-530.
M. Holub, O.A.F. Bodamer, C. Item, A. Mhl, A. Pollak, S. Stckler-Ipsiroglu. Correlation
between disorders of fatty acid oxidation and HELLP syndrome? Acta Paediat 2005;
94:48-52.
G. Mitterer, O.A.F. Bodamer, C. Harwanegg, W. Maurer, M.W. Mueller, W.M. Schmidt.
Performance of Microarray Based SNP Detection in a Routine Clinical Setting. Gene
Testing 2005; 9:6-13.
S. Klkens, I. Harting, S. Sauer, A. Schulze-Bergkamen, J. Zschocke, G. F. Hoffmann, S.
Gruber, O. A. F. Bodamer, S. Klker. Late-onset neurologic disease in two patients with
glutaryl-CoA dehydrogenase deficiency. Neurology 2005; 64:2142-2144.
M. Huemer, B. Fowler, O.A.F. Bodamer, T. Suormala, B. Simma, J.O. Sass. Pre- and
postnatal treatment in the cblC defect. J Pediatr. 2005; 147:469-472.
K.A. Strnadov, F. Votava, J. Lebl, A. Mhl, C. Item, O.A.F. Bodamer, T. Torresani,
Bouka, F. Waldhauser, W. Sperl. Prevalence of congenital adrenal hyperplasia and inborn
errors of metabolism among sudden infant death in two Middle European countries:
A retrospective analysis. Europ J Ped 2007;166:1-4
S.Fischer, G. Mann, M. Konrad, M. Metzler, G. Ebetsberger, N. Jones, B. Nadel,
page 32 of 168
O. A. Bodamer, O. Haas, K. Schmitt, E. Panzer-Grunmeyer. Lack of leukemia-and clone

Specific markers at birth in children with T cell precursor ALL suggests a predominantly
postnatal origin. Blood 2007 Jun 8; (print)
page 33 of 168
Wilfred DRUML
Clinical Division of Nephrology and Dialysis, Department of Internal Medicine III
wilfred.druml@meduniwien.ac.at
Curriculum Vitae
Name:
Home address:
31. 7. 1949
1969 - 1972
1972 - 1975
1975
1975 - 1991
1982
1985 - 1987
1986
1986 - 1987
1987
1987
1991
since 1991
1995
Prof. Dr. med. Wilfred Johannes DRUML

married with Mrs. Dr. jur. Christiane Druml
3 children (Hephzibah 22, Zino 20, Carl 16)
Gottfried Keller-Gasse 13, A-1030 Vienna, Austria
born in Mauthen/ Carinthia, Austria
Medical training (preclinical part) in Innsbruck, Austria
Medical training (clinical part) Vienna, Austria
Graduation; MD
Residence/ fellow in medicine, Department of Internal Medicine I,
University of Vienna, Austria
Borad certification Internal Medicine
Postdoctoral research fellow Harvard University, Boston, USA
US-certification (ECFMG)
Medical Fellow, Harvard University
(Brigham and Womens Hospital) Boston
Board Certification in Austria : Nephrology
Associate Professor of Medicine
Professor of Medicine, Tenure
Director, Nephrology Intensiv Care Programme
Vienna General Hospital, Vienna, Austria
Board certification: Intensive Care Medicine
Research Focus : Metabolism and nutrition in the critically ill, in patients with renal failure,
development of the first dipeptide-containing amino acid solution worldwide and of many
nutritional programs, intravenous lipids, acute renal failure, continuous renal replacement
therapies, general infusion therapy.
Society (Founding) Member /Officer : Austrian Society of Clinical Nutrition
(AKE)(president, responsible for publication of nutritional recomendations), Austrian
Society of Medical Intensive Care Medicine (president, responsible for consensus reports)
European, Society of Parenteral and Enteral Nutrition, European Society of Intensive Care
Medicine
Congress Organization : Numerous national and international seminars and workshops in
the field of intensive care medicine, clinical nutrition, of acute renal failure
Editor, Editorial Board : Editor-in-Chief of Wiener klinische Wochenschrift (The Middle
European Journal of Medicine),
founder and editor-in-chief of an intensive care newsletter (INTENSIV-News), editorial
board of several national and international journals
Manuscript Reviewer: Regular reviewer for the major journals in the fields of clinical
nutrition, of nephrology and intensive care medicine.
page 34 of 168
Manuela FDINGER
Clinical Institute of Medical and Chemical Laboratory Diagnostics
manuela.foedinger@meduniwien.ac.at
Effect of iron therapy on cellular iron homeostasis - safety of iron therapy?

Abstract
Most patients with chronic renal failure must receive erythropoietic agents and iron to
maintain a hemoglobin level above 11 g/dL. Intravenous iron is more effective than oral iron
substitution. Intravenously iron is mainly supplied as iron sucrose and iron gluconate.
However, non-transferrin bound labile iron can produce side effects possibly by affecting
endothelial cells, polymorphonuclear leukocytes and cytokines. Moreover, labile iron may act
as a catalytic agent in the formation of hydroxyl radicals, and could hence contribute to cell
damage. Therefore, iron must be carefully administered intravenously, particularly when
supplied in high doses.
Data in the literature suggest that iron is an important factor in the process of atherosclerosis,
but exact mechanisms are still unknown. The iron hypothesis suggests that iron depletion
protects against ischemic heart disease. Furthermore, iron promotes bacterial growth and thus
is potentially related to infectious complications.
End-stage renal disease patients require iron therapy to benefit from treatment with
recombinant human erythropoietin or novel erythropoiesis stimulating proteins. Monitoring of
iron status in these patients includes the determination of the percentage of hypochromic red
blood cells and/or the reticulocyte hemoglobin content, in addition to ferritin serum
concentration and transferrin saturation.
Concerning safe and optimal correction of renal anemia by intravenous iron therapy the
principal questions are to be answered are the following: Does intravenous iron application
indeed contribute to 1) atherogenesis, 2) infectious disease, and 3) cell damage?
A first step to clarify these issues is to identify genes that are responsive to intravenous iron
therapy (i.e. up- or down-regulated genes). This is to be accomplished by using gene
expression microarrays in cells isolated from chronic renal failure patients that have received
intravenous iron or not. Identification of genes regulated by iron therapy will provide basic
information to support or reject the hypothesis of an involvement of iron in atherogenesis,
infections, and cell damage.
Thesis Subjects
Effects of intravenous iron therapy on gene expression in human cells
Molecular effects of intravenous iron therapy on oxidative stress in human cells

Cell culture, isolation of RNA, microarray analysis; quantitative real-time PCR; all required
equipment available.
page 35 of 168
Curriculum Vitae
Manuela FDINGER
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of
Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; Phone +43 1 40400 5388; Fax
+43 1 40400 6752; Email manuela.foedinger@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
09.02.1964
Steyr, Austria
Austria
Education
1997 present
specialist in Laboratory Medicine
1990
1982 1990
1974 1982
International Diploma of Tropical Medicine

secondary school
Career History
2004 present
2000 present
2000
1992 - present
1991 - 1992
2001 2002
Head of the section Molecular Endocrinology,

Pharmacology & Metabolism and medical head of the
division Endocrinology at the Clinical Institute of
Medical and Chemical Laboratory Diagnostics
associate Professor at the Clinical Institute of Medical and
Chemical Laboratory Diagnostics, Medical University of
Vienna
venia docendi for Laboratory Medicine
University Assistant, Clinical Institute of Medical and
Chemical Laboratory Diagnostics, Medical University of
Vienna
Research fellow at the Institute of General and
Experimental Pathology and the Institute of Specific
Prophylaxis and Tropical Medicine at the (Medical)
University of Vienna
Postgraduate University Course for Medical Leaders at the

University of Salzburg
page 36 of 168
2004
Section leader "Science and Development", Austrian

Society for Clinical Chemistry
Awards
2001
ERA-EDTA Award of the European Dialysis and

Transplantation Association
Preis der sterreichischen Gesellschaft fr Nephrologie
Award der National Kidney Foundation
Young Investigator Award of the American Society of
Transplant Physicians
Best Scientific Abstract of the International Society of
Peritoneal Dialysis
Preis der sterreichischen Gesellschaft fr Labormedizin
1999
1998
1996
Memberships

Austrian Society for Laboratory Medicine and Clinical Chemistry
Austrian Society for Good Analyses and Laboratory Praxis
Society for Nephrology
Period
Organization
Short Title
K/yr
1998
2001
Else-KrnerFresenius-Stiftung,
Germany
Effect of homocysteine on vascular

endothelial cells
17.9

Name
Title of thesis
Period (expected)
Acad.Title
Anita Jallitsch
Molecular background of
Anderson-Fabry disease
2007 (2009)
(Dr. scient.
med.)
Publications
2 editorials, 3 book contributions
Sunder-Plassmann G, Winkelmayer WC, Fdinger M. 2006. Genetic aspects of
page 37 of 168
hyperhomocysteinemia in chronic kidney disease. Semin Nephrol. 26:8-13. (review)

Winkelmayer WC, Kramar R, Sunder-Plassmann G, Fdinger M. 2005. Effects of singlenucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney
transplant recipients. Kidney Int. 68:2857-62.
Winkelmayer WC, Huber A, Wagner OF, Hrl WH, Sunder-Plassmann G, Fdinger M. 2005.
Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin
B in kidney transplant recipients. Kidney Int. 67:1980-5.
Lorenz M, Kletzmayr J, Huber A, Hrl WH, Sunder-Plassmann G, Fdinger M. 2005.
Ironoverload in kidney transplants: prospective analysis of biochemical and genetic markers.
Kidney Int. 67:691-7.
Fritsche-Polanz R, Wallner M, Cohen G, Eberle C, Sunder-Plassmann G, Fdinger M.
2004.Granulocyte function in patients with L-ferritin iron-responsive element (IRE) 39C-->Tpositive hereditary hyperferritinaemia-cataract syndrome. Eur J Clin Invest. 34:701-8.
Sunder-Plassmann G, Fdinger M. 2004. Underuse of Hardy-Weinberg equilibrium. Kidney
Int. 66:1711. (letter)
Winkelmayer WC, Sunder-Plassmann G, Huber A, Fdinger M. 2004. Patterns of cooccurrence of three single nucleotide polymorphisms of the 5,10 methylenetetrahydrofolate
reductase gene in kidney transplant recipients. Eur J Clin Invest. 2004: 613-8.
Feix A, Winkelmayer WC, Eberle C, Sunder-Plassmann G, Fdinger M. 2004. Methionine
synthase reductase MTRR 66A > G has no effect on total homocysteine, folate, and Vitamin
B12 concentrations in renal transplant patients. Atherosclerosis. 2004 174:43-8.
Fdinger M, Sunder-Plassmann G. 2003. Low clinical penetrance of homozygosity for HFE
C282Y: implications for genetic testing? Eur J Clin Invest. 33:737-9. (editorial)
Fdinger M, Veitl M, Skoupy S, Wojcik J, Rohrer C, Hagen W, Puttinger H, Hauser AC,
Vychytil A, Sunder-Plassmann G. 2003. Effect of TCN2 776C>G on vitamin B12 cellular
availability in end-stage renal disease patients. Kidney Int. 64:1095-100.
Winkelmayer WC, Eberle C, Sunder-Plassmann G, Fdinger M. 2003. Effects of the
glutamate carboxypeptidase II (GCP2 1561C>T) and reduced folate carrier (RFC1 80G>A)
allelic variants on folate and total homocysteine levels in kidney transplant patients. Kidney
Int. 63:2280-5.
Fdinger M, Dierkes J, Skoupy S, Rhrer C, Hagen W, Puttinger H, Hauser AC, Vychytil A,
Sunder-Plassmann G. 2003. Effect of glutamate carboxypeptidase II and reduced folate carrier
polymorphisms on folate and total homocysteine concentrations in dialysis patients. J Am Soc
Nephrol. 14:1314-9.
Sunder-Plassmann G, Fdinger M. 2003. Genetic determinants of the homocysteine level.
Kidney Int Suppl. 84:S141-4. (review)
page 38 of 168
Sunder-Plassmann G, Kittler H, Eberle C, Hirschl MM, Woisetschlager C, Derhaschnig U,

Laggner AN, Hrl WH, Fdinger M. 2002. Angiotensin converting enzyme DD genotype is
associated with hypertensive crisis. Crit Care Med. 30:2236-41.
Sunder-Plassmann G, Fdinger M. 2002. Cost-effectiveness of homocysteine-lowering
therapy to prevent coronary heart disease. JAMA. 287:190. (letter)
Trndle U, Sunder-Plassmann G, Burgmann H, Buchmayer H, Kramer L, Bieglmayer C, Hrl
WH, Fdinger M. 2001. Molecular and clinical characterisation of homocystinuria in two
Austrian families with cystathionine beta-synthase deficiency. Acta Med Austriaca 28:145-51.
Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Hrl WH, Sunder-Plassmann G,
Fdinger M. 2001. Increased prevalence of combined MTR and MTHFR genotypes among
individuals with severely elevated total homocysteine plasma levels. Am J Kidney Dis.
38:956-64.
Fdinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayr J, Perschl A, Vychytil
A, Hrl WH, Sunder-Plassmann G. 2001. Association of two MTHFR polymorphisms with
total homocysteine plasma levels in dialysis patients. Am J Kidney Dis. 38:77-84.
Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, Fdinger M.
2001. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without
mastocytosis and cases of systemic mastocytosis. Br J Haematol. 113:357-64.
Fdinger M, Sunder-Plassmann G. 2001. Increased cysteine plasma levels in kidney
transplants: a potential vascular disease risk factor? Transplantation. 71:713-5.
Fdinger M, Wagner OF, Hrl WH, Sunder-Plassmann G. 2001. Recent insights into the
molecular genetics of the homocysteine metabolism. Kidney Int Suppl. 78:S238-42. (review)
Sunder-Plassmann G, Winkelmayer WC, Fdinger M. 2000. Therapeutic potential of total
homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 9:263751. (review)
Buchmayer H, Sunder-Plassmann G, Hirschl MM, Kletzmayr J, Woisetschlager C, Laggner
AN, Hrl WH, Fdinger M. 2000. G-protein beta3 subunit gene (GNB3) polymorphism 825C->T in patients with hypertensive crisis. Crit Care Med. 28:3203-6.
Fdinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayr J, RasoulRockenschaub S, Hrl WH, Sunder-Plassmann G. 2000. Effect of MTHFR 1298A-->C and
MTHFR 677C-->T genotypes on total homocysteine, folate, and vitamin B(12) plasma
concentrations in kdiney graft recipients. J Am Soc Nephrol. 11:1918-25.
Floth A, Sunder-Plassmann G, Fdinger M. 2000. Polymerase chain reaction amplification of
bacterial 16s rRNA in biopsy samples. Urology. 55:788-9. (letter)
Sunder-Plassmann G, Floth A, Fdinger M. 2000. Hyperhomocysteinemia in organ
transplantation. Curr Opin Urol. 10:87-94. (review)
page 39 of 168
Fdinger M, Fritsche-Polanz R, Buchmayer H, Skoupy S, Sengoelge G, Hrl WH, SunderPlassmann G. 2000. Erythropoietin-inducible immediate-early genes in human vascular
endothelial cells. J Investig Med. 48:137-49.
Fdinger M, Hrl WH, Sunder-Plassmann G. 2000. Molecular biology of 5,10methylenetetrahydrofolate reductase. J Nephrol. 13:20-33. (review)
Steiner S, Winkelmayer WC, Kleinert J, Grisar J, Seidinger D, Kopp CW, Watschinger B,
Minar E, Hrl WH, Fdinger M, Sunder-Plassmann G. 2006. Endothelial progenitor cells in
kidney transplant recipients. Transplantation. 81:599-606.
Schaeffner ES, Fdinger M, Kramar R, Frei U, Hrl WH, Sunder-Plassmann G, Winkelmayer
WC. 2006. Prognostic associations between lipid markers and outcomes in kidney transplant
recipients. Am J Kidney Dis. 47:509-17.
Lechner K, Fdinger M, Grisold W, Puspok A, Sillaber C. 2005. Vitamin B12 deficiency.
New data on an old theme. Wien Klin Wochenschr. 117:579-91. (review)
Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Hrl WH, Fdinger
M, Sunder-Plassmann G, Vychytil A. 2005. Intravenous iron increases labile serum iron but
does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 68:2814-22.
Tylicki L, Fdinger M, Puttinger H, Rutkowski P, Strozecki P, Tyszko S, Rutkowski B, Hrl
WH. 2005. Methylenetetrahydrofolate reductase gene polymorphisms in essential
hypertension relation: with the development of hypertensive end-stage renal disease. Am J
Hypertens. 18:1442-8.
Hauser AC, Gessl A, Lorenz M, Voigtlander T, Fdinger M, Sunder-Plassmann G. 2005. High
prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit
Metab Dis. 28:715-22.
Krokowski M, Sotlar K, Krauth MT, Fdinger M, Valent P, Horny HP. 2005. Delineation of
patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25,
correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J
Clin Pathol. 124:560-8.
Steiner S, Schaller G, Puttinger H, Fdinger M, Kopp CW, Seidinger D, Grisar J, Hrl WH,
Minar E, Vychytil A, Wolzt M, Sunder-Plassmann G. 2005. History of cardiovascular disease
is associated with endothelial progenitor cells in peritoneal dialysis patients. Am J Kidney Dis.
46:520-8.
Valent P, Arock M, Bischoff SC, Buhring HJ, Brockow K, Escribano L, Fdinger M, Grabbe
J, Hartmann K, Henz BM, Horny HP, Kluin-Nelemans HC, Lima M, Marone G, Orfao A,
Parwaresch RM, Sillaber C, Sotlar K, Sperr WR, Triggiani M, Van Doormaal JJ, Wolff K,
Zuberbier T. 2004. The European Competence Network on Mastocytosis (ECNM). Wien Klin
Wochenschr. 116:647-51.
page 40 of 168
Kleinert J, Lorenz M, Hauser AC, Becherer A, Staudenherz A, Fdinger M, SunderPlassmann G. 2005. Measurement of renal function in patients with Fabry disease. Acta
Paediatr Suppl. 94:19-23.
Florian S, Krauth MT, Simonitsch-Klupp I, Sperr WR, Fritsche-Polanz R, Sonneck K,
Fdinger M, Agis H, Bohm A, Wimazal F, Horny HP, Valent P. 2005. Indolent systemic
mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe
anaphylactoid episodes. Int Arch Allergy Immunol. 136:273-80.
Huemer M, Huemer C, Ulmer H, Crone J, Fdinger M, Falger J, Sailer-Hock M. 2005. No
evidence for hyperhomocysteinemia or increased prevalence of genetic polymorphisms in the
homocysteine pathway in patients with moderate juvenile idiopathic arthritis. J Rheumatol.
32:170-4.
Valent P, Akin C, Sperr WR, Mayerhofer M, Fdinger M, Fritsche-Polanz R, Sotlar K,
Escribano L, Arock M, Horny HP, Metcalfe DD. 2005. Mastocytosis: pathology, genetics, and
current options for therapy. Leuk Lymphoma. 46:35-48. (review)
Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G, Fdinger
M, Fonatsch C, Simonitsch-Klupp I, Kalhs P, Valent P. 2005. Myelomastocytic leukemia:
evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic
stem cell transplantation. Clin Cancer Res. 11:6787-92.
Winkelmayer WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fdinger M, Hrl WH,
Sunder-Plassmann G. 2005. Fasting plasma total homocysteine levels and mortality and
allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol. 16:25560.
Kleinert J, Hauser AC, Lorenz M, Fdinger M, Sunder-Plassmann G. 2004. Therapy of Fabry
disease. Kidney Int. 66:1288. (letter)
Sengoelge G, Rainer V, Kletzmayr J, Jansen M, Derfler K, Fdinger M, Hrl WH, SunderPlassmann G. 2004. Dose-dependent effect of parenteral iron therapy on bleomycin-detectable
iron in immune apheresis patients. Kidney Int. 66:295-302.
Winkelmayer WC, Lorenz M, Kramar R, Fdinger M, Hrl WH, Sunder-Plassmann G. 2004.
C-reactive protein and body mass index independently predict mortality in kidney transplant
recipients. Am J Transplant. 4:1148-54.
Lorenz M, Wolzt M, Weigel G, Puttinger H, Hrl WH, Fdinger M, Speiser W, SunderPlassmann G. 2004. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in
kidney transplant patients. Am J Kidney Dis. 43:1098-103.
Wimazal F, Schwarzmeier J, Sotlar K, Simonitsch I, Sperr WR, Fritsche-Polanz R, Fdinger
M, Schubert J, Horny HP, Valent P. 2004. Splenic mastocytosis: report of two cases and
detection of the transforming somatic C-KIT mutation D816V. Leuk Lymphoma. 45:723-9.
Hauser AC, Lorenz M, Voigtlander T, Fdinger M, Sunder-Plassmann G. 2004. Results of an
ophthalmologic screening programme for identification of cases with Anderson-Fabry disease.
Ophthalmologica. 218:207-9.
page 41 of 168
Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada

M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner
M, Wieser C, Wiesholzer M, Zodl H, Fdinger M, Sunder-Plassmann G. 2004. Results of a
nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol.
15:1323-9.
Winkelmayer WC, Skoupy S, Eberle C, Fdinger M, Sunder-Plassmann G. 2004. Effects of
TCN2 776C>G on vitamin B, folate, and total homocysteine levels in kidney transplant
patients. Kidney Int. 65:1877-81.
Vychytil A, Fdinger M, Pleiner J, Mullner M, Konner P, Skoupy S, Rhrer C, Wolzt M,
Sunder-Plassmann G. 2003. Acute effect of amino acid peritoneal dialysis solution on vascular
function. Am J Clin Nutr. 78:1039-45.
Sengoelge G, Kletzmayr J, Papagiannopoulos M, Bohle B, Hrl WH, Fdinger M, SunderPlassmann G. 2003. TGF-beta1 impairs homocysteine metabolism in human renal cells:
possible implications for transplantation. Transpl Int. 16:843-8.
Jordan JH, Jger E, Sperr WR, Schwarzinger I, Fdinger M, Fritsche-Polanz R, hler L,
Geissler K, Valent P. 2003. Numbers of colony-forming progenitors in patients with systemic
mastocytosis: potential diagnostic implications and comparison with myeloproliferative
disorders. Eur J Clin Invest. 33:611-8.
Huemer M, Fdinger M, Huemer C, Sailer-Hock M, Falger J, Rettenbacher A, Bernecker M,
Artacker G, Kenzian H, Lang T, Stockler-Ipsiroglu S. 2003. Hyperhomocysteinemia in
children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic
acid supplementation: a pilot study. Clin Exp Rheumatol. 21:249-55.
Hauswirth AW, Sperr WR, Ghannadan M, Schernthaner GH, Jordan JH, Fritsche-Polanz R,
Simonitsch-Klupp I, Fdinger M, Lechner K, Valent P. 2002. A case of smouldering
mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res. 26:601-6.
Jordan JH, Schernthaner GH, Fritsche-Polanz R, Sperr WR, Fdinger M, Chott A, Geissler K,
Lechner K, Horny HP, Valent P. 2002. Stem cell factor-induced bone marrow mast cell
hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic
evaluation with special reference to recently established SM-criteria. Leuk Lymphoma.
43:575-82.
Ignatescu MC, Kletzmayr J, Fdinger M, Bieglmayer C, Hrl WH, Sunder-Plassmann G.
2002. Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. Kidney
Int. 61:1894-8.
Skoupy S, Fdinger M, Veitl M, Perschl A, Puttinger H, Rohrer C, Schindler K, Vychytil A,
Hrl WH, Sunder-Plassmann G. 2002. Riboflavin is a determinant of total homocysteine
plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol. 13:1331-7.
Hagen W, Fdinger M, Hrl WH, Sunder-Plassmann G. 2001. Therapy of
hyperhomocysteinemia in end-stage renal disease patients. Minerva Urol Nefrol. 53:159-70.
(review).
page 42 of 168
Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Fdinger M, Schernthaner GH,

Christian Bankl H, Gebhart W, Chott A, Lechner K, Valent P. 2001. A case of 'smouldering'
mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp816-Val. Leuk Res. 25:627-34.
Hauser AC, Hagen W, Rehak PH, Buchmayer H, Fdinger M, Papagiannopoulos M,
Bieglmayer C, Apsner R, Koller E, Ignatescu M, Hrl WH, Sunder-Plassmann G. 2001.
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in
hemodialysis patients. Am J Kidney Dis. 37:758-65.
Hagen W, Fdinger M, Heinz G, Buchmayer H, Hrl WH, Sunder-Plassmann G. 2001. Effect
of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney
transplant recipients. Kidney Int Suppl. 78:S253-7.
Sunder-Plassmann G, Fdinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr
J, Enzenberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Hrl WH.
2000. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis
patients: results of the Vienna multicenter study. J Am Soc Nephrol. 11:1106-16.
Schindler K, Zauner C, Buchmayer H, Fdinger M, Wlfl G, Bieglmayer C, Heinz G, Wilfing
A, Hrl WH, Sunder-Plassmann G. 2000. High prevalence of hyperhomocysteinemia in
critically ill patients. Crit Care Med. 28:991-5.
page 43 of 168
Clemens FRNSINN
Dept. Internal Medicine III, Div.Endocrinol.Metab.
clemens.fuernsinn@meduniwien.ac.at
Type 2 diabetes, glucose metabolism, and the role of skeletal muscle.

Abstract
Changes in environment and lifestyle presently cause a worldwide distinct increase in
diabetes mellitus, which is particularly due to increasing numbers of patients afflicted by type
2 diabetes. This disease is strongly associated with sedentary life style and obesity. A better
understanding of the natural etiology and the metabolic disturbances of type 2 diabetes, as
well as the development of new therapeutic strategies and drugs is therefore among the most
important challenges in medical research.
In type 2 diabetes, the predominant cause of increased blood glucose, which defines the
diabetic state, is resistance of target tissues to the actions of insulin, i.e., target tissues
stimulated by the hormone fail to take up an appropriate amount of glucose from circulating
blood. Hence, it is important to understand, how tissue insulin sensitivity is regulated and can
be manipulated. In this regard, skeletal muscle is of particular interest, because muscle is the
quantitatively most important target tissue for insulin-stimulated glucose lowering and
accounts for up to 80% of glucose disposal under insulin-stimulated conditions.
Since many years our research is focused on several aspects of the problem: (i) the description
of antidiabetic potentials of new compounds in the whole organism (experimental animal); (ii)
analysis of the modes and mechanisms of actions of new as well as of established antidiabetic
drugs, particularly with regard to their effects on muscle insulin sensitivity; (iii) the
investigation of mechanisms involved in the physiological regulation of insulin sensitivity,
e.g., via adipocyte-derived hormones.
More specifically, we have studied the role and demonstrated the importance of the cellular
energy state for the long-term modulation of muscle insulin sensitivity. In this context, we
have developed a working hypothesis that a reduced cellular energy load can serve as a
trigger for delayed insulin sensitization leading to an amelioration of deranged glucose
homeostasis ("the energy charge hypothesis of insulin sensitivity").
We are experienced in metabolic studies on whole animals (e.g. rat models for type 2
diabetes) and in the use of native rat soleus muscle strips in a pharmacological setting. The
latter allows to analyze in detail the substrate flux rates through the most important
biochemical pathways of muscle fuel metabolism and can be used for many different
experiments including, e.g., ex vivo as well as in vitro approaches.
Thesis Subjects
Effects of antidiabetic agents on glucose metabolism of rat skeletal muscle in vivo and in
vitro.

Incubation of native rat skeletal muscle strips; analysis of muscle metabolism with
radiolabelled substrates and enzymatic methods; basic methods for animal experimentation;
hormone analysis; Northern and Western blotting; all necessary infrastructure and equipment
available
page 44 of 168
Curriculum Vitae
Clemens FRNSINN
40400 4785; Fax +43 1 40400 7790; Email clemens.fuernsinn@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
6.3.1964
Vienna, Austria
Austria
Education
1982 1990
studies of Biology (zoology/botany)
1970 1982
school
Career History
2000 present
X/1997
1991 present
XI/1993-II/1994
X/1990 V/1991
V/1990 X/1990
3.4.1990
1985
1982
Associate Professor at the Department of Internal Medicine

III, Medical University of Vienna. Basic medical research
on fuel metabolism and antidiabetic agents
venia docendi for Metabolic Physiology
University Assistant at the Clinical Division of
Endocrinology Metabolism, Department of Internal
Medicine III, (Medical) University of Vienna, Austria
4 Months of Research at the Department of Biochemistry
of the University of Oxford, England, UK
Civil Service
University Assistant at the Division of Endocrinology &
Diabetes Mellitus, 1st Medical Department, Vienna
Ph.D. Graduation
7 Months of Research at the Laboratory of Animal
Physiology, University of Groningen, the Netherlands.
Begin of Study of Biology (Zoology/Botany) at the
1998 present2003
Member of the Editorial Board, Diabetologia
Awards
page 45 of 168
1996
Winner of the Poster-Prize at the Diabetes Three Countries

Meeting at Basel, Switzerland (organized by German,
Swiss, and Austrian Diabetes Associations)
1992
Winner of the Award of the HOECHST-Company
Memberships
German Diabetes Society
Sources of funding in last 5 years (2000-2005)
Period
Organization
Short Title
K/yr
2006
2007
FFG (Nr.812095)
Investigation of antidiabetic activities of

established medical plants. (Project Leader:
B.Brunmair)
175
2003
2005
FWF (P16352-B08)
Antidiabetic effects caused by inhibition of

cell respiration?
63
1998
2000
FWF (P13049-MED)
Osmosis, insulin sensitizers, and muscle

glucose metabolism.
31

Name
Title of thesis
Period (expected)
Acad.Title
Susanne Neschen
"Effect of GLP1/GLP1
2000
Dr. rer.
analogues, lithium ions, and

troglitazone on rat glucose
metabolism; University of
Vienna (Zoology)
Barbara Brunmair
Wirkung und
nat.
2001
Wirkungsmechanismen von
Agonisten nuklerer Rezeptoren
auf den Glukose- und
Fettstoffwechsel der Ratte;
University of Vienna (Zoology)
page 46 of 168
Dr. rer.
nat.
Name
Title of thesis
Period (expected)
Acad.Title
Thomas Kstenbauer
Prospektive,
plazebokontrollierte,
randomisierte und doppelblinde
Studie zum Nachweis der
Wirksamkeit einer Behandlung
der peripheren diabetischen
Polyneuropathie mit Ginko
bilboa Extrakt Egb 761;
2003
Dr. rer.
nat.
Florian Gras*
Vergleichende Untersuchung der

Wirkung von Thiazolidindionen,
einem Isoxazolidindion und
Dexlipotam auf den
Glukosestoffwechsel der Ratte,
Humboldt University, Berlin
Germany
2004
MD
Karin Stadlbauer*
Modulation von
Glukosestoffwechsel und
Insulinsignalkaskade durch
Aminosuren und Fettsuren in
Muskel und Leber der Ratte
(Working Title); University of
Vienna (Zoology)
(2007)
Dr. rer.
nat.
(2008)
Dr. rer.
nat.
Zsuzsanna Szcs*
Wirkung mutmalich
antidiabetischer Naturheilmittel
in einschlgigen Nagermodellen;
* Supervision together with B. Brunmair
Publications
42 peer reviewed publications in scientific journals,
4 invited lectures

Frnsinn C, Brunmair B, Neschen S, Roden M, Waldhusl W: Troglitazone directly inhibits
CO2 production from glucose and palmitate in isolated rat skeletal muscle. Journal of
Pharmacology and Experimental Therapeutics 293, 487-493, 2000.
page 47 of 168
Brunmair B, Neschen S, Gras F, Roden M, Nowotny P, Waldhusl W, Frnsinn C: Metabolic

response to anisoosmolarity of rat skeletal muscle in vitro. Hormone Metabolic Research 32,
251-255, 2000.
(Erratum: Horm Metab Res 32, 440, 2000)
Englisch R, Wurzinger R, Frnsinn C, Schneider B, Frisch H, Waldhusl W, Graf J, Roden M:
Effects of insulin-like growth factor I on basal and stimulated glucose fluxes in rat liver.
Biochemical Journal 351, 39-45, 2000.
Oberkofler H, Neschen S, Esterbauer H, Waldhusl W, Patsch W, Frnsinn C: UCP3 gene
expression does not correlate with muscle oxidation rates in Troglitazone-treated Zucker fatty
rats. Biochimica et Biophysica Acta 1517, 113-118, 2000.
Roden M, Anderwald C, Frnsinn C, Waldhusl W, Lohninger A: Short-term leptin exposure
stimulates triglyceride deposition in rat liver. Hepatology 32, 1045-1049, 2000.
Stingl H, Krssak M, Krebs M, Bischof M, Nowotny P, Frnsinn C, Shulman GI, Waldhusl
W, Roden M: Lipid-dependent control of hepatic glycogen stores in healthy man.
Diabetologia 44, 48-54, 2001.
Krebs M, Krssak M, Nowotny P, Weghuber D, Gruber S, Mlynarik V, Bischof M, Stingl H,
Frnsinn C, Waldhusl W, Roden M: Free fatty acids inhibit glucose-stimulated increase of
intramuscular glucose-6-phosphate concentration in humans. Journal of Clinical
Endocrinology and Metabolism 86, 2153-2160, 2001.
Brunmair B, Gras F, Neschen S, Roden M, Waldhusl W, Frnsinn C: Direct
thiazolidinedione action on rat skeletal muscle glucose handling is independent of peroxisome
proliferator-activated receptor- -mediated changes in gene expression. Diabetes 50, 23092315, 2001.
Frnsinn C, Nowotny P, Brunmair B, Gras F, Roden M, Waldhusl W, Vierhapper H:
Thiazolidinediones influence plasma steroids of male obese Zucker rats. Endocrinology 143:
327-330, 2002 (Rapid Communication).
Anderwald C, Mller G, Koca G, Frnsinn C, Waldhusl W, Roden M: Short-term leptindependent inhibition of hepatic gluconeogenesis is mediated by insulin receptor substrate-2.
Molecular Endocrinology 16: 1612-1628, 2002.
Frnsinn C, Waldhusl W: Thiazolidinediones: metabolic actions in vitro. Diabetologia 45:
1211-1223, 2002 (Review).
Anderwald C, Koca G, Frnsinn C, Waldhusl W, Roden M: Inhibition of glucose production
and stimulation of bile flow by R (+)- -lipoic acid enantiomer in rat liver. Liver 22: 356-362,
2002.
Gras F, Brunmair B, Roden M, Waldhusl W, Frnsinn C: Differences in troglitazone action
on glucose metabolism in freshly isolated versus long-term incubated rat skeletal muscle.
British Journal of Pharmacology 138: 1140-1146, 2003.
page 48 of 168
Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H,

Waldhusl W, Frnsinn C: Thiazolidinediones, like metformin, inhibit respiratory complex I:
A common mechanism contributing to their antidiabetic actions. Diabetes 53:1052-1059,
2004.
Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Waldhusl W, Frnsinn
C: Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I.
Journal of Pharmacology and Experimental Therapeutics 311:109-114, 2004.
Brunmair B, Gras F, Wagner L, Artwohl M, Zierhut B, Waldhusl W, Frnsinn C: Expression
of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by
thiazolidinediones: an exercise-like effect? Diabetologia 47: 1611-1614, 2004 (Short
Communication)
Artwohl M, Frnsinn C, Waldhusl W, Hlzenbein T, Rainer G, Freudenthaler A, Roden M,
Baumgartner-Parzer SM: Thiazolidinediones inhibit proliferation of microvascular and
macrovascular cells by a PPAR -independent mechanism. Diabetologia 48, 586-594, 2005.
Artwohl M, Hlzenbein T, Frnsinn C, Freudenthaler A, Huttary N, Waldhusl W,
Baumgartner-Parzer SM: Thiazolidinediones inhibit apoptosis and heat shock protein 60
expression in human vascular endothelial cells. Thrombosis and Haemostasis 93, 810-815,
2005 (Short Communication).
Dorfmeister B, Brandhofer S, Schaap FG, Herman M, Frnsinn C, Hagerty BP, Stangl H,
Patsch W, Strobl W: Apolipoprotein AV does not contribute to hypertriglyceridemia or
triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Diabetologia,
in press.
Brunmair B, Staniek K, Drig J, Szcs Z, Stadlbauer K, Marian V, Gras F, Anderwald C,
Nohl H, Waldhusl W, Frnsinn C: Activation of PPAR- in isolated rat skeletal muscle
switches fuel preference from glucose to fatty acids. Diabetologia, 49:2713-2722, 2006.
Frnsinn C, Willson TM, Brunmair B: PPAR-, a regulator of oxidative capacity, fuel
switching, and cholesterol transport. Diabetologia, 50:8-17, 2007 (Review).
Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, Roth E, Frnsinn C,
Promintzer M, Anderwald C, Bischof M, Roden M: The mammalian target of rapamycin
pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56:1600-1607, 2007.
Anderwald C, Brunmair B, Stadlbauer K, Krens M, Frnsinn C, Roden M: Effects of free fatty
acids on carbohydrate metabolism and insulin signalling in perfused rat liver. European
Journal of Clinical Investigation, submitted
page 49 of 168
Gabriele HUSLER
Pediatric Department, Medical University of Vienna
gabriele.haeusler@meduniwien.ac.at
An in vitro model of growth plate chondrocytes

Abstract
Longitudinal growth takes place at the growth plate (GP), or physis - a highly organized
structure within the distal ends of long bones. Elongation of bone is established by the process
of enchondral ossification, where a synchronized sequence of chondrocyte differentiation and
proliferation is regulated by means of endocrine, paracrine and autocrine mechanisms. From a
clinical point of view, a reduction or increase of relevant hormones (e.g., growth hormone,
thyroid hormone, sex steroids, glucocorticoids) is accompanied by distinct pictures of growth
failure or excess. At the level of the growth plate, the mechanisms underlying these growth
disorders are poorly understood and concepts have derived from animal models, mainly
rodents. While the local actions of growth stimulating factors like GH and IGF-I have been
well documented, at least in animal models, the mode of action of skeletal maturation/closure
of the growth plate during puberty is obscure. It has been shown that both estrogen receptors
(ER) alpha and ER beta are expressed within the growth plate throughout childhood and
puberty and that estrogen is the hormone mediating closure of the growth plate in both sexes.
As estrogens can be synthesized locally by means of aromatization of precursors, even within
the cell (intracrine), these processes are not mirrowed by serum levels of hormones.
Investigation of growth plate tissue has mainly been performed in rodents (which do not close
their GPs completely), and human material is very limited.
In previous work our group has investigated the presence of ERs, matrix composition and the
role of matrix degrading encymes (metalloproteinases) in human childhood and adolescent
growth plates in vivo by immunohistochemistry. For further studies, we are currently
developing an porcine in vitro model of growth plate chondrocytes. After characterization of
the model and comparison with in vivo findings, it is the aim to study the effects of relevant
hormones and growth factors (GH, IGF-I, estrogens) and of different treatments
(chemotherapy, irradiation) on chondrocyte proliferation, differentiation and matrix
production.
Thesis Subjects
Characterization of a porcine in vitro model of growth plate differentiation, proliferation and
matrix synthesis.
Effect of sex steroids on chondrocyte differentiation and matrix production in vitro.
Tissue preparation, cell isolation, cell culture, immunohistochemistry , immunocytochemistry,
quantitativeRT-PCR, Immunoblot. Collaborations within the Medical University and the
University of Veterinary MedicineVienna.
page 50 of 168
Curriculum Vitae
Gabriele HUSLER
Department of Pediatric, Medical University of Vienna, Whringer Grtel 18-20, A-1090
Vienna, Austria; Phone +43 1 40400 3238; Email: gabriele.haeusler@meduniwien.ac.at
Personal Data
Date of Birth:
Nationality
Education
June 1996
01.03.1996
1994-1995
Nov 1986 Oct 1987
1980 1986
Career History
Since 2006
Since 1996
Since 01.06.1996
Since 1989
Oct 1987-1989
Since 1987
05/2006
Since 2006
Since 2003
28.04.1962
Austria
Habilitation
Fully qualified in Paediatrics
Research scholarship of Austrian Ministery for Education
& Science
Postdoctoral research fellow
Medical School Vienna/Medical doctor
Head of the Endocrine Outpatient Clinic

Associate Professor
Consultant for Pediatric Endocrinology at the University
Childrens Hospital Vienna
Registrar
Junior physician
Participation in several clinical trials in Endocrinology.

Special fields: Growth and growth disorders.
Clinical Resarch: Growth and hormone deficiency in
children with brain tumors, Ullrich-Turner-Syndrom,
Basic Research: Hormonal regulation of the growth plate.
Opponent of PHD thesis at Karolisnka Hospital
Board Member of Bone club ((ESPE)
Board Member of Growth plate working group (ESPE)
Memberships
ESPE
MESPE
page 51 of 168
APED
GKJ
Publications (since 2000)

Helmreich M, Haeusler G, Egerbacher M. Distribution of Laminin, Fibronectin, Collagen
I,II,IV, and X in the human adolescent and childhood growth plate. Scanning 2000 (A)
Meszaros F, Vergesslich K, Riedl S, Hausler G, Frisch H: Posterior pituitary ectopy in
children with idiopathic growth hormone deficiency. J Pediatr Endocrinol Metab 13(6):62935 (2000)
Frisch H, Kim C, Hausler G, Pfaffle R: Combined pituitary hormone deficiency and pituitary
hypoplasia due to a mutation of the Pit-1 gene. Clin Endocrinol (Oxf) 52(5):661-665 (2000)
Haeusler G, Egerbacher M, Marlovits S, Helmreich M. Integrins and extracellular matrix
proteins in the childhood and adolescent growth plate. Calcif Tiss Int 71(3):212-218 (2002)
Egerbacher M, Haeusler G: Estrogen receptor-alpha and estrogen-receptor-beta are present in
the human growth plate in childhood and adolescence, in identical distribution. Horm Res 58:
99-103 (2002)
Egerbacher M, Haeusler G: Integrins in growth plate cartilage (invited review). Pediatric
Endocrinology reviews 1: 2-8 (2003)
Wachstum und Pubertt. DFP Fortbildung. rztemagazin Ausgabe 45/20003
Binder G, Renz A, Martinez A, Keselman A, Hesse V, Riedl S, Haeusler G, Fricke-Otto S,
Frisch H, Heinrich JJ, Ranke MB: SHOX Haploinsufficiency and Leri-Weill
dyschondrosteosis: prevalence and growth failure in relation to mutation, sex, and degree of
wrist deformity. J Clin Endocrinol Metab 89: 4403-4408 (2004)
Haeusler G, Walter I,. Helmreich M, Egerbacher M: Localization of matrix
metalloproteinases, (MMPs) their tissue inhibitors, and vascular endothelial growth factor
(VEGF) in growth plates of children and adolescents indicates a role for MMPs in human
postnatal growth and skeletal maturation. Calcif Tiss Int 76:326-335 (2005)
Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG: Absence of
functional acid labile subunit (ALS), resulting in severe IGF deficiency and moderate growth
failure. J Clin Endocrinol Metab 91:1826-1831 (2006)
page 52 of 168
Michael J. HIESMAYR
Div. Cardiac- Thoracic- Vascular Anaesthesia & Intensive Care,
Stress-induced hyperglycaemia: strategies for optimal perioperative risk

management
Abstract:
Hyperglycemia is a frequent observation during acute illness such as myocardial infarction
and after major surgery. The proportion of patients with hyperglycemia may be as high as 95100% after cardiac surgery. Stress induced hyperglycemia has a detrimental effect on the
outcome after myocardial infarction and cardiac surgery. Mortality may increase by a factor
of 4 especially in previously non-diabetic patients. Control of hyperglycemia in order to
normalize blood glucose is associated with a clear clinical benefit. This effect is most
beneficial in previously non-diabetic patients with hyperglycemia. The exact target level of
glycemic is still a matter of investigation, but normalization to values between 80-125 mg/dl
is probably optimal.
The strategy to maintain normoglycemia has been challenged since recent findings in several
categories of patients such as those in septic shock and with acute medical illnesses were less
encouraging. In contrast to these patients in whom therapy can only start after injury, surgical
patients have a scheduled injury where deviations can be anticipated and preventive
interventions to stimulate insulin secretion or maintain insulin responsiveness can be
implemented. Thus surgical patients allow a precise determination of the optimal timing of
strategies to normalise glycemia.
Thesis subjects:
What is the time course and optimal target value for perioperative glycemia control?
Do preventive nutritional interventions (preoperative carbohydrates, arginine, etc) affect the
metabolic status of surgical patients?
Techniques and infrastructure:
epidemiological analysis of 10.000 patients from a prospective database
intervention trial with preoperative nutritional supplements and determination of insulin
resistance with clamp-techniques and metabolic rate with indirect calorimetry
page 53 of 168
Curriculum Vitae
Michael J HIESMAYR
Department of Cardiac Thoracic Vascular Anaesthesia & Intensive Care, Medical University
Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria;
Personal Data
Date of Birth:
Place of Birth:
Nationality
Education
10.07.1979
1973-1979
1960-1972
Career History
10/2002-present
1-3/2000
Since 1992
Since 1990
1987 1988
1987
From 01.01.1984
1981-1983
1979-1980
08.01.1954
Bregenz, Vorarlberg, Austria
Austria
Graduation: Dr. med.

Medical School: University Innsbruck and Vienna
Primary, secondary School and College: Lyce francais de
Vienna, Baccalaurat scientifique
Administrative Director, Department of Cardiac Thoracic

Vascular Anaesthesia & Intensive Care, Medical
University Vienna
Visiting Professor, Department of Anaesthesia II,
University Joseph Fourier, Grenoble France
Vice-Chairman Department of Cardiothoracic and Vascular
Anaesthesia and Intensive Care
Director Cardiothoracic Intensive Care Univ, University
Hospital
Research Grant Erasmus University Rotterdam (5+1
month) Pathophysiological Laboratory (Prof.A.Versprille)
Board Certification Anaesthesia and Intensive Care
Residency for Anaesthesia and General Intensive Care,
University School of Medicine, Vienna
Residency for General and Family Medicine
Regional Hospital Feldkirch, Bregenz and Dornbirn,
Vorarlberg, Austria
Postpromotional fellowship: Department Internal
Medicine, University of Zrich (Prof.W.Siegenthaler)
page 54 of 168
Organisation and Participation in the Programming of
Postgraduate Educational Programs:
1989, 1990, 1991, 1993, 1994,
1995, 1996, 1997, 1998, 1999,
2001, 2002
AKE (Association for clinical nutrition):Workshop for

nutritional and infusion therapy:
EACTA( European Association of Cardiothoracic

Anaesthetists) (since 2000 Austrian Council representative)
Annual Meeting in Vienna: 1990
1990, 1992, 1993, 1994, 1995,
IZI (Interdisciplinary Centre for Research and
1996, 1997, 1998, 1999, 20th
Development in Intensive Care) (Chairman) Annual
Meeting 2000, 2001, 2002, 2003 Meeting
Interactive Workshops for Clinical Epidemiology and
Evidence Based Medicine since 1998 in Hittisau,
Vorarlberg, 11th Workshop October 2004.
EWCI (Workgroup for Postoperative Intensive Care
Medicine / European Society of Intensive Care Medicine)
(member since 1989, president since 2001)
European Workgroup for Cardiothoracic Intensivists
Annual Meeting 1996 Vienna
Section Perioperative Intensive Care of the ESICM:
Chairman 2003
Lecturer University of Vienna:
- Theory and Practice of Artificial Ventilation
- Clinical Symptoms in Intensive Care
- Evidence Based Medicine: Application in Intensive Care
- Malnutrition & acute illness
- Heart failure in the ICU
- Fluid replacement in the ICU
- Sepsis & septic shock
Awards
1999
Hoechst Price of the Medical Faculty

Period
Organization
Short Title
1997
Medical Scientific
Fuzzy-KBWEAN Expert System for

page 55 of 168
K/yr
Foundation of the
Federal Capital
Vienna
Weaning from the Ventilator
Areas of research and interest:

Continuous quality assessment in Intensive Care
Performance comparison in Intensive Care between Institutions
Organ specific metabolic and nutritional interventions
Stress-induced hyperglycemia
Malnutrition in hospitals
Evidence Based Medicine
Publications
6 publications
Lassnigg, A., A. Punz, R. Barker, P. Keznickl, N. Manhart, E. Roth, and M. Hiesmayr,
Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative
stress: a double-blinded, randomized, controlled study. Br J Anaesth, 2003. 90(2): p.
148-54.
Lassnigg, A., M.J. Hiesmayr, P. Bauer, and M. Haisjackl, Effect of centre-, patient- and
procedure-related factors on intensive care resource utilisation after cardiac surgery.
Intensive Care Med, 2002. 28(10): p. 1453-61.
Dworschak, M., M. Franz, C. Khazen, M. Czerny, M. Haisjackl, and M. Hiesmayr,
Mechanical trauma as the major cause of troponin T release after transvenous
implantation of cardioverter/defibrillators. Cardiology, 2001. 95(4): p. 212-4.
Haider, W. and M. Hiesmayr, [Glucose-insulin-potassium (GIK) in prevention and therapy of
myocardial ischemia]. Wien Klin Wochenschr, 2000. 112(7): p. 310-21.
Lassnigg, A., E. Donner, G. Grubhofer, E. Presterl, W. Druml, and M. Hiesmayr, Lack of
renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc
Nephrol, 2000. 11(1): p. 97-104.
Rajek, A., T. Pernerstorfer, J. Kastner, P. Mares, M. Grabenwoger, D.I. Sessler, G. Grubhofer,
and M. Hiesmayr, Inhaled nitric oxide reduces pulmonary vascular resistance more
than prostaglandin E(1) during heart transplantation. Anesth Analg, 2000. 90(3): p.
523-30.
page 56 of 168
Alexandra KAUTZKY-WILLER
Dept. Internal Medicine III, Clin. Div. Endocrinology and Metabolism;
alexandra.kautzky-willer@meduniwien.ac.at
Gestational diabetes (GDM) - a model of type 2 diabetes (DM2)

Abstract
Women with prior GDM display a wide range of abnormalities in insulin secretion and action
postpartum. The cumulative incidence of DM2 in subjects with a history of GDM ranges from
5% to 70% depending on applied diagnostic criteria, ethnicity and the length of follow-up.
GDM is a heterogeneous disease reflecting any cause of diabetes emerging during pregnancy.
DM 2 results from a decline in insulin sensitivity associated with a -cell defect. However, it
is still unclear whether the molecular mechanisms that underlie the metabolic defects of DM2
are also effective in GDM, which displays an identical metabolic profile throughout
pregnancy and in part also afterwards.
The Viennese Post-Gestational Diabetes Project (VPGDP) therefore describes prospectively a
cohort of middle European women with prior GDM with well defined glucose metabolism
both during pregnancy and postpartum and aims to determine their risk to develop an
impaired glucose metabolism or type 2 diabetes (DM 2) within the first ten years after
delivery. We will study changes in beta-cell function and insulin sensitivity and predictive
factors for the progression to prediabetes or DM 2. These results should help to better
understand the pathophysiology of the disease and to establish prevention programs.
Furthermore, insulin secretion and sensitivity as well as lipid metabolism are studied
throughout pregnancy in women with GDM compared to women with normal glucose
tolerance during pregnancy. The relationship between metabolic parameters and
adipocytokines, cytokines and inflammatory parameters will be studied in order to elucidate
the changes occurring during pregnancy and the factors responsible for development of
diabetic fetopathy.
Thesis Subjects
Adipocytokines and cardiovascular disease in Diabetes mellitus Type 2
Gestational Diabetes a model of Type 2 Diabetes: vascular dysfunction, atherosclerosis,
inflammation in relation to changes in adipocytokines and hormones in the natural course
of the disease
Diabetic pregnancy: impact of maternal metabolism on diabetic fetopathy
oGTT + FSIGT with mathematical models for evaluation of insulin secretion and sensitivity
parameters; clamp technique; indirect calorimetry; IMT measurements; RIA, ELISA
page 57 of 168
Curriculum Vitae
Alexandra KAUTZKY-WILLER
40400 2126; Email alexandra.kautzky-willer@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
1962
Vienna, Austria
Austria
Education
1999
Subspecialty/Boards: Encorinology and Metabolism
1998 present
1997
1996
1988
Career History
1998 - present
Associate Professor (a.o. Univ.-Prof.)

Habilitation (Univ.Doz.)
Specialist in Internal Medicine
Doctor Medicinae Universae Diploma (MD): Medical
School, University of Vienna
Associate Professor, tenured position, Department of

Internal Medicine III, Div. of Endocrinology and
Metabolism, Medical University of Vienna
2003 - 2005
2001 - 2003
1999 - 2001
2003 2007
Reviewer:
Diabetologia, Diabetes Care, Am J Obstet Gyn, J
Endocrinol & Metab, Diabetic Medicine, Eur J Clin Invest,
Horm Med Res, Wien Klin Wschr
Member of the Board: Austrian Diabetes Association
- First Secretary
- Member
- Auditor
Federation of International Danube Symposia (FID)
- First Secretary
Member of Expert Panels:
Diabetes Guidelines (Austrian Diabetes Association
page 58 of 168
Diabetes and Pregnancy Guidelines (German Diabetes

Association)
Awards
2003
1995
Poster Award of the Austrian Diabetes Association

Hoechst Award (AGDP)
Memberships
Austrian Diabetes Association; Initiation: Diabetes and Pregnancy Study Group
Austrian Obesity Association
Austrian Society of Internal Medicine
EASD (European Association for the Study of Diabetes
Diabetes Pregnancy Study Group (2001, Oxford)
Period
Organization
Short Title
2001
2003
FWF, Austrian
Science Foundation
P14515-B08
Austrian Diabetes
Association/Clin
Project Award
Austrian Gestation Diabetes Project
sterr. Nationalbank
Jubiliumsfonds
Nr. 11198

Name
Title of thesis
Period (expected)
Acad.Title
Thomas Prikoszovich
Inflammation und endotheliale
2005 (2007)
(Dr. scient.
Dysfunktion bei Patientinnen 5

Jahre nach Gestationsdiabetes
Ammon Handisurya
Dynamic profile of plasma

ghrelin, obestatin, visfatin and
retinol-binding protein 4
concentrations in relation to
parameters of insulin resistance
in women with gestational
diabetes mellitus
page 59 of 168
med.)
2006 (2008)
(Dr. scient.
med.)
Publications (2000 - 2005)

25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
Modeling beta cell secretion and kinetics of proinsulin during an oral glucose test. Tura
A, Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. In Health Science
Simulation, N, Anderson JG and Katzper M (Eds.) , SCS Press, San Diego, USA, 2000
Dexamethasone lowers circulating E-selectin and ICAM-1 in healthy men. Yilma B,
Blann AD, Stohlawetz P, Eichler HG, Kautzky-Willer A, Wagner OF. J Lab Clin Med,
2000; 135 (3): 270-274
The increased insulin sensitivity in growth hormone-deficient adults is reduced by
growth hormone replacement therapy. Riedl M, Ludvik B, Pacini G, Clodi M,
Kotzmann H, Wagner O, Kautzky-Willer A, Prager R, Luger A. Eur J Clin Invest 2000;
30 (9): 771-778
Elevated plasma leptin in gestational diabetes. Kautzky-Willer A, Prager R, Ludvik B,
Pacini G, Tura A, Bieglmeyer Ch, Schneider B, Waldhusl W. Diabetologia 2001; 44:
164-172
Ocular Hyperperfusion following onset of intensified insulin therapy is associated with
decreased plasma endothelin-1 in type 1 diabetes. G. Fuchsjger-Mayrl, A. KautzkyWiller, B. Kiss, G. Rainer, O. Findl, M. Roden, O. Wagner, J. Pleiner, M. Wolzt, L.
Schmetterer. Diabetologia 2002; 45: 883-889
The effects of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol
in patients with type 2 daibetes: a randomized study. Ludvik B, Mahdjoobian K,
Waldhusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G. Diabetes Care 2002, 25:
239-240P.
Influence of metabolic control on splanchnic glucose uptake, insulin sensitivity, and the
time required for glucose absorption in patients with type 1 diabetes. Georg M, A.
Kautzky-Willer, K. Mahdjoobian , A. Hofer , R. Prager , G. Pacini , B. Ludvik. Diabetes
Care 2002, 25: 2042-2047
Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women
with previous gestational diabetes. F. Mittermayer, BX. Mayer, A. Meyer, C. Winzer,
OF. Wagner, M. Wolzt, A. Kautzky-Willer. Diabetologia 2002, 45: 1372-1378
Mathematical models of glucose and free fatty acids kinetics during oral glucose
tolerance tests. K. Thomaseth, A. Pavan, G. Pacini, A. Kautzky-Willer, A. Avogaro.
Proceedings of the Internat. Symp. on Health Sciences Simulation 2003, p103-107
Increased intramyocellular lipid concentration identifies impaired glucose metabolsim in
women with previous gestational diabetes. A. Kautzky-Willer, M. Krssak, Winzer Ch,
Pacini G, A. Tura, Farhan S, Wagner W, Brabant G, Horn R, Stingl H, Schneider B,
Waldhusl W, Roden M. Diabetes 2003, 52: 244-251
Basal and dynamic proinsulin-insulin relationship to assess b-cell function during OGTT
in metabolic disorders. A. Tura, G. Pacini, A. Kautzky-Willer, B. Ludvik, R. Prager, K.
Thomaseth. Am J Physiol 2003, 285: E155-E162
Mode of action of Ipomoea Batatas (Caiapo) in type 2 diabetic patients. B. Ludvik, W.
Waldhusl, R. Prager, A. Kautzky-Willer, G. Pacini. Metabolism 2003, 52: 875-880
Plasma adiponectin, insulin sensitivity and subclinical inflammation in women with
prior gestational diabetes. Ch. Winzer, A. Festa , B. Schneider , D. Bancher-Todesca, G.
Pacini , T. Funahashi , OF. Wagner , A. Kautzky-Willer. Diabetes Care 2004, 27: 17211727
Decreased plasma adiponectin concentrations in women with gestational diabetes
mellitus. Ch. Worda, H. Leipold, Ch. Gruber, A. Kautzky-Willer, Kfler M., D.
Bancher-Todesca. Am J Obstet Gynecol 2004, 191: 2120-2124
Haptoglobin phenotype and gestational diabetes. S Mustafa, Th Vukovich, Th
page 60 of 168
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
Prokiszovich, Ch Winzer, B. Schneider, H. Ester-bauer, OF Wagner, A. Kautzky-Willer

Diabetes Care 2004, 27: 2103-2107
Fetal hyperinsulinism and maternal one hour postload plasma glucose level. H. Leipold,
A. Kautzky-Willer, zbal A., Ch. Worda, Bancher-Todesca D., Ch. Worda. Obstet
Gynecol 2004, 104: 1301-1306
Large-for-gestational-age newborns in women with insulin-treated gestational diabetes
under strict metabolic control. H. Leipold,Ch. Worda, Ch. J. Gruber, A. Kautzky-Willer,
PW. Husslein, D. Bancher-Todesca. Wien Klin Wochenschr 2005, 117: 521-5
Severe diabetic fetopathy despite strict metabolic control. H Leipold, J Schwindt, A
Kautzky-Willer, D Bancher-Todesca, Ch Worda, PW. Husslein. Wien Klin Wochenschr
2005, 117: 561-4
Metabolic indices for improved characterization of subjects with impaired glucose
tolerance. Tura A., Mari A., Winzer Ch., Kautzky-Willer A., Pacini G. In Proc. X
Mediterranean Conf. On Medical and Biological Engineering (MEDICON 2004), CDROM, ISSN 1727-1983, ISBN 88-7780-308-8, paper # 295
Gestational diabetes mellitus is associated with increased C-reactive protein
concentrations in the third but not the second trimester. Leipold H, Worda C, Gruber CJ,
Prikoszovich T, Wagner O, Kautzky-Willer A. Eur J Clin Invest 2005, 35: 752-7
Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide:
comparison of beta-cell function from OGTT and IVGTT. Diab Res & Clin Pract 2006,
72: 298-301
Tura A, Mari A, Winzer C, Kautzky-Willer A, Pacini G. Impaired beta cell function in
lean normotolerant former gestational diabetic women. Eur J Clin Invest 2006, 36: 22-8
Kautzky-Willer A, Tura A, Winzer C, Wagner OF, Ludvik B, Hanusch-Enserer U,
Prager R, Pacini G. Insulin sensitivity during OGTT and its relations to parameters of
glucose metabolism and endothelial function in type 2 diabetic subjects under metformin
and thiazolidinediones. Diab Obesity Metab 2006, in press
S. Farhan, C. Winzer, P Quehenberger, C Bieglmaier, O. F. Wagner, G. Pacini, A. Tura,
K. Huber, W. Waldhusl, A. Kautzky-Willer. PAI-1 plasma levels in women with a
history of gestational diabetes. Eur J Clin Invest 2006, 36: 345-352
Morbiducci U, Di Benedetto G, Kautzky-Willer A, PaciniG, Tura A. Improved usability
of the minimal model of insulin sensitivity based on automated approach and genetic
algorithisms for parameter estimation. Clinical Science 2007, 112: 257-263
Mittermayer F, Kautzky-Willer A (corresponding author), Winzer Ch, Krzyzanoska K,
Prikoszovich Th, Demehri S, Wagner O, Wolzt M. Elevated concentrations of
asymmetric dimethylarginine are associated with deterioration of glucose tolerance in
women with previous gestational diabetes mellitus. Journal of Internal Medicine 2007,
261: 392-398
Gasic S, Winzer Ch, Bayerle-Eder M, Roden A, Pacini G, Kautzky-Willer A.Impaired
cardiac autonomic function in women with prior gestational diabetes. Eur J Clin Invest
2007, 37: 42-47
Haider D, Handisurya A, Storka A, Vojtassakova E, Luger A, Pacin G, Tura A, Wolzt
M, Kautzky-Willer A. Visfatin response to glucose is reduced in women with
gestational diabetes mellitus. Diabetes Care 2007, in press
Riedl M, Maier C, Handisury A, Luger A, Kautzky-Willer A. Ghrelin regulation in
pregnancy is independent of glucose metabolism. Journal of Internal Medicine 2007, in
press
Reviews
1.
Epidemiologie, tiologie und neue therapeutische Konzepte bei Adipositas. B Ludvik,
page 61 of 168
2.
3.
4.
5.
A. Kautzky-Willer, R Prager. Therapiewoche sterreich 1992, 7:10-16.

Gestationsdiabetes. Kautzky-Willer A. Diabetes und Stoffwechsel 1998, 7: 197-203
Diabetes-Screening in der Schwangerschaft. D. Bancher-Todesca, H. Leipold, P.
Husslein, A. Kautzky-Willer. Geburtshilfe und Frauenheilkunde 2003, 63: 223-229
bergewicht und Diabetes in der Schwangerschaft. A. Kautzky-Willer, Ch. Winzer.
Journal fr Ernhrungsmedizin 2002, 3: 7-12
Gestationsdiabetes. Kautzky-Willer A und Bancher-Todesca Dagmar. Wien. Med.
Wochenschr. 2003, 153: 478-485
page 62 of 168
Michael KREBS
michael.krebs@meduniwien.ac.at
Hepatic glycogen metabolism and profiles of glucose and glucoregulatory

hormones in patients with type 1 diabetes mellitus after pancreatic
transplantation
Abstract
Background: Subjects with poorly controlled type 1 diabetes mellitus have a major defect in
postprandial hepatic glycogen synthesis resulting in lower hepatic glycogen content and
higher hepatic glucose output. Pancreatic transplantation is an effective treatment of diabetes
mellitus and results in postprandial glucose metabolism similar to that in nondiabetic subjects
on comparable immunosuppressive agents. However, in contrast to the physiological
secretion of insulin into the portal vein, insulin is usually drained into the systemic circulation
in pancreas transplanted patients. Therefore, this operation results in peripheral
hyperinsulinemia and relative low portal insulin concentrations.
Hypothesis: An optimized peripheral insulin supplementation achieved by pancreas
transplantation might correct not only hyperglycaemia but also defects in postprandial
glycogen synthesis in liver associated with type 1 diabetes. Alternatively, peripheral
hyperinsulinemia and portal insulin deficiency associated with pancreas transplantation and
systemic drainage of insulin might augment the impairment in postprandial hepatic glycogen
storage observed in patients with type 1 diabetes treated with s.c. insulin. The successfully
pancreas transplanted type 1 diabetic patients might also serve as a model to elucidate the
question whether an optimized peripheral insulin therapy (including s.c. insulin application
which is the current standard of care) is in principal able to correct impaired hepatic glycogen
metabolism observed in type 1 diabetes.
Objectives: To evaluate glycogen metabolism in liver, rates of endogenous glucose
production as well as day-time profiles of plasma glucose and glucoregulatory hormones in
patients with type 1 diabetes mellitus after pancreas-kidney transplantation compared to
nondiabetic patients after successful kidney transplantation and healthy humans.
Population: Three groups will be studied: 10 patients with type 1 diabetes mellitus and
functioning pancreas-kidney transplants with systemic venous drainage, 10 nondiabetic
subjects with functioning kidney transplants, and 10 healthy control subjects
Outcome Variables: Postprandial glycogen synthesis (moll-1 livermin-1) in liver as
calculated from the slope of the glycogen concentration over time before and after ingestion
of a standardized meal. Repetitive in vivo NMR spectroscopy of natural abundance 13C
glycogen in the liver to calculate net hepatic glycogen synthesis after standardized test-meals.
Rates of fasting endogenous glucose production will be calculated as the tracer (D-[6,6-2H2]glucose) infusion rate divided by the average percentage of 2H2 enrichment in C6 of plasma
glucose under steady-state conditions.
Thesis Subjects
Hepatic glycogen metabolism and profiles of glucose and glucoregulatory hormones in
patients with type 1 diabetes mellitus after pancreatic transplantation
Morbid obesity and weight reduction: Impact on molecular mechanisms of insulin
resistance
page 63 of 168
metabolic research ward; various clamp techniques, nuclear magnetic resonance

spectroscopy, tracer studies -glucose turnover, analysis of signaling events in biopsies of
skeletal muscle by immunoblotting, all equipment available
page 64 of 168
Curriculum Vitae
Michael KREBS
40400 4310; Fax +43 1 40400 7790; Email thomas.stulnig@meduniwien.ac.at
Personal Data
Date of Birth
Place of Birth:
Nationality
Education
1996-07-02
Jan 1994 June 1996
Nov 1992 Feb 1993

Oct 1990 July 1996
Career History
Oct 2005
Aug 1999 Aug 2005
Aug 1999
Oct 1998 Aug 1999
July 1996 Dec 1998
28.07.1971
Austria
MD degree
Research work for my MD-thesis Function of heparin
cofactor II outside the hemostatic system at the
Department for Vascular Biology and thrombosis
Research (Head: Prof.B.R. Binder, MD)
Research training in the Laboratory for Clinical &
Experimental Physiology
Associate Professor of Internal Medicine

Residency in Internal Medicine at the Division of
Endocrinology and Metabolism, Department of Internal
Medicine III, (Head: Prof.W.Waldhusl) with rotations
in Endocrinology and Metabolism, Gastroenterology
and Hepatology, Hematology, Nephrology and
Transplantation, Emergency Medicine and Intensive
Care
Successful participation at the EASD Clinical
Scientists Training Course in Uppsala
Post doctoral training in the group of Prof.M.Roden at
the Dep. of Internal Medicine III, Div. of
Endocrinology & Metabolism (Head:
Prof.Dr.W.Waldhusl)
Postdoctoral training at the Department of Vascular
page 65 of 168
Biology and thrombosis Research (Head: Prof.BR

Binder), Univ of Vienna, Medical School
Research experience:
I received an in depth training in all basic biochemical
techniques (protein purification, affinity- and gel
chromatography, FPLC, ELISA, PAGE, W - blot,
various activity assays for enzymes and inhibitors). In
addition I gained comprehensive experience in the field
of tissue culture and cell biology (FACS, NorthernBlot, Immunohistochemistry). A major focus of my
research work was the pathogenesis of vascular disease
associated with the insulin resistance syndrome and
renal insufficiency. During the recent years I performed
studies on glucose metabolism in normal volunteers
and diabetic subjects using NMR spectroscopy (noninvasive determination of glycogen concentrations in
skeletal muscle and liver, muscular glucose-6phosphate, and intracellular lipids). Our group also
applies various tracer techniques and biopsies of
skeletal muscle in combination with hyperinsulinemicand pancreatic-clamp tests to determine rates of
glucose turnover, gluconeogenesis, and molecular
mechanisms insulin resistance. I am especially
interested in elucidating the mechanisms of nutrient
induced insulin resistance in humans.
Awards
1992, 1993, 1994, 1995
1994
February, 1997
I received achievement awards from the Faculty of

Medicine, University of Vienna for excellent
performances in medical school
Research award granted by the University of Vienna
for the project Inhibition of serine proteases of the
alternative pathway of complement by heparin cofactor
II
Best abstract award for Complex formation of heparin
cofactor II (HCII) and complement factor D (Adipsin)
at the 41st Annual Meeting of the Society for
page 66 of 168
June, 2002
December, 2002
April, 2003
November, 2003
April, 2004
October, 2005
Thrombosis and Hemostasis Research

Aventis-Award for: Effects of short-term improvement
of insulin treatment and glycemia on hepatic glycogen
metabolism in type 1 diabetes mellitus
Theodor Billoth-Award for: Mechanism of amino acidinduced skeletal muscle insulin resistance in humans
Theodor Krner-Award for: Investigation of direct
Effects of Amino Acids on Insulin Resistance and
Glucose Metabolism in Humans.
Project award by the Austrian Diabetes Association
(35.000 ) for: Molecular mechanisms of amino acid
induced insulin resistance in human skeletal muscle
Best abstract award of the European Society for
Clinical Investigation for: Amino acid induced hepatic
and skeletal muscle insulin resistance in humans.
Josef Skoda-Project Award of the Austrian Society of
Internal Medicine (40 000 ) for: Morbid obesity and
weight reduction: Impact on molecular mechanisms of
insulin resistance
Memberships
Austrian Diabetes Association
Austrian Society of Nephrology
European Association for the Study of Diabetes
Period
Organization
2003-2005
Austrian Diabetes
Association
2005 -
Austrian Society of
Internal Medicine
2007 -
Austran National
Bank
Short Title
K
Molecular mechanisms of amino acid
35
induced insulin resistance in human
skeletal muscle
Morbid obesity and weight reduction:
Impact on molecular mechanisms of
insulin resistanc
Hepatic glycogen metabolism and profiles
of glucose and glucoregulatory hormones
in patients with type 1 diabetes mellitus
after pancreatic transplantation
page 67 of 168
40
54

Name
Title of thesis
Period (expected)
Acad.Tit
Miriam
Promintzer
Morbid obesity and weight reduction:

Impact on molecular mechanisms of
insulin resistanc
11.2005 (11.2008)
(PhD)
Publications
A. Original research:
Krebs M, Stingl H, Nowotny P, Weghuber D, Bischof M, Waldhusl W, Roden M:
Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem 46:950-954, 2000 (IP:
5.538)
Bischof MG, Ludwig C, Hofer A, Kletter K, Krebs M, Stingl H, Nowotny P, Waldhusl
W, Roden M: Hormonal and metabolic counterregulation during and after high dose
insulin induced hypoglycemia in diabetes mellitus type 2. Hormon Metabol Res 32:417423, 2000 (IP: 1.669)
Polak K, Schmetterer L, Luksch A, Gruber S, Polska E, Peternell V, Bayerle-Eder M,
Wolzt M, Krebs M, Roden M: Free fatty acids/triglycerides increase ocular and
subcutaneous blood flow. Am J Physiol Regulatory Integrative Comp Physiol 280:R56R61, 2001 (IP: 3.627)
Bischof MG, Krssak M, Krebs M, Bernroider E, Stingl H, Waldhusl W, Roden M:
Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen
metabolism in type 1 diabetes mellitus. Diabetes 50:392-398, 2001 (IP: 8.298)
Stingl H, Krssak M, Krebs M, Bischof M, Nowotny P, Frnsinn C, Shulman GI,
Waldhusl W, Roden M: Lipid-dependent control of hepatic glycogen stores in healthy
man. Diabetologia 44:48-54, 2001 (IP: 5.689)
Krebs M, Krssak M, Weghuber D, Nowotny P, Gruber S, Mlynarik V, Bischof MG,
Stingl H, Frnsinn C, Waldhusl W, Roden M: Free fatty acids inhibit the glucosestimulated increases of intramuscular glucose-6-phosphate concentrations in man. J Clin
Endocrinol Metab 86:2153-2160, 2001 (IP: 5.876)
Bischof MG, Bernroider E, Krssak M, Krebs M, Stingl H, Nowotny P, Yu C, Schulman
G, Waldhusl W, Roden M: Hepatic glycogen metabolism in type 1 diabetes mellitus after
long-term near normoglycemia. Diabetes 51:49-54, 2002 (IP: 8.298)
Krebs M, Krssak M, Bernroider E, Nowotny P, Anderwald C, Brehm A, Roth E,
Waldhusl W, Roden M: Mechanism of amino acid-induced skeletal muscle insulin
resistance in humans. Diabetes 51:599-605, 2002 (IP: 8.298)
Krebs M, Brehm A, Krssak M, Anderwald C, Bernroider E, Nowotny P, Roth E,
page 68 of 168
Chandramouli V, Landau BR, Waldhusl W, Roden M: Direct and indirect effects of

amino acids on hepatic glucose metabolism. Diabetologia, 46:917-925, 2003 (IP: 5.689)
Krebs M, Geiger M, Polak K, Vales A, Schmetterer L, Waldhusl W, Binder BR, Roden
M: Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell
adhesion molecule after triacylglycerol infusion in man. Thromb Heamostas 90:422-428,
2003 (IP: 4.950)
Tremblay F*, Krebs M*, Brehm A, Bernroider E, Pfeiler G, Novotny P, Waldhusl W,
Marette A, Roden M: Overactivation of S6K1 as a cause of human insulin resistance
during increased amino acid availability. Diabetes 54: 2674-84, 2005 (IP: 8.298)
*both authors equally contributed to this work
Bischof MG, Brehm A, Bernroider E, Krssak M, Mlynarik V, Krebs M, Roden M:
Cerebral glutamate metabolism during hypoglycemia in healthy and type 1 diabetic
humans. Eur J of Clin Invest, 36:164-9, 2006 (IP: 2.346)
Krebs M, Brunmair B, Brehm A, Artwohl M, Szendrdi J, Nowotny P, Roth E, Frnsinn
C, Promintzer M, Anderwald C, Bischof M, Roden M: The mTOR-pathway regulates
nutrient sensitive glucose uptake in man. Diabetes 56:1600-1607,2007
Anderwald C, Anderwald-Stadler M, Promintzer M, Prager G, Mandl M, Nowotny P,
Bischof MG, Wolzt M, Ludvik B, Kstenbauer T, Pacini G, Luger A, Krebs M: Clamplike Index: a Novel, Highly Sensitive Insulin Sensitivity Index to Calculate
Hyperinsulinemic Clamp Glucose Infusion Rates from Oral Glucose Tolerance Test in
Nondiabetic Humans. Diabetes Care 2007; E-pub
B. Reviews:
Geiger M, Krebs M, Jerabek I, Binder BR: Protein C inhibitor (PCI) and heparin cofactor
II (HCII): Possible alternative roles of these heparin-binding serpins outside the
hemostatic system. Immunopharmacology 36:279-284, 1997 (IP: 0.776)
Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW:
Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News
Physiol Sci 17:56-61, 2002 (IP:3.682)
Krebs M, Roden M: Nutrient induced insulin resistance in human skeletal muscle. Current
Medicinal Chemistry, 11:901-908, 2003 (IP: 4.409)
Krebs M, Roden M: Molecular mechanisms of lipid induced insulin resistance. Diabetes
Obes Metab, 7:621-32, 2005 (IP: 1.528)
Krebs M: Amino acid-dependent modulation of glucose metabolism in humans. Eur J of
Clin Invest, 35:351-354, 2005 (IP: 2.346)
page 69 of 168
Bernhard LUDVIK
Dept. of Internal Medicine III, Clin. Div. Endocrinology & Metabolism
bernhard.ludvik@meduniwien.ac.at
Metabolic, nutritional and endocrine characteristics of morbid obesity and

their changes following weigth loss
Abstract
Morbid obesity is characterized by an increased morbidity and mortality. The pathogenesis
involves a variety of disturbed patterns of adipocytokines and satiety factors. The standard
treatment of morbid obesity is bariatric surgery, which involves several methods such as
gastric banding, gastric bypass or pace makers that help to reduce weight. The success rate of
the respective methods is highly variable and not predictable. In addition, the enormous
weight loss following bariatric surgery leads to profound changes in body composition,
among them an undesirable loss of muscle mass.
Current research focuses on three major topics related to surgery-induced weight loss:
1. Profiles of satiety factors and adipocytokines before and following weight reduction.
Among other factors, recent research in our laboratory focused on visfatin, which for the first
time has been shown to decrease following weight loss as well as on adipocyte fatty acid
binding protein (AFABP), which, again for the first time, has been found to be increased in
morbid obesity and reduced following weight reduction.
2. A major focus lies on the changes in body composition and the nutritional status before and
after weight loss. We have demonstrated that the decrease in muscle mass cannot be
prevented by additional oral protein supplementation. In the future we plan to investigate the
impact of several surgical approaches on nutritional status and body composition and whether
they can be prevented by appropriate nutritional intervention.
3. Morbid obesity is characterized by an increased incidence of psychiatric comorbidity such
as eating disorders, which have to be taken into account as regards to optimizing treatment
outcome. Current research focuses on the quality of life in these patients and whether the
health benefits following weight loss correspond with improvement in general well being.
Thesis Subjects
Assessment of endocrine (adipocytokines), nutritional and psychological parameters in
morbid obesity and their impact on overall efficacy following bariatric surgery

Measurement of body composition (MRI, DEXA, BIA), analysis of adipocytokines and
satiety factors (RIA, ELISA), assessment of nutritional (eating questionnaire) and
psychological status, measurement of parameters of insulin secretion and insulin sensitivity,
all equipment at site
page 70 of 168
CURRICULUM VITAE
Bernhard LUDVIK
Department of Internal Medicine III, Division of Endocrinology and Metabolism, Waehringer
Guertel 18-20, A-1090 Vienna, Austria ; Phone/Fax:: ++43 (01) 40 400 4364,
Mobile: 0664-308 67 63; E-mail: bernhard.ludvik@meduniwien.ac.at,
Homepage: http://www.bernhard-ludvik.at
Personal Data
Date of Birth:
June 21, 1961
Place of Birth:
Vienna
Nationality:
Austria
Education
June 19, 1979
High School, Schottengymnasium in Vienna, graduation
Languages:
English, French
Feb. 7, 1985
Medical School, University of Vienna, graduation, MD
Career History
1985 1992
Internship and residency from March 1, 1985 to June 30,

1992 at the Medical Department II, University of Vienna
Since July 1, 1991
1991 1992
Military Service in the Austrian Army Hospital
1992 - 1994
Research Fellow at the University of California San

Diego
Since June 27, 1995
Assistant Professor of Medicine
Since 1996
Specialist in Endocrinology and Metabolism
Since October 01, 1998
Associate Professor of Medicine
current employment
Associate Professor of Medicine, University of Vienna;

Attending in Internal Medicine and Endocrinology at the
Division of Endocrinology and Metabolism, Department
of Internal Medicine III, University of Vienna (Vienna
page 71 of 168
General Hospital)
Leader of the working group on Obesity and
Endocrinology
Honors and Awards

1992
Research Grant Erste sterreichische Sparkasse;

presented by the Austrian Medical Association
1992-1994
Fellowship Max Kade Foundation; Research at the

University of San Diego, California
1995
Hoechst Award presented by the Dean of the Faculty of

Medicine of Vienna in
1995
2nd Secretary of the Austrian Society of Internal

Medicine
1996-1997
1st Secretary of the Austrian Diabetes Association
1996-1999
1st Secretary of the Federation of the International

DONAU-SYMPOSIA on Diabetes mellitus
1996-1998
Vice President of the Austrian Obestiy Association
1998-2000
President of the Austrian Obestiy Association
2001
Chairman of the European Congress of Obestiy ECO

2001
2002
2nd Secretary of the Austrian Society of Internal

Medicine
2002-2003
Vice President of the Austrian Obestiy Association
1998-2003
Assistant Editor of DIABETOLOGIA
2004
Founding Fellow of the SCOPE program (EASO) 2004
Memberships
Austrian Medical Association
Austrian Society of Endocrinology
Austrian Obesity Association
Austrian Diabetes Association
American Diabetes Association
page 72 of 168
European Association for the Study of Obesity (EASO)

European Group on Insulin Resistance (EGIR)
Federation of International Donau Symposia on Diabetes mellitus
Lipidforum Austriacum
Current Positions
Member of the Editoral Board Current Diabetes Reviews
Advisory Board Jatros. Zeitschrift fr Diabetologie und Stoffwechsel
Member of the Editorial Board and Editor in Chief of Journal fr Ernhrungsmedizin
2nd Secretary of the Austrian Society of Internal Medicine (2005)

Period
Organization
Short Title
2003 2007
Austrian National
Bank Jubilee Fund
Project no. 10329
Einflu von akuter und chronischer

Alkoholaufnahme auf Insulinsensitivitt
und Endothelfunktion bei Typ 2 Diabetes
Mellitus
70
1996 2000
Austrian National
Bank Jubilee Fund
Project no. 6138
Anwendung einer neuen, nicht- invasiven

Methode (OG- Clamp) zur Evaluierung der
splanchnischen Glukoseaufnahme
22

Name
Title of thesis
Period (expected)
Acad.Title
Barbara Trip
Der Einfluss einer
2004 2007
PhD
proteinreichen (v.a.
ovolactovegetabilen) Dit auf
Parameter des Glukose- und
Fettstoffwechsels bei mit Insulin
behandelten Typ 2 Diabetikern
page 73 of 168
Name
Title of thesis
Period (expected)
Acad.Title
Raphaela Riener
Selbstwirksamkeitserwartungen
bei extremer Adipositas und
deren Einfluss auf die
Lebensqualittsuerungen nach
operativer Therapie anhand der
Diskrepanzen zwischen Befund
und Befinden
2005 (2008)
(PhD)
Publications since 2000

Original papers and reviews
Ludvik B: [Diabetes therapy related to etiology. Indications, uses and side effects of new
insulin sensitizers]. MMW.Fortschr.Med. 142:27-28, 2000
Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager
R, Luger A: The increased insulin sensitivity in growth hormone-deficient adults is reduced
by growth hormone replacement therapy. Eur.J.Clin.Invest 30:771-778, 2000
Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B, Prager R,
Waldhausl W: Increased plasma leptin in gestational diabetes. Diabetologia 44:164-172, 2001
Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ: A model-based method for assessing
insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539-548, 2001
Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K: Insulin and C-peptide secretion and
kinetics in humans: direct and model-based measurements during OGTT. Am.J.Physiol
Endocrinol.Metab 281:E966-E974, 2001
Ludvik B, Mahdjoobian K, Waldhaeusl W, Hofer A, Prager R, Kautzky-Willer A, Pacini G:
The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in
patients with type 2 diabetes: a randomized study. Diabetes Care 25:239-40, 2002
Georg P, Kautzky-Willer A, Mahdjoobian K, Hofer A, Prager R, Pacini G, Ludvik B:
Influence of metabolic control on splanchnic glucose uptale, insulin sensitivity, and the time
required for glucose absorption in patients with type 1 diabetes. Diabetes Care 25:2042-2047,
2002
Ludvik B, Thomaseth K, Nolan, JJ, Clodi M, Prager R, Pacini G: Inverse relation between
amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest 33,
316-322, 2003
Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic
proinsulin-insulin relationship to assess {beta}-cell function during OGTT in metabolic
disorders. Am J Physiol Endocrinol Metab 285, E155-E162, 2003
Ludvik B, Waldhaeusl W, Prager R, Kautzky-Willer A, Pacini G: Mode of Action of
Ipomoea batatas (Caiapo) in type 2 diabetic patients. Metabolism 52:875-880, 2003
page 74 of 168
Pichler B, Ludvik B: Future perspectives of pharmacotherapy of obesity. Journal fr

Kardiologie 10:427-429, 2003
Ludvik B, Neuffer B, Pacini G: Efficacy of Ipomoea batatas (Caiapo) on diabetes control in
type 2 diabetic patients. Diabetes Care 27:436-440, 2004
Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, Maier C, Luger A,
Ludvik B: The Impact of Laparoscopic Adjustable Gastric Banding (LABG) on Plasma
Ghrelin, Eating Behaviour and Body Weight. Eur J Clin Invest 34(8):549-54, 2004
Schindler K, Ludvik B: Methodische und praktische Aspekte der Bestimmung der
Krperzusammensetzung [Assessment of Body Composition - methods and practical aspects].
Wien Med Wochenschr 154(13-14):305-12, 2004
Tripp B, Ludvik B: Medikamentse Therapie der Adipositas [Pharmacotherapy of Obesity].
Wien Med Wochenschr 154(13-14):320-8, 2004
Bohdjalian A, Langer FB, Hoda A, Felberbauer FX , Silberhumer G, Zacherl J, Schindler K,
Luger A, Ludvik B, Prager G: Chirurgische Therapie der Adipositas. Wien Med Wochenschr
154(13-14):329-33, 2004
Tripp B, Ludvik B: Neue Antiadiposita [Novel Anti-Obesity Drugs]. Acta Medica Austriaca
31(4):133138, 2004
Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, Wagner O,
Georg P, Prager R, Kostner K, Dunky A, Haber P: The Relative Benefits of Endurance and
Strength Training on the Metabolic Factors and Muscle Function of People with Type 2
Diabetes Mellitus. Arch Phys Med Rehabil 86(8):1527-33, 2005
Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, Schindler K,
Luger A, Ludvik B, Prager G: Sleeve Gastrectomy and Gastric Banding: Effects on Plasma
Ghrelin Levels. Obes Surg 15(7):1024-9, 2005
Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Kostner K, Dunky A, Haber P:
Continuous Glucose Monitoring in Diabetic Long Distance Runners. Int J Sports Med
26(9):774-80, 2005
Abrahamian H, Ludvik B, Schernthaner G, Prager R, Zellenka U, Knudsen L, Wascher T:
Improvement of glucose tolerance in type 2 diabetic patients: traditional vs. modern insulin
regimens (results from the Austrian Biaspart Study).Horm Metab Res. 37(11):684-9, 2005
Langer FB, Bohdjalian A, Felberbauer FX, Fleischmann E, Reza Hoda MA, Ludvik B,
Zacherl J, Jakesz R, Prager G: Does gastric dilatation limit the success of sleeve gastrectomy
as a sole operation for morbid obesity? Obes Surg 16 (2):166-71, 2006
Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B: Increased plasma
visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin
Endocrinol Metab. 91(4):1578-81, 2006
Riener R, Schindler K, Ludvik B: Psychosocial Variables, Eating Behavior, Depression and
Binge Eating in Morbidly Obese Subjects. Eating Behaviors, 2006, in press
page 75 of 168
Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, Riener R, Zacherl J,

Ludvik B: One year experience with Tantalus: a New Surgical Approach to Treat Morbid
Obesity. Obes Surg, 2006, in press
Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhart B, Luger A, Nowotny P, Ludvik B:
Impact of Antiretroviral Therapy on Visfatin and Retinol Binding Protein 4 in HIV+ Subjects,
Eur J Clin Invest, 2006, submitted
Haider DG, Schindler K, Mittermayer F, Mller M, Nowotny P, Rieger A, Ludvik B, Wolzt
M: Effect of rosiglitazone on visfatin and retinol binding protein-4 plasma concentrations in
HIV-positive patients. Metabolism, 2006, submitted
Ludvik B, Hanefeld M, Pacini G: Improved Metabolic Control by Ipomoea (Caiapo) is
Associated with Increased Adiponectin and Decreased High Sensitive C-reactive Protein and
Fibrinogen Levels. Diabetes Care, 2006, submitted
Chapters in Books
Ludvik B: Adipositas Diagnostik und Therapie. In Ernhrungsmedizin. Widhalm K, DialloGinstl E, Eds. AK 2000, 334-346
Ludvik B: Konservative Therapie der morbiden Adipositas. In Morbide Adipositas Klinik
und Therapie. Hell E, Miller K, Eds. Ecomed 2000, 20-25
Ludvik B: Sekundre Diabetesformen. In Diabetes in der Praxis. Waldhaeusl W, Gries FA,
Scherbaum W, Eds. Springer Verlag Berlin 2004
Ludvik B: Diabetes mellitus: ein progerones Krankheitsbild. Therapie, Prvention und
Einfluss von Lifestyle. In Angewandte Anti-Aging-Medizin. Gasser R (Hg). Verlagshaus der
rzte 2004
Books
Ludvik B (Hrsg.): Risikofaktor Diabetes Konzepte fr ein Langzeitproblem. Uni-MedVerlag Bremen, 1.Aufl. 2004 [ISBN: 3-89599-824-9]
Ludvik B, Toplak H: Medikamentse Therapie der Adipositas. Springer Verlag Wien, 1.Aufl.
2006 [ISBN: 3-211-83815-5]
Mihaljevic K, Feffer S, Ludvik B: Essen mit Spass + Aktivsein mit Mass. So entkommen Sie
dem Metabolischen Syndrom, Verlagshaus der rzte, 1. Aufl. 2006
page 76 of 168
Anton LUGER
Dept. Internal Medicine III, Div. Endocrinology and Metabolism;
anton.luger@meduniwien.ac.at
Non-genomic effects of glucocorticoids on carbohydrate metabolism

Abstract
Glucocorticoids are known to bind to intracellular receptors and initiate genomic signaling
mechanisms leading to combined actions on glucose metabolism (suppression of insulin
secretion, inhibition of glucose uptake in peripheral tissues and promotion of gluconeogenesis
in the liver). The final result is an increase in blood glucose levels.
Although glucocorticoids are released at high levels within minutes in response to any stress
or threat to homeostasis (e.g. hypoglycemia), the discovery of intracellular receptors that
translocate to the nucleus and modify the transcription of target genes has focused research on
genomic signaling mechanisms, which lead to effects more than 30 min after glucocorticoid
exposure. In the last decade, there is a booming research in the field of non-genomic steroid
signaling whose effects occur within minutes. Nevertheless, very little is known about rapid
effects of glucocorticoids on carbohydrate metabolism and there are no data on the respective
signaling mechanisms. Such work dates many decades ago and is mainly focused on the rapid
impact on insulin secretion in vivo and peripheral glucose uptake in vitro.
Glucocorticoids are important therapeuticals with, unfortunately, major metabolic side effects.
A full knowledge of other signaling mechanisms and possibly receptors, mediating
glucocorticoid effects would help in discovering novel drug targets with an optimized benefitrisk-ratio.
Starting from this current knowledge, we began to study the rapid (within minutes) effects of
glucocorticoids on carbohydrate metabolism and found a significant increase in insulin
secretion from the INS-1E and Rinm5F rat beta-cell lines after stimulation with 100nM
Dexamethasone for 15 minutes. Therefore, we plan to study the second messengers and other
signaling mechanisms involved in this effect and to check the presence of possible
glucocorticoid membrane binding sites using fluorescence correlation spectroscopy (FCS), a
method recently established in our laboratory. At the same time we plan to study the rapid
effects of glucocorticoids in the periphery, namely their effect on glucose uptake in primary
cultures of adipocytes and muscle cells. Glucocorticoid membrane binding will be
investigated in both these models using FCS. The 3T3-L1 fibroblast pre-adipocyte cell line
will be used for studying the signaling mechanisms involved. In summary, this work could
contribute to a hitherto unknown part of the physiology of glucocorticoid effects on
carbohydrate metabolism.
Thesis Subjects
Rapid (non-genomic) effects of glucocorticoids on insulin release in beta cells and peripheral
glucose uptake.
Signaling mechanisms (receptors, second messengers, etc.) mediating these effects.

Models: rat beta-cell lines, murine pre-adipocyte cell line, primary cultures of human
adipocyte and muscle cells. Experiments: stimulation experiments, RIA, intracellular free
calcium & cAMP measurement, Western Blotting. All required equipment available.
page 77 of 168
Curriculum Vitae
Anton LUGER
University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; Phone +43 1 40400
4310; Fax +43 1 405 93 234; Email anton.luger@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
03.10.1952
Vienna
Austria
Education
June 1978
MD Degree, University of Vienna, Austria
1987
Habilitation
Career History
01.10.2005 present
1991 present
1986 1991
1985 1986
1980 1985
1978 1980
1995 2005
2005 present
2003 2004
1999 present
Acting Head/Division of Endocrinology and Metabolism of

the Department of Medicine III, Unviersity of Vienna,
Austria
Department of Medicine III, Unviersity of Vienna, Austria
Department of Medicine II, University of Vienna
Visiting Fellow at the Developmental Endocrinology Branch,
National Institute of Child Health and Human Development,
National Institutes of Health, Bethesda, Maryland, USA
Resident, Departments of Medicine II and Cardiology,
University of Vienna, Austria
Institute of Pharmacology, University of Vienna, Austria
Deputy Head/Division of Endocrinology and

Metabolism/Department of Medicine III, Unviersity of
Vienna, Austria
Member of the Executive Committee of the European
Neuroendocrine Association
President of the Austrian Society for Endocrinology and
Metabolism
Austrian Delegate at the Section of Endocrinology at the
page 78 of 168
1985 1986
UEMS (European Union of Medical Specialists)

Deputy Chairman of the Medical Faculty Assembly,
Max Kade Fellowship
Awards
2004
1986
1986
1985
1985
1982
Award of the Erste Bank

Award of the Austrian Society of Nephrology
Max Kade Fellowship
Max Kade Fellowship
Hoechst Award
Hoechst Award
1998 2002
Memberships
Period
Organization
Short Title
2002
2006
FWF (P15958-B08)
Membrane bound Glucocorticoid-Receptors
2003
2006
Jubilumsfond der
sterr.Nationalbank
(10321)
Ghrelin: Regulation der Ausschttung und

Zusammenspiel mit autonomem
Nervensystem und Nhrstoffen
2004
2006
Brgermeisterfonds
Microarray-Analyse von
der Bundeshauptstadt Hypophysentumoren
Wien
2004
2005
Hochschuljubilums
stifung Stadt Wien
2002
2003
Brgermeisterfonds
Untersuchungen zur physiologischen und
der Bundeshauptstadt pathophsiologischen Regulation des
Wien (2179)
Peptidhormons Ghrelin
Microarray-Analyse von
Hypophysentumoren
page 79 of 168
total K
166
70
30
27

Name
Title of thesis
Period (expected)
Acad.Title
Maier Christina
SLE & IDDM eine seltene
2000-2001
Thesis MD
(toghether with
J.Smolen)
Kombination
Schmidt Adele
Untersuchungen zur Regulation
2002-2003
Thesis MD
2004-2006
Thesis
der Ghrelin-Sekretion
Altenberger Tibor
Aberrant Gene Expression
(toghether with
L.Wagner)
Patterns in Pituitary Tumors
Kasses Dominik
Auswirkungen der Stoffwech-
PhD
ongoing
seleinstellung auf das Endokrinium bei Diabetikern

Gorczyca Monika
Hypercortisolismus als Ursache
Diploma
MD
ongoing
einer unzureichenden Stoffwechseleinstellung bei Typ 2

Diabetikern
Diploma
MD
Publications
Blank D, Riedl M, Reitner A, Schnack C, Schernthaner G, Clodi M, Frisch H, Luger A 2000
Growth hormone replacement therapy is not associated with retinal changes. J Clin Endocrinol
Metab 85:634-636
Luger A 2000 Trau keinem ber 30, Testosteron fr alle Mnner ber 50? Wien Klin
Wochenschr 112:339-340
Riedl M, Clodi M, Kotzmann H, Hainfellner JA, Schima W, Reitner A, Czech T, Luger A 2000
Apoplexy of a pituitary macroadenoma with reversible third, fourth and sixth cranial nerve
palsies following administrastion of hypothalamic releasing hormones: MR features. Eur J
Radiol 36:1-4
Riedl M, Ludvik B, Pacini G, Clodi M, Kotzmann H, Wagner O, Kautzky-Willer A, Prager R,
Luger A 2000 The increased insulin sensitivity in growth hormone-deficient adults is reduced
by growth hormone replacement therapy : Eur J Clin Invest 30:771-778
Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G,
Frisch H, Hrl WH, Mayer G, Luger A 2001 Differential effects of growth hormone therapy in
malnourished hemodialysis patients. Kidney Int 60:1578-1585
page 80 of 168
Riedl M, Kotzmann H, Luger A 2001 Wachstumshormon beim lteren Mann. Wien Med
Hernberg-Stahl E, Luger A, Abs R, Bengtsson B, Feldt-Rasmussen U, Wilton P, Westberg B,
Monson JP 2001 Healthcare consumption decreases in parallel with improvements in quality of
life during growth hormone (GH) replacement in hypopituitary adults with GH deficiency. J
Clin Endocrinol Metab 86:5277-5281
Kehely A, Bares PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KKY,
Lombardi G, Luger A, Marek J, Russell-Jones D, Snksen P, Attanasio AF 2002 Short-term
safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a
comparison of two dosage algorithms. J Clin Endocrinol Metab 87:1974-1979
Schmidt A, Luger A, Hrl WH 2002 Sexual hormone abnormalities in male patients with renal
failure. Nephrol Dial Transplant 17:368-371
Maier C, Rnzler D, Wagner L, Grabner G, Khler G, Luger A 2002 Evidence for specific
glucocorticoid binding sites on the cell membrane by fluorescence correlation spectroscopy.
Single Mol 3:211-216
Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. 2003 Plasma ghrelin
concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes 52:16-20.
Kotzmann H, Schmidt A, Riedl M, Schuster E, Geyer G, Frisch H, Hrl WH, Mayer G, Luger
A. 2003 One year growth hormone therapy improves granulocyte function, but not nutritional
and anthropometric parameters in malnourished hemodialysis patients. Nephron Clin Pract
93:c75-c82.
Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P,
Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J,
Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A. 2003 Effect of low-dose perindopril/
indapamide on albuminuria in type 2 diabetes. Preterax in albuminuria regression: PREMIER.
Hypertension 41:1063-1071.
Weitgasser R, Lechleitner M, Luger A, Klingler A. 2003 Effects of glimepiride on HbA1C and
body weight in type 2 diabetes: results of a 1.5 year follow-up study. Diabetes Res Clin Pract
61:13-19.
Pfeiffer C, Winkler F, Luger A, Pieber T, Saudek F, Skrha J, Hermansen K, Lervang HH,
Nistrup-Holmegaard S, Bergkulla S, Lembcke HJ, Schulze J, Petersen KG, Haslbeck M, Jonker
JJC, Vaaler S, Rolstad OJ, Distiller LA, Robertson LI, Omar MAK, Wing J, Arner P, Arnqvist
H, Lager I, Lennerhagen P, Borthwick LJ, Hattersley A, Owens DR, Mathews DR, Nattrass M.
2003 Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with
oral treatment in Type 2 diabetic patients. Diabetic Med 20:545-551.
Luger A. 2003 Erkrankungen der Hypophyse: Klinische Symptomatik und biochemische
Diagnostik. Wien Klin Wochenschr 115 (Suppl 2):19-22.
Feinbck C, Luger A, Klingler A, Egger T, Kacerovsky Bielesz G, Winkler F, Siebenhofer A,
Groschdl F, Frank E, Irsigler K 2003 Prospective multicentre trial comparing the efficacy of,
and compliance with, glimepiride or acarbose treatment in patients with type diabetes not
controlled with diet alone. Diab Nutr Metab 16:214-221
Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster J, Kreuzer S, Frisch H, Geyer G,
Hrl WH, Mayer G, Luger A 2004 Effects of 12 months of recombinant growth hormone
therapy on parameters of bone metabolism and bone mineral density in malnourished patients
page 81 of 168
on chronic hemodialysis. J Nephrol, 17:87-94

Schmidt A, Maier C, Schaller G, Nowotny P, Bayerle-Eder M, Buranyi B, Luger A, Wolzt M
2004 Acute exercise has no effect on ghrelin plasma concentrations. Horm Metab Res 36:174177
Maier C, Riedl M, Clodi M, Bieglmayer C, Mlynarik V, Trattnig S, Luger A 2004 Dynamic
contrast-enhanced MR imaging of the stimulated pituitary gland, Neuroimage 22:347-352
Schmidt A, Fabrizii V, Maier C, Riedl M, Schmidt A, Kotzmann H, Geyer G, Luger A. 2004
Normal regulation of elevated plasma ghrelin concentrations in dialysis patients. Wien Klin
Kller MD, Templ E, Riedl M, Clodi M, Wagner O, Smolen JS, Luger A 2004 Pituitary
function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum
Dis 63:1677-1680
Maier C, Schaller G, Buranyi B, Nowotny P, Geyer G, Wolzt M, Luger A 2004 The cholinergic
system controls ghrelin release and ghrelin induced GH release in humans. J Clin Endocrinol
Metab 89:4729-4733
Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, Maier C, Luger A,
Ludvik B 2004. The impact of laparoscopic banding (LABG) on plasma ghrelin, eating
behaviour and body weight. Eur J Clin Invest 34:549-554
Maier C, Luger A 2004 Endokrinologie und Adipositas. Acta Med Austriaca 31:112-114
Frossard M, Blank D, Joukhadar C, Bayegan K, Schmid R, Luger A, Mller M 2005 Interstitial
glucose in skeletal muscle of diabetic patients during an oral glucose tolerance test. Diabetic
Med 22:56-69
Maier C, Rnzler D, Schindelar J, Grabner G, Waldhusl W, Khler G, Luger A 2005 G-protein
coupled glucocorticoid receptors on the pituitary cell membrane. J Cell Sci 118:3353-3361
Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzel E, Schindler K,
Luger A, Ludvik B, Prager G 2005 Sleeve gastrectomy and gastric banding: effects on plasma
ghrelin levels. Obes Surg 15: 1024-1029
Ziegler S, Kudlacek S, Luger A, Minar E 2005 Osteoprotegerin plasma concentrations correlate
with severity of peripheral artery disease. Atherosclerosis 182:175-180
Luger A 2005 Schilddrse und Polyendokrinopathien. Wiener Med Whschr, 155: 454-457
Maier C, Mustapic D, Schuster E, Luger A, Eher R 2006 Effect of a pocket-size tablet
dispensing device on glycemic control in type 2 diabetic patients. Diabetic Medicine 23:40-45
Altenberger T, Bilban M, Auer M, Knosp E, Wolfsberger S, Gartner W, Mineva I, Zielinski C,
Wagner L, Luger A 2006 Identification of DLK1 variants in pituitary and neuroendocrine
tumors. Biochem Biophys Res Comm 340:995-1005
Riedl M, Maier C, Zettinig G, Nowotny P, Schima W, Luger A 2006 Long term control of
hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 154:519524
Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M 2006 The release of the
adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49: 1909-1914
Gartner W, Koc F, Nabokikh A, Daneva T, Niederle B, Luger A, Wagner L 2006 Long-term in
vitro growth of human insulin-secreting insulinoma cells. Neuroendocrinol 83: 123-130
Schindler K, Haider D, Wolzt M, Rieger A, Gmeinhart B, Luger A, Nowotny P, Ludvik B 2006
page 82 of 168
The adipocytokines visfatin and retinol binding protein 4 (RBP-4) before and following 12
months of antiretroviral therapy in HIV infected subjects. Eur J Clin Invest 36: 640-646
Zettinig G, Wrba F, Trautinger F, Peloschek P, Luger A 2006 Necrobiotic panniculitis due to
repeated Insulin injection: A rare cause of a false positive Somatostatin receptor scintigraphy.
Nuklearmedizin 45: N64-N66
Wieselthaler G, Riedl M, Templ E, Wolner E, Wagner O, Luger A, Clodi M 2007 Endocrine
function is not impaired in patients with a continuous MicroMed-DeBakey axial flow pump. J
Thorac Cardiovasc Surg 133: 2-6
Haider DG, Schindler K, Mittermayer F, Mller M, Nowotny P, Rieger A, Luger A, Ludvik B,
Wolzt M 2007 Effect of rosiglitazone on visfatin and retinol binding protein-4 plasma
concentrations in HIV-positive patients. Clin Pharmacol Ther 81: 580-585
Maier C, Mustapic D, Schuster E, Luger A, Eher R 2007 Effect of a pocket-size tabletdispensing device on glycaemic control in type 2 diabetic patients. Authors response. Diabet
Med 24: 102
Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik B 2007 Serum
retinol-binding protein-4 is reduced after weight loss in morbidly obese subjects. J Clin
Endocrinol Metab 92: 1168-1171
Haider DG, Schindler K, Mittermayer F, Mller M, Nowotny P, Rieger A, Luger A, Ludvik B,
Woltz M 2007 Plasma adipocyte and epidermal fatty acid binding protein is reduced after
weight loss in obesity. Diabetes Obes Metab, in press
Haider DG, Handisurya A, Storka A, Vojtassakova A, Luger A, Pacini G, Tura A, Wolzt M,
Kautzky-Willer A 2007 Visfatin response to glucose is reduced in women with gestational
diabetes mellitus. Diabetes Care, 30: 1889-1891
Gartner W, Vila G, Daneva T, Nabokikh A, Koc-Saral F, Ilhan A, Majdic O, Luger A, Wagner
L 2007 New functional aspects of the neuroendocrine marker secretagogin based on the
characterization of its rat homologue. Am J Physiol-Endoc M, 293: E347-354
Riedl M, Maier C, Handisurya A, Luger A, Kautzky-Willer A 2007 Insulin resistance has no
impact on ghrelin suppression in pregnancy. J Int Med, in press
Anderwald C, Stadler M, Promintzer M, Prager G, Mandl M, Nowotny P, Bischof M, Wolzt M,
Ludvik B, Pacini C, Luger A, Krebs M 2007 Clamp-like index: a novel, highly sensitive insulin
sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose
tolerance test in nondiabetic humans. Diab Care, in press
Nabokikh A, Ilhan A, Bilban M, Gartner W, Vila G, Niedlere B, Nielsen JH, Wagner O, Base
W, Luger A, Wagner L 2007 Reduced TGF-1 expression and its target genes in human
insulinomas. Exp Clin Endocr Diab, in press
page 83 of 168
Wolfgang MARKTL
Zentrum fr Physiologie und Pathophysiologie der Medizinischen Universitt Wien
wolfgang.marktl@meduniwien.ac.at
Curriculum Vitae
Geboren am 14. 5. 1944 in Waiern/Krnten.
Besuch der Volksschule in den Jahren 1950 bis 1954 in Klagenfurt.
Besuch des Realgymnasiums in Klagenfurt von 1954 bis 1962,
Matura am 4. 7. 1962.
Medizinstudium in Innsbruck und Wien in den Jahren 1962 bis 1968.
Promotion zum Dr.med.univ. am 15. 6. 1968 in Innsbruck.
Vom 1.11.1968 bis 31.12. 1969 sowie vom 1. 4. 1970 bis zum 31. 5. 1972 Assistenzarzt am
Institut fr allgemeine und experimentelle Pathologie der Universitt Wien, vom 1. 1. 1970
bis zum 31. 3. 1970 Assistenzarzt an der 1. Chirurgischen Univ. Klinik in Wien.
Seit 1. 6. 1972 am Institut fr Medizinische Physiologie der Universitt Wien.
Erlangung des Ius practicandi im Jahre 1976.
Habilitation fr medizinische Physiologie am 14. 1. 1983.
Leiter der Abteilung fr Umweltphysiologie und Balneologie am Zentrum fr Physiologie
und Pathophysiologie der Med.Univ. Wien
Seit 1. 4. 1986 Leitung des Ludwig Boltzmann Institutes zur Erforschung physiologischer
Rhythmen in Bad Tatzmannsdorf.
Juni 1994 Anerkennung als Facharzt fr medizinische Leistungsphysiologie
Ernennung zum tit.a.o.Univ.Prof. mit 4.10.1994
Verleihung des Ehrenkreuzes fr Wissenschaft und Kunst, I. Klasse, durch den
Bundesprsidenten mit Datum von 28.09.2001
Wissenschaftliche Arbeitsgebiete: Ernhrungs- und Stoffwechselphysiologie,
Balneologie und medizinische Klimatologie,
Chronobiologie
Funktionen in wissenschaftlichen Vereinigungen und Verbnden:
Leitung der Abteilung Wissenschaft im sterr. Heilbder- und Kurorteverband,
Mitglied des erweiterten Vorstandes und Ehrenmitglied des Verbandes sterr. Kurrzte,
derzeit 1. Vorsitzender der sterr. Gesellschaft fr Balneologie und
medizinische Klimatologie,
Grndungsmitglied der European Society for Chronobiology,
Mitglied der International Society for Chronobiology,
Vorstandsmitglied der sterreichischen Gesellschaft fr Ernhrung,
korrespondierendes Mitglied der geologischen Bundesanstalt,
Mitglied der European Academy of Nutritional Sciences,
sowie Mitglied zahlreicher weiterer wissenschaftlicher Gesellschaften des In- und Auslandes.
Schriftleiter der Zeitschrift Forschende Komplementrmedizin des Karger-Verlags bis 2007
Mitglied des Redaktionskollegiums der Zeitschrift Physikalische Medizin,
Rehabilitationsmedizin, Kurortemedizin des Thieme-Verlags,
Vorsitzender des Akademischen Rates der Wr. Internat. Akademie fr Ganzheitsmedizin; von
Juni 2000 bis Juni 2003 Vizeprsident der Wr. Internat. Akademie fr Ganzheitsmedizin,
Seit 24.06.2003 Prsident der Wr. Internat. Akademie fr Ganzheitsmedizin,
Mitglied der Codex-Kommission bis 2007
page 84 of 168
Seit 01.01.2002 Med.-Wiss. Leiter der Akademie fr den Ditdienst und

ernhrungsmedizinischen Beratungsdienst im AKH Wien,
Seit 29.01.2002 Vizeprsident des Akademischen Institutes fr Ernhrungsmedizin
Publikationsttigkeit: derzeit 271 wissenschaftliche Publikationen, wissenschaftlicher
Redakteur des Handbuchs der natrlichen Heilmittel sterreichs 1985, laufende
Vortragsttigkeit im In- und Ausland, Teilnahme an Sendungen von Rundfunk und
Fernsehen.
page 85 of 168
Bruno NIEDERLE
Section Endocrine Surgery, Division of General Surgery, Department of Surgery
bruno.niederle@meduniwien.ac.at
Surgical strategy in thyroid nodules classified as "follicular neoplasia"

Abstract
The surgical strategy in thyroid nodules classified as "follicular neoplasia" by fine-needle
aspiration (FNA) is still under discussion. The treatment of follicular adenoma is
hemithyroidectomy (lobectomy and isthmectomy) while follicular thyroid carcinoma has to
be treated by total thyroidectomy. If follicular lesions cannot be classified in frozen-sections
completion thyroidectomy has to be performed in a second procedure. Therefore the role of
frozen section, gender, age and tumor size in the differentiation of follicular adenoma from
carcinoma has to be analyzed retrospectively to define risk factors. As a consequence a
prospective protocol for the surgical treatment of "follicular thyroid lesions" should be
developed. Molecular genetic studies on fresh tissue and on tissue samples will help to
differentiate follicular adenoma, follicular carcinoma and the follicular variant of papillary
thyroid cancer.
Thesis Subjects
Is it justified to treat follicular thyroid lesions larger than 25 mm by total thyroidectomy to
avoid re-operations?
Retrospective multivariate analysis of demographic, clinical, surgical, histopathological and
follow-up data of 150 patients with follicular thyroid lesions classified as "follicular lesions"
by FNA: Correlation of FNA - frozen section - histopathology and clinical outcome
page 86 of 168
Curriculum Vitae
Bruno NIEDERLE
Department of Surgery , Division of General Surgery, Medical University of Vienna,
Waehringer Guertel 18-20, A-1090 Vienna, Austria; Phone +43 1 40400 6943; 5621, 5622;
Fax +43 1 40400 6827; Email bruno.niederle@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
25-08-1953
Steyr, Upper Austria
Austria
Education
Oct. 1st, 197 May 20th, 1976
University of Vienna, Medical School - MD
Career History
May 1,1974 - April 30, 1976
June 1, 1976 - Sept 30, 1977
June 1, 1977 -Nov 30, 1977
Sept 19, 1978 Sept 16, 1979
March 1, 1982 - August 31,
1982
March 1, 1983 - September 1,
1983
March 1, 1987 - August 31,
1987
Oct 1, 1988 - Feb 28, 1989
Since Oct 1, 1977 - pres.
June 1, 1989/July 7, 1989

Nov 25, 1992/Sept 8, 1993
Student Lecturer, Department of Anatomy, University of

Vienna
Assistant Lecturer, Department of Anatomy, University of
Vienna
Intern, Department of Internal Medicine, Cardiology,
Resident, Department of Traumatology I, University of
Vienna
Resident, Department of Anesthesiology, Intensive Care
Unit, University of Vienna
Senior Resident, Department of Surgery (incl.
traumatology, pediatric surgery) Provincial Hospital
Oberpullendorf
Intern, Department of
Pediatric Surgery , Mautner
Markhof'sche Kinderspital
Resident, Department of Surgery II, University of Vienna
(Thoracic/Heart Surgery)
Resident/Chief Resident/ Senior Resident
Department of Surgery, Division of General Surgery,
University of Vienna, Medical School
Assistant Professor of Surgery (Venia docendi)
Associate Professor of Surgery
page 87 of 168
July 1, 1999/March 1, 2000

December 7, 1983
May 15, 1992
April 6. 2003
Fellowships
Feb 1, 1977 - April 30, 1977
2002 2003
2004 present
1980
1984
1985
1986
1987
1989
1990
1991
1993
1989
1990
Professor of Surgery (Endocrine Surgery)

Registration:
Registered to practice surgery in Austria
Registered to practice vascular surgery in Austria
Qualification for Endocrine Surgery - European Board of
Surgery
Research Fellowship at the University of Fribourg,

Switzerland, Department of Anatomy
Management Training for Medical Leaders at the Univ.

Salzburg
Section leader "Obesity and Lipid Disorders", Austrian
Society for Endocrinology and Metabolism
Visiting Physician
National Institutes of Health, Cancer Institute, Surgical
Branch, Bethesda, USA
Memorial Sloan Kettering Cancer Center, Department of
Surgery, New York, USA
Toronto General Hospital, Division of Thoracic Surgery,
Toronto, Canada
Mayo Clinics, Department of Surgery, Rochester,
Minnesota, USA
Department of Surgery, University of Chicago, Chicago,
USA
Department of General Surgery, Division of Endocrine
Surgery, University of Michigan, Ann Arbor, USA
Department of General Surgery, Division of Endocrine
Surgery, University of Michigan, Ann Arbor, USA
Baylor College of Medicine, Department of Surgery,
Methodist Hospital and M.D. Anderson, Cancer Center,
University of Texas, Houston, USA
Department Surgery II, University of Nagoya, Japan
Visiting Professor:
Invited Guest Speaker - 1st International Postgraduate
Course in Endocrine Surgery
Department of Surgery, The Mary Imogene Bassett
page 88 of 168
1991
1993
1993
1993
1995
1997
1997
1999
1999
2001
2001
2002
2003
2003
Hospital Cooperstown, New York, USA

Faculty Member: 2nd International Postgraduate Course in
Endocrine Surgery (British Virgin Islands)
Faculty Member/Organizer: 3rd International Postgraduate
Course in Endocrine Surgery (Austria)
Invited Guest Speaker - 26th Annual Meeting of the
Japanese Society of Thyroid Surgeons, Nagoya
Department of Endocrine Surgery, Tokyo Women's
Medical College, Tokyo, Japan
Surgical Training Course Endocrine Surgery,
Department of Surgery, Martin Luther University Halle
Wittenberg, Germany
Department of Surgery, Heinrich Heine University
Dsseldorf, Germany
Department of Surgery, Martin Luther University Halle
Wittenberg, Germany
1st Postgraduate Course in Endocrine Surgery,
Chirurgische Arbeitsgemeinschaft fr Endokrinologie
(CAEK), German Association of Surgery, Braunlage/Harz,
Germany
Department of Surgery, Philipps University Marburg,
Germany
2nd Postgraduate Course in Endocrine Surgery,
(CAEK), German Association of Surgery, St. Johann,
Austria
4th International Post-graduate Course of Minimal-invasive
Endocrine Surgery, IRCAD/EITS Strasbourg, France
Faculty Member: 7th International Postgraduate Course in
Endocrine Surgery, France
(CAEK), German Association of Visceralsurgery,
Wernigerode, Germany
5th International Post-graduate Course of Minimal-invasive
Endocrine Surgery, IRCAD/EITS Strasbourg, France
page 89 of 168
2003
2004
2005
2005
1. Internationaler Operationskurs fr minimal-invasive

endokrine Chirurgie Klinik fr Chirurgie und Zentrum
fr Minimla-invasive Chirurgie der Kliniken Essen-Mitte
(10.11. 11.11.2003)
2. Internationaler Operationskurs fr minimal-invasive
endokrine Chirurgie Klinik fr Chirurgie und Zentrum
fr Minimla-invasive Chirurgie der Kliniken Essen-Mitte
(8.11. 9.11.2004)
4. Postgradualer Kurs fr Endokrine Chirurgie ,
Chirurgische Arbeitsgemeinschft fr Endokrinologie der
Deutschen Gesellschaft fr Viszeralchirurgie,, Bad
Blumau, Austria (3. - 5. Mrz 2005)
(6th) International Post-graduate Course of Minimalinvasive Endocrine Surgery, IRCAD/EITS Strasbourg,
France
1992
1993
1996
1996
1996
2001
1997
1998
1999
2000
Coordinator/Organizer of International Congresses and

Workshops
How to treat parathyroid hyperplasia, Vienna, Austria
3rd Postgraduate Course of the International Association of
Endocrine Surgeons (IAES), St. Johann, Austria
Carcinoids (Jejunum, ileum, colon. rectum, other
localization), 15. u CAEK, Feldkirch Austria
How to treat lymph node metastases in differentiated
thyroid cancer, Vienna, Austria
8th Annual Meeting of Euro-MEN, Vienna, Austria
(CAEK), German Association of Surgery, St. Johann,
Austria
Member of Organizing- and Scientific Committee of
International Congresses and Workshops
International Conference on the Management of Nonfunctioning Adrenal Tumors, Athens, Greek
Advanced Course on Endocrine Surgery, Rome, Italy
Local Organizer IAES-International Surgical Week,
Vienna, Austria
Thyroid Two, Linz, Austria
page 90 of 168
2002
2004
2004
2005
Awards
1985
1986
1986
1987
1987
1988
1989
1991
1998
2003
2004
2005
Editorial Board
1991 2002
Thyroid Three, Pichlarn, Austria

Endocrine Surgery International Meeting, Rom, Italy
Thyroid Four, Pichlarns, Austria
Member of International Consensus Conferences
Consensus Conference on the ENETS:
Guidelines for the Diagnosis and Treatment of
Neuroendocrine Gastrointestinal Tumors
Theodor Billroth Preis, sterreichische Gesellschaft fr

Chirurgie
Wissenschaftlicher Frderungspreis der sterreichischen
Gesellschaft fr Gefchirugie
Wissenschaftlicher Frderungspreis der Ersten
sterreichischen Sparkasse
Austrotransplantpreis
Wissenschaftlicher Anerkennungspreis des Landes
Niedersterreich
Wissenschaftlicher Frderungspreis der Ersten
sterreichischen Sparkasse
Billroth Preis, rztekammer fr Wien
Wissenschaftlicher Frderungspreis der sterreichischen
Gesellschaft fr Gefchirugie
BRAHMS Forschungspreis fr Schilddrsenerkrankungen
together with the sterreichischen Gesellschaft fr
Nuklearmmedizin
BRAHMS Forschungspreis fr Schilddrsenerkrankungen
Nuklearmmedizin
Sandoz Forschungspreis fr Schilddrsenerkrankungen
Nuklearmedizin
Sandoz Forschungspreis fr Schilddrsenerkrankungen
Nuklearmedizin
Editor-in-Chief: European Surgery - Acta Chirurgica
Austriaca
page 91 of 168
2002- present
Consultant Board
1998 - 2002
2001 2002
1998 - 2002
1998 - present
2006 - present
British Journal of Surgery
Minimal Invasive Chirurgie (Germany)

The European Journal of Surgery (Sweden)
Onkologie Aktuell (Germany)
Langenbeck`s Archives of Surgery (Germany)
Wiener Klinsiche Wochenschrift Middle European
Journal of Medicine (Austria)
Invited Reviews for

Surgery (USA)
World Journal of Surgery (USA)
Onkologie (Germany)
Transplant International (Germany)
European Journal of Endocrinology (Switzerland)
European Journal of Clinical Investigation (Great Britain)
European Journal of Surgical Oncology (Great Britain)
Wiener klinische Wochenschrift (Austria)
Memberships
Member of National Societies:
1978 Vienna Medical Association
1979 Austrian Society of Surgeons
1979 Austrian Society for Gastroenterology
1981 Society of Surgeons in Vienna
1985 Austrian Society of Surgical Research
1987 Austrian Society of Vascular Surgeons
1990 Austrian Society of Bone and Mineral Electrolyte Metabolism
1994 Austrian Society of Endocrinology and Metabolism
Member of International Societies
1984 International Association of Endocrine Surgeons (IAES)
1985 International Society of Surgery (ISS)
1985 German Society of Surgeons
1985 German Association of Endocrine Surgeons (CAEK)
1987 German Society of Endocrinology
page 92 of 168
2002
2003 2003 2004
- Fellow of the Royal College of Surgeons FRCS (London)

German Society of Viszeral Surgery
Fellow of the American College of Surgeons - FACS
Eurpean Neuroendocrine Tumour Society (ENETS)
Corresponding Member of International Societies

1992 Society of Head and Neck Surgeons, USA
1994 American Association of Endocrine Surgeons (AAES); USA
Council Member of National Societies
1991 2002.
Austrian Society of Surgeons
1992 pres.
Austrian Society of Surgical Oncology (ASSO)
[1992-1996 Chairman Thyroid Section; Secretary General 2003 - ]
1994 pres.
Austrian Society of Endocrinology and Metabolism
[2002-pres Coordinator: Section Endocrine Surgery]
1996 pres.
Society of Surgeons in Vienna
[President 1999 2000; Past-President 2000-2001]
Council Member of International Societies
1991 - 1997
International Association of Endocrine Surgeons (IAES)
1991 - 1996
Member of the Scientific Committee European School of
Oncology (ESO) Vienna Office
1996 pres.
Chirugische Arbeitsgemeinschaft fr Endokrinologie (CAEK),
German Association of Viszeral Surgeons [Co-chairman 1996 2000; Chairman 2003- ]
2003 European Society of Endocrine Surgeons (ESES) [Member of
the founding committee; 2003 - Secretary Treasurer]
Period
Organization
Short Title
2001-2003
Hochschuljubilumsf
onds (project no. H144/2001; together
with M. Schindl/K.
Kaczirek)
Irinotecan (Campt) und Paclitaxel

(Taxol) in der Behandlung
neuroendokriner Tumore
page 93 of 168
2001-lfd
Austrian National
Bank Jubilee Fund
(project no. 9307;
together with K.
Kaczirek, G. Prager)
Intraoperatives Parathomron-Monitoring:
Untersuchungen zur Parathormonkinetik
bei primrem und sekundrem
Hyperparathyreoidismus

Name
Title of thesis
Philipp Riss
Primrer
Period (expected)
Acad.Title
2006 (2008)
Dr. scient.
Hyperparathyreoidismus
intraoperatives PTH-Monitoring
Martin Bruno
Gastro-Enteropankreatische
Niederle
neuroendokrine Tumore GEPNET. Eine prospektive Studie

zur Inzidenz in sterreich
page 94 of 168
med.
Publications
586 peer reviewed publications in scientific journals (263 Original Papers, 10 invited
Commentaries, 6 Letters, 66 Short Papers, 29 Invited Reviews)
List of Original Publications (since 2000)
168 Wagner, B., Ludwig, C., Riedl, M., Niederle, B., Cejna, M., Vierhapper, H., Waldhusl,
W., Roden, M.: Severe chronic hypoglycemia in a lean young woman. PANCREAS 21,
97-99 (2000)
169 Raderer, M., Kurtaran, A., Leimer, M., Angelberger, P., Niederle, B., Vierhapper, H.,
Vorbeck, F., Hejna, M.,H.,L., Scheithauer, W., Pidlich, P Virgolini, I.: Value of peptide
receptor scintigraphy using 123-I Vasoactive Intestinale Peptide and 111-In DTPA-DPhe- Octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998.
J CLIN ONCOL 18, 1331-1336 (2000)
170 Muhm, M., Polterauer, P., Gstoettner, W., Temmel, A., Losert, H., Richling, B., Undt,
G., Niederle, B., Staudacher, M., Kretschmer, G., Ehringer, H.,.: Glomus caroticum Chemotectom., bersicht ber die aktuelle Diagnostik und Therapie. WIEN KLIN
WOCHENSCHR 112, 115 - 120 (2000)
171 Hrandner, H., Mrzl, E., Neyer, U., Breiteneder-Geleff, S., Niederle, B., Haid, A.,
Breitfellner, G.: Fokale Proliferationen in reaktiv hyperplastischen Nebenschilddrsen
bei terminaler Niereninsuffizienz - Implikation fr die Autotransplantation nach totaler
Parathyreoidektomie. WIEN KLIN WOCHENSCHR 112, 353 - 357 (2000)
172 Raber, W., Raffesberger, W., Kmen, E., Hamwi, A., Niederle, B., Waldhusl, W.,
Roden, M.: Pheochromocytoma with normal urinary and plasma catecholamines but
elevated plasma free metanephrines in a patient with adrenal incidentaloma.
ENDOCRINOLOGIST 10, 65 - 68 (2000)
173 Scheuba, Ch., Kaserer, K., Kortzmann, H., Bieglmayer, Ch., Niederle, B., Vierhapper,
H.: Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrinstimulated calcitonin. THYROID 10, 413 - 416 (2000)
174 Schindl, M., Kaczirek, K., Kaserer, K., Niederle, B.: Is the new classification of
neuroendocrine pancreatic tumors of clinical help? WORLD J SURG 24, 312 - 318
(2000)
175 Zacherl, J., Scheuba, Ch., Prager, G., Zacherl, M., Jakesz, R., Niederle, B.: Wie
kostengnstig ist die laparoskopische Adrenalektomie wirklich? MINIMAL INVASIVE
CHIRURGIE 9, 79 - 84 (2000)
176 Neunteufl, Th., Heher, S., Prager, G., Katzenschlager, R., Abela, C., Niederle, B.,
Stefenelli, Th.: Effects of sucessful parathyroidectomy on altered arterial reactivity in
patients with hypercalcemia: results of a 3-year follow-up study. CLIN ENDOCRINOL
53, 229 - 232 (2000)
177 Raber, W., Kaserer, K., Niederle, B., Vierhapper, H., Raber, W., Kaserer, K., Niederle,
B., Vierhapper, H.: Risk factors for malignancy of thyroid nodules initially identified as
follicular neoplasia by fine-needle aspiration: results of a prospective study of 120
patients. THYROID 10, 709 - 712 (2000)
178 Zettinig, G., Kaserer, K., Passler, Ch., Flores, J.,A., Niederle, B., Dudczak, R.:
Advanced insular thyroid carcinoma in a fourteen-year old girl: twenty-four years of
follow-up. THYROID 10, 435 - 437 (2000)
179 Raber, W., Raffesberger, W., Bischof, M., Scheuba, Ch., Niederle, B., Gasic, S.,
Waldhusl, W., Roden, M.: Diagnostic efficacy of unconjugated plasma metanephrines
page 95 of 168
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
for the detection of pheochromocytoma. ARCH INTERN MED 160, 2957 - 2963
(2000)
Virgolini, I., Traub, T., Leimer, M., Novotny, C., Pangerl, T., Ofluoglu, S., Halvadjieva,
E., Smith-Jones, P., Flores, J., Li, S.,R., Angelberger, P., Havlik, E., Andreae, F.,
Raderer, M., Kurtaran, A.,. Niederle, B., Dudczak, R.: New radiopharmaceuticals for
receptor scintigraphy and radionuclide therapy. Q J NUCL MED 44, 50 - 58 (2000)
Weinhaeusel, A., Vierhapper, H., Schlegl, R., Wagner, T., Muhr, D., Scheuba, Ch.,
Niederle, B., Haas, O.,A.: A novel mutation E 179K of the MEN1 gene predisposes for
multiple endocrine neoplasia-type 1 (MEN1). HUMAN MUTATION 16, 533 (2000)
Niederle, B., Prager, G., Scheuba, Ch., Passler, Ch., Schindl, M.: Minimal invasive
chirurgische Endokrinologie. ACTA CHIR AUSTRIACA 32, Suppl 165, 39-46 (2000)
Schindl, M., Kaserer, K., Niederle, B.: Treatment of gastric neuroendocrine tumors.
ARCH SURG 136, 49 - 54 (2001)
Kaserer, K., Knezevic, V., Passler, Ch., Niederle, B., Krizmann, D.: Expressionsanalyse
follikulrer Schilddrsenlsionen mittels cDNA Arrays auf Basis mikrodissezierter
Zellen:
Anwendungsmglichkeiten
fr
die
properative
Schilddrsen
Punktionszytologie. VERH DTSCH GES ZYT 22, 29-34 (2001)
Zettinig, G., Leitha, Th., Niederle, B., Kaserer, K., Becherer, A., Kletter, K., Dudczak,
R.: FDG positron emission tomographic, radioiodine, and MIBI imaging in a patient
with poorly differentiated insular thyroid carcinoma. CLIN NUCL MED 26, 599-601
(2001)
Roden, M., Raber, W., Bernroider, E., Niederle, B., Waldhusl, W., Gasic, S.:
Quantification of unconjugated metanephrines in human plasma without interference by
acetaminophen. CLIN CHEM 47, 1061-1067 (2001)
Prager, G., Czerny, Ch., Kurtaran, A., Passler, Ch., Scheuba, Ch., Bieglmayer, Ch.,
Niederle, B.: Minimally invasive open parathyroidectomy in an endemic goiter area.
ARCH SURG 136, 810 - 816 (2001)
Kaserer, K., Scheuba, Ch., Neuhold, N., Weinhaeusl, A., Vierhapper, H., Haas, O.,A.,
Vierhapper, H., Niederle, B.: Sporadic versus familial medullary thyroid
microcarcinoma - A histopathological study of 50 consecutive patients. AM J SURG
PATHOL 25, 1245-1251 (2001)
Passler, Ch., Avanessian, R., Kaczirek, K., Paregr, G., Scheuba, Ch., Schindl, M.,
Niederle, B.: Schilddrsenchirurgie im Alter. ACTA CHIR AUSTRIACA 33, 288-293
(2001)
Schmaldienst, S., Dittrich, E., Pietschmann, P., Niederle, B., Becherer, A., Watschinger,
B.: A patient with evidence of two underlying diseases causing hypercalcemia.
NEPHROL DIAL TRANSPLANT 16, 2413-2425 (2001)
Prager, G., Heinz-Peer, Gertraud Passler, Ch., Kaczirek, K., Schindl, M., Scheuba, Ch.,
Niederle, B.: Surgical strategy in adrenal masses. EUR J RADIOL 41, 70-77 (2002)
Hnigschnabl, Selma., Gallo, Sylvia., Niederle, B., Prager, G., Kaserer, K., Lechner, G.,
Heinz-Peer, Gertraud: How accurate is MR imaging in characterisation of adrenal
masses: update of a long-term study. EUR J RADIOL 41, 113-122 (2002)
Kandioler-Eckersberger, Daniela, Niederle, B., Herbst, F., Wenzl, E: A magnetic probe
to retrieve broken matallic parts of instruments during laparoscopuic procedures.
SURGICAL ENDOSCOPY 16, 208-209 (2002)
Steurer, M., Passler, Ch., Denk, Doris M., Schneider, Berit Niederle, B., Biegenzahn,
W.: Advantages of recurrent laryngeal nerve identification in thyroidectomy and
parathyroidectomy and the importance of preoperative and postoperative laryngoscopic
examination in more than 1000 nerves at risk. LARYNGOSCOPE 112, 124-133 (2002)
page 96 of 168
195 Bachleitner-Hofmann, T., Stift, A Friedl, J., Pfragner Roswitha., Radelbauer, K.,
Dubsky, P., Schller, G., Benk, T., Niederle, B., Brostjan, C., Jakesz, R., Gnant, M.:
Stimulation of autologous antitumor T-cell responses against medullary thyroid
carcinoma using tumor lysate-pulsed dendritic cells. J CLIN ENDOCRINOL METAB
87, 1098-1104 (2002)
196 Niederle, B., Haas, O.,A.: Multiple endocrine neoplasia syndromes. WIEN KLIN
WOCHENSCHR 114, 239-245 (2002)
197 Weinhusel, A., Kaserer, K., Vierhapper, H., Niederle, B., Haas, O.,A., : Multiple
endocrine neoplasia type 1 (MEN1) in Austria. WIEN KLIN WOCHENSCHR 114,
252-257 (2002)
198 Kaczirek, K., Prager, G., Schindl, M., Kaserer, K., Gessl, A., Vierhapper, H., Niederle,
B.: Multiple endocrine neoplasia 1- current recommendations for diagnosis and
treatment. WIEN KLIN WOCHENSCHR 114, 258-266 (2002)
199 Bieglmayer, C., Scheuba, C., Niederle, B., Flores, J., Vierhapper, H.: Screening for
medullary thyroid carcinoma: Experience with different immunoassays for human
calcitonin. WIEN KLIN WOCHENSCHR 114, 267-273 (2002)
200 Kaserer, K., Scheuba, C., Neuhold, N., Weinhusel, A., Vierhapper, H., Niederle, B.:
Recommendations for reporting C cell pathology of the thyroid. WIEN KLIN
WOCHENSCHR 114, 274-278 (2002)
201 Pfragner, R., Wirnsberger, G., H., Ingolic, E., Niederle, B.: Medullary thyroid
cartcinoma in cell culture - models for future therapies. WIEN KLIN WOCHENSCHR
114, 279-283 (2002)
202 Zettinig, G., Fueger Barbara J., Passler, Ch., Kaserer, K., Pirich, Ch., Dudczak, R.,
Niederle, B.: Long-term follow-up of patients with bone matastases from differentated
thyroid cancer-surgery or conventional treatment? CLIN ENDOCRINOL 56, 377-382
(2002)
203 Neyer, U., Hrandner, H., Haid, A., Zimmermann, G., Niederle, B.: Total
parathyroidectomy with autotransplantation in renal hyperparathyroidism: low
recurrence after intra-operative tissue selection. NEPHROL DIAL TRANSPLANT 17,
625-629 (2002)
204 Zettinig, G., Prager, G., Kurtaran, A., Kaserer, K., Czerny, Ch., Dudczak, R., Niederle,
B.: Stellenwert eines strukturierten Befunsschemas zur Interpretation der
Nebenswchilddrsenszintigraphie bei primrem Hyperparathyreoidismus. ACTA MED
AUSTRIACA 29, 68 - 71 (2002)
205 Zettinig, G., Kurtaran, A., Prager, G., Kaserer, K., Dudczak, R., Niederle, B.:
""Suppressed"" double adenoma - a rare pitfall in minimally invasive
parathyroidectomy. HORMONE RES 57, 57 -60 (2002)"
206 Prager, G., Heinz-Peer, G., Passler, Ch., Kaczirek, K., Schindl, M., Scheuba, Ch.,
Vierhapper, H., Niederle, B.: Can dynamic Gadolinium-enhanced magnet resonance
imaging with chemical shift studies predict the status of adrenal masses? WORLD J
SURG 26, 958 - 964 (2002)
207 Schindl, M., Kaczirek, K., Passler, Ch., Kaserer, K., Prager, G., Scheuba, Raderer, M.,
Niederle, B.: Treatment of small intestinal neuroendocrine tumos: Is an extended
multimodal approach justified? WORLD J SURG 26, 976 - 984 (2002)
208 Bieglmayer, C., Prager, G., Niederle, B.: Kinetic analyses of parathyroid hormone
clearence as measured by three rapid immunoassays during parythyroidectomy. CLIN
CHEM 48, 1731-1738 (2002)
209 Passler, Ch., Avanessian, R., Kaczirek, K., Prager, G., Scheuba, Ch., Niederle, B.:
Thyroid surgery in the elderly. ARCH SURG 137, 1243 - 1248 (2002)
page 97 of 168
210 Prager, G., Kalaschek, A., Kaczirek, K., Passler, Ch., Scheuba, Ch., Sonneck, G.,
Niederle, B.: Parathyroidectomy improves concentration and retentiveness in patients
with primary hyperparathyroidism. SURGERY 132 , 930 - 936 (2002)
211 Gimm, O., Niederle, Barbara.,E., Weber, Theresia Bockhorn, M., Ukkat, J., Brauckhoff,
M., Nguyen Thanh, P., Frilling, Andreja Klar, E., Niederle, B., Dralle, H.: RET protooncogene mutations affecting codon 790/791: a mild form of MEN 2A? SURGERY
132 , 952 - 952 (2002)
212 Kaserer, K., Knezevic, V., Pichlhofer, B., Scheuba, C., Passler, C., Worth, J., Niederle,
B., Krizman, D.: Construction of cDNA libraries from microdissected benign and
malignant thyroid tissue. LAB INVEST 82, 1707-1714 (2002)
213 Passler, C., Prager, G., Scheuba, C., Kaserer, K., Zettinig, G., Niederle, B: Application
of staging systems for differentiated thyroid carcinoma in an endemic goiter region with
iodin substitution. ANN SURG 237, 227-234 (2003)
214 Saeger, W., Fassnacht, M., Chita, R., Prager, G., Nies, C., Lorenz, K., Bhrlehner, E.,
Simon, D., Niederle, B., Beuschlein, F., Allolio, B., Reincke, M.: High diagnostic
accuracy of adrenal core biopsy: Results of the German and Austrian adrenal network
multicenter trial in 220 consecutive patients. HUMAN PATHOL 34, 180-186 (2003)
215 Prager, G., Czerny, Ch., Ofluoglu, S., Kurtaran, A., Passler, Ch., Kaczirek, K., Scheuba,
Ch., Niederle, B.: Impact of localization studies on feasibility of minimally invasive
parathyroidectomy in an endemic goiter region. J AM COLL SURG 196, 541-548
(2003)
216 Loewe, Ch., Schindl, M., Cejna, M., Niederle, B., Lammer, J., Thurnher, S.: Permanent
transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate
and lipiodol: Assessment of mid- and long-term results. AM J ROENTGENOL 180,
1379-1384 (2003)
217 Kaczirek, K., Soleiman, A., Schindl, M., Passler, Ch., Scheuba, C., Prager, G., Kaserer,
K., Niederle, B.: Nesidioblastosis in adults: a challenging cause of organic
hyperinsulinism. EUR J CLIN INVEST 33, 488-492 (2003)
218 Niederle, B., Prager, G: Advanced endoscopic adrenal surgery - new developments.,
EUR SURG 35, 71-75 (2003)
219 Brauckhoff, M., Kaczirek, K., Than, PN., Gimm, O., Br Anette Niederle, B., Dralle,
H.: Technikal aspects of subtotal endoscopic adrenalectomy. EUR SURG 35, 84-88
(2003)
220 Rauhofer, U., Prager, G., Hoermann, M., Auer, H., Kaserer, H., Niederle, B.: Cystic
echninococcosis of the thyroid gland in children and adults. THYROID 13, 497-502,
(2003)
221 Kaczirek, K., Prager, G., Kienast, O., Dobrozemsky, G., Dudczak, R., Niederle, B.,
Kurtaran, A.: Combined transmission and 99Tc-Sestamibi emission tomography for
localization of mediastinal parathyroid glands. NUKLEARMEDIZIN 42, 220-223
(2003)
222 Passler, C., Prager, G., Scheuba, C., Niederle, Barbara E., Kaserer, K., Zettinig, G.,
Niederle, B.: Follicular Variant of Papillary Thyroid Carcinoma - A long-term followup. ARCH SURG 138, 1362-1366 (2003)
223 Niederle, B., Prager, G., Kaczirek, K., Scheuba, C., Passler, C., Asari, R.: Minimalinvasive Chirurgische Endokrinologie: Aspekte der Radiodiagnostik. WIEN KLIN
WOCHENSCHR 115, SUPPL 2, 10 - 18 (2003)
224 Weinhusel, A., Behmel, A., Ponder, BAJ., Haas, OA., Niederle, B., Gessl, A.,
Vierhapper, H., Pfragner, R.: Long-term follow-up revealed ""sporadic""
pheochromocytoma as multiple endocrine neoplasia type 2A-2 (MEN2A-2).
ENDOCRINE PATHOLOGY 14, 375 - 382 (2003)"
page 98 of 168
225 Prager, G., Riss, P., Bieglmayer, C., Niederle, B: The role of intraoperative quick PTH
measurements in primary hyperparathyroidism., ANN ITAL CHIR 74, 395-399 (2003)
226 Prager, G., Heinz-Peer, G., Passler, C., Kaczirek, K., Scheuba, C., Niederle, B.:
Applicability of laparoscopic adrenalectomy in 150 consecutive patients a prospective
study. ARCH SURG 139, 46-49 (2004)
227 Karges W, Dralle, H, Raue, F, Mann, K., Reiners, C, Grussendorf M, Hfner, M,
Niederle, B, Brabant, G, : Calcitonin Measurement to Detect Medullary Thyroid
Carcinoma in Nodular Goiter: German Evidence-Based Consensus Recommendation.
EXP CLIN ENDOCRINOL DIABETES 112, 42-58 (2004)
228 Karanikas G, Moameni A, Poetzi C, Zettinig G, Kaserer K, Bieglmayer C, Niederle B,
Dudczak R, Pirich Ch.: Frequency and Relevance of Elevated Calcitonin Levels in
Patients with Neoplastic and Nonneoplastic Thyroid Disease and in Healthy Subjects. J
CLIN ENDOCRINOL METAB 89, 1098-1104 (2004)
229 Passler, C., Scheuba, C., Prager, G., Kaczirek, K., Kaserer, K., Zettinig, G., Niederle,
B.: Prognostic factors of papillary and follicular thyroid cancer: Differences in an
iodine-repleted endemic goiter region. ENDOCRINE-RELATED CANCER 11, 129137 (2004)
230 Stadler A, Schima W, Prager G, Homolka P, Heinz G, Saini S, Eisenhuber E, Niederle
B.: CT Density Measurements for Characterization of Adrenal Tumors Ex Vivo:
Variability Among Three CTScanners. AM J ROENTGENOL 182, 671-675 (2004)
231 Kaczirek, K., Schindl, M., Weinhusl, A., Scheuba, C., Passler, C., Prager, G., Raderer,
M., Hamilton, G., Mittlbck, M., Siegl, V., Pfrganer, Roswitha Niederle, B: Cytotoxic
Activity of Camtothecin and Palitaxel in Newly Established continuous Human
Medullary Thyroid Carcinoma Cell Lines. J CLIN ENDOCRINOL METAB 89, 23972401(2004)
232 Stift, A., Sachet, Monika Yagubian, Rubina Bittermann, C., Dubsky, P., Brostjan,
Christina Pfragner, Roswitha Niederle, B., Jakesz, R., Gnant, M., Friedl, J.: Dendritic
Cell Vaccination in Medullary Thyroid Carcinoma. CLIN CANCER RES 10, 29442953 (2004)
233 Zierhut, Barbara Mechtler, K., Gartner, W., Daneva, T., Base, W., Weissel, M.,
Niederle, B., Wagner, L.: Heat shock protein 70 (Hsp70) subtype expression in
neuroendocrine tissue and identification of neuroendocrine tumour-specific Hsp70
truncation. ENDOCRINE-RELATED CANCER 11, 377-389 (2004)
234 Kaczirek, K., Ba-Ssalamh, A., Schima, W., Niederle, B.: The importance of
preoperative localisation procedures in organic hyperinsulinism -Experience in 67
patients. WIEN KLIN WOCHENSCHR 116, 373-378, (2004)
235 Zettinig, G., Mitterhauser, M., Wadsak, W, Becherer, A., Pirich, C., Vierhapper, H.,
Niederle, B., Dudczak, R., Kletter, K.: Positron emission tomography imaging of
adrenal masses: 18F-fluorodeoxyglucose and the 11-hydroxylase tracer 11Cmetomidate. EUR J NUCL MED MOL IMAGING 31, 1224-1230 (2004)
236 zer, S., Dobrozemsky, G, Kienast, O., Beheshti, M., Becherer, A., Niederle, B.,
Kainberger, F., Dudczak, R., Kurtaran, A.: Value of combined XCT/SPECT technology
for avoiding false positive planar 123I-MIBG scintigraphy. NUCLEAR MEDICINE 43,
164-170, (2004)"
237 Kaczirek, K, Niederle, B.: Nesidioblastosis: an old term and a new understanding.
WORLD J SURG 28, 1227-1230 (2004)
238 Gimm, O., Ukkat, J., Niederle, Barbara.,E., Weber, Theresia Nguyen Thanh, P.,
Brauckhoff, M., Niederle, B., Dralle, H.: Timing and extent of surgery in patients with
familial medullary thyroid carcinoma/Multiple endocrine neoplasia 2A-related RET
mutations not affecting codon 634. WORLD J SURG 28, 1312 -1316 (2004)
page 99 of 168
239 Passler, C., Scheuba, C., Asari, R., Kaczirek, K., Kaserer, K., Niederle, B: Importance
of tumour size in papillary and follicular thyroid cancer. BR J SURG 92, 184-189
(2005)
240 Kaczirek, K., Asari, R., Scheuba, C., Niederle, B.: Organic hyperinsulinism and
endoscopic surgery. WIEN KLIN WOCHENSCHR 117 (2005)
241 Kaczirek, K., Prager, G., Bieglmayer, C., Asari, R., Scheuba, C., Niederle, B: Quick
PTH assay cannot predict incomplete parathyroidectomy in patients with renal
hyperparathyroidism. SURGERY 137, 431-435 (2005)
242 Gartner, W., Mineva, I., Daneva, T., Baumgartner.,Parzer, Sabine., Niederle, B.,
Weissel, M., Wagner, L.: A new identified RET proto-oncogen polymorphism is found
in a high number of endocrine tumor patients. HUM GENET 117, 143-153 (2005)
243 Deicher, R., Kirsch, B., Mullner, M., Kaczirek, K., Niederle, B., Horl, WH.: Impact of
parathyroidectomy on neutrophil cytosolic calcium in chronic kidney disease patients: a
prospective parallel group trial. J INTERN MED., 258, 67-76 (2005)
244 Baumgartner-Parzer, S.,M., Lang, R., Wagner, L., Heinze, G., Niederle, B., Kaserer, K.,
Waldhusl, W., and Vierhapper, H.: Polymorphism in exon 13 and intron 14 of the RET
protooncogen: Genetic modifiers of medullary thyroid carcinoma? J CLIN
ENDOCRINOL METAB 90, 6323-6236 (2005)
245 Pfragner, R., Skowitsch, G., Hger, H., Jech, M., Rinner, B., Siegl, V., Niederle, B.,
Gnant, M., Friedl, J., Stift, A.: Medullary thyroid carcinoma: Autologous tumor cell
lines for dendritic cell vaccinationin. ANTICANCER RESEARCH 25, 4121-4126
(2005)
246 Vierhapper, H., Niederle, B., Bieglmayer, C., Kaserer, K., Baumgartner-Parzer; S.:
Early Diagnosis and Curative Therapy of Medullary Thyroid Carcinoma by Routine
Measurement of Serum Calcitonin in Patients with Thyroid Disorders. THYROID 15,
1267-1272.(2005)"
247 H., Vierhapper, H., Rondot, S., Schulze, E., Wagner, L., Hanslik, S., Niederle, B.,
Bieglmayer, C., Kaserer, K., Baumgartner-Parzer, S.: Primary Hyperparathyroidism as
the Leading Symptom in a Patient with an Y791F RET Mutation. THYROID 15, 13031308 (2005)
248 Niederle, B.,E., Schmidt, G., Organ, C.,H., Niederle, B.: Albert J and His Surgeon: A
Historical Reevaluation of the First Parathyroidectomy. J AM COLL SURG 202, 181190 (2006)
249 Kaczirek, K., Prager, G., Riss, Ph., Wunderer, G., Asari, R., Scheuba, C., Bieglmayer,
C., Niederle, B.: Novel Parathyroid Hormone (1-84) Assay as Basis for Parathyroid
Hormone Monitoring in Renal Hyperparathyroidism. ARCH SURG 141, 129-134
(2006)
250 Schuetz, M., Beheshti, M., Oezer, S., Novotny, C., Paul, M., Hofmann, A., Bieglmayer,
C., Niederle, B., Kletter, K., Dudczak, R., Karanikas, G., Pirich, C.: Calcitonin
measurements for early detection of medullary thyroid carcinoma or its premalignant
conditions in Hashimotos thyroiditis. ANTICANCER RESEARCH 26, 723-728 (2006)
251 Scheuba, C. Kaserer, K. Kaczirek, K. Asari, R. Niederle, B.: Desmoplastic stromal
reaction in medullary thyroid cancer - an intraoperative "marker" for lymph node
metastases. WORLD J SURG 30, 853-859 (2006)
252 Bieglmayer, C., Kaczirek, K. Prager, G. Niederle, B.: Parathyroid hormone monitoring
during total parathyroidectomy for renal hyperparathyroidism: pilot study of the
impact of renal function and assay specifity. CLIN CHEM 52, 1112-1119 (2006)
253 Gartner W, Koc F, Nabokikh A, Daneva T, Niederle B, Luger A, Wagner L: LongTerm in vitro Growth of Human Insulin-Secreting Insulinoma Cells.
NEUROENDOCRINOLOGY 83, 123-130 (2006)
page 100 of 168
254 Schima W, Ba-Ssalamah A, Plank C, Kulinna-Cosentini C, Prokesch R, Tribl B,

Sautner T, Niederle B.: Pankreas : Teil II Tumore. RADIOLOGE 46, 421-438 (2006)
255 Asari R, Scheuba, C, Kaczirek, K., Niederle B: Estimated risk of pheochromocytoma
recurrence after adrenal sparing surgery in patients with MEN 2A. ARCH SURG
141,1199-1205 (2006)
256 Jensen, R.T. Niederle, B. Mitry, E. Ramage, J.K. Steinmller, T. Lewington, V.
Scarpa, A. Sundin, A. Perren, A. Gross, D. O'Connor, J.M. Pauwels, S. Klppel, G.:
Gastrinoma (Duodenal and Pancreatic). NEUROENDOCRINOLOGY 84:173-182
(2006)
257 de Herder, W.W. Niederle, B. Scoazec, J.-Y. Pauwels, S. Klppel, G. Falconi, M.
Kwekkeboom, D.J. berg, K. Eriksson, B. Wiedenmann, B. Rindi, G. O'Toole, D.
Ferone, D.:
Well-Differentiated
Pancreatic
Tumor/Carcinoma:
Insulinoma.
NEUROENDOCRINOLOGY 84:183-188 (2006)
258 Heinz-Peer G, Memarsadeghi M, Niederle B.: Imaging of adrenal masses. CURR OPIN
UROL 17, 32-38 (2007)
259 Scheuba C, Bieglmayer, C, Asari R, Kaczirek K, Izay B, Kaserer K, Niederle B.: The
value of intraoperaitve pentagastrin testing in medullary thyroid cancer. SURGERY 141
(2007)
260 Bieglmayer C., Vierhapper, H., Dudczak, R., Niederle, B.: Measurement of calcitonin
by immunoassay analyzers. CLIN CHEM LAB MED 45, 662-666 (2007)
261 Koperek O, Scheuba C, Puri C, Birner P, Haslinger C, Rettig W, Niederle B, Kaserer K,
Garin Chesa P.: Molecular characterization of the desmoplastic tumor stroma in
medullary thyroid carcinoma. INT J ONCOL 3: 59-67 (2007)
262 Riss P, Kaczirek K, Bieglmayer C, Niederle B: PTH spikes during parathyroid
exploration-a possible pitfall during PTH monitoring? LANGENBECKS ARCH SURG
392: 427-30 (2007)
263 Neumayer C, Moritz A, Asari R, Weinhusel A, Hlzenbein T, Kretschmer G, Niederle
B, Haas OA: Novel SDHD germ-line mutations in pheochromocytoma patients. EUR J
CLIN INVEST 37, 544-551 (2007)
## Riss P, Kaczirek K, Heinze G, Bieglmayer C, Niederle B: A defined baseline in PTH
monitoring increases surgical success in patients with multiple gland disease. Surgery,
in press (2007)
page 101 of 168
Peter PIETSCHMANN
Institute of Pathophysiology
peter.pietschmann@meduniwien.ac.at
Osteoblastic gene expression patterns and microarchitecture of bone in

male osteoporosis
Abstract
Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength
predisposing a person to an increased risk of fracture. Bone strength primarily reflects the
integration of bone density and bone quality. In osteoporosis histomorphometric findings
typically include reduced trabecular bone volume, low trabecular number, reduced trabecular
thickness and poor connectivity. Osteoporosis results from an imbalance of bone resorption
and bone formation and traditionally has been regarded as a disease of postmenopausal
women. Nevertheless, although definitely underestimated, osteoporosis in men is a frequent
and severe disease. In the European Vertebral Osteoporosis Study, which enrolled over
15.000 men and women from 36 countries, the mean prevalence of vertebral deformities was
12% in women and 12% in men. The prevalence increased with age in both sexes,
nevertheless, the curve was steeper in women than in men. Moreover, poor outcome
following hip fracture is gender-dependent; it has been reported that male gender increases
mortality risk after hip fracture by fourfold.
No pathogenetic model for idiopathic male osteoporosis has reached common consent
yet; nevertheless a number of factors influencing the male skeleton have been discussed.
Estrogen deficiency traditionally has been associated with postmenopausal osteoporosis but
also plays a prominent role in the pathogenesis of male osteoporosis. Several studies have
suggested that increased serum levels of sex hormone binding globulin lead to a decrease in
free androgens and estrogen. Moreover, calcium absorption is low in osteoporotic men; renal
calcium loss and hypercalciuria may be further pathogenetic aspects. In addition, low plasma
levels of insulin-like growth factor-1 have been found. In studies on bone histomorphometry
in idiopathic osteoporosis in men, some authors described an impaired bone formation while
others found that bone resorption is increased. Studies from our laboratory on biochemical
markers demonstrated that in men with idiopathic osteoporosis bone resorption is increased
and exceeds bone formation.
In order to further elucidate the pathogenesis of male osteoporosis, we will analyze
osteoblastic gene expression patterns in bone from men with hip fractures due to primary
osteoporosis. Femoral heads will be obtained from men undergoing hip arthroplasty either for
hip fracture or osteoarthritis (as a control group). We will assess the gene expression of
osteoblast specific transcription factors (such as runx2 or osterix) as well as cytokines that
control osteoclast generation (e.g. RANKL and osteoprotegerin at the mRNA and protein
level). Gene expression patterns will be related to parameters that reflect the
microarchitecture of bone as assessed by bone histomorphometry and microCT.
Thesis subjects
Molecular mechanisms of excessive bone resorption and defective bone formation in male
osteoporosis. / Relationship between the microarchitecture of bone and gene expression
patterns of osteoblasts. / Pathogenesis of osteoporosis in elderly subjects. / Bone metabolism
in a model of ankylosing spondylitis
Cell and RNA isolation from tissues, primary culture, quantitative real time PCR, Western
blotting, FACS analysis, bone histomorphometry, microCT; all required equipment available.
page 102 of 168
Curriculum Vitae
Peter PIETSCHMANN
Department of Pathopyhsiology, Medical University of Vienna, Waehringer Grtel 1820, A 1090 Vienna, Austria, Phone +43-1-40400-51-22; Fax: +43-1-40-400-51-30; Email peter.pietschmann@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
May 13, 1960

Vienna
Austria
Education
2006-present
Deputy Head of the Department of Pathophysiology
2006-present
2002
2001
1994
1992
1990
1984
1979 1984
1978 1979
1970-1978
1966-1970
Career History
2002 present
1999-present
1998-present
Head of the Division of Molecular and Biochemical

Pathology
Appointment
as
Associate
Professor
of
Pathophysiology, Medical School,University of
Vienna
Certification as Specialist of Pathophysiology
Certification as Specialist of Rheumatology
Appointment as Associate Professor of Internal
Medicine, Medical School,University of Vienna
Certification as Specialist of Internal Medicine
Graduation as Medical Doctor
Medical School, University of Vienna
Military Service
Secondary School (Vienna)
Elementary School (Vienna)
Associate Professor of Pathophysiology at the

Department of Pathophysiology,Medical University of
Vienna
Head of the Bone, Cartilage and Connective Tissue
Research Group
Department of Pathophysiology (former Department of
page 103 of 168
1997-1998
1992-1997
1992-present
1991-1992
1990-1991
1984-1990
2000-present
1998-present
1993-present
Awards
1986
1996
General and Experimental Pathology), University of

Vienna (since 2004: Medical University of Vienna)
Institute of Immunology, University of Vienna
Division of Rheumatology/Department of Internal
Medicine 3, University of Vienna
Associate Professor of Internal Medicine,(Medical)
Rheumatic Diseases Division, Department of Internal
Medicine, Southwestern Medical Center at Dallas,
University of Texas, Dallas, TX, USA
Department of Medicine 2, University of Vienna
Treasurer of the Austrian Society for Bone and

Mineral Research
Board member of the Austrian Society for Geriatrics
and Gerontology
Scientific colaborationwith the Luwdig Boltzmann
Institute of Aging Research, Vienna
Paracelsus Award Austrian Society for Internal

Medicine
Young Investigator Award World congress on
Osteoporosis
Memberships
International Bone and Mineral Society
Austrian Society for Bone and Mineral Research (Member of the Board)
Austrian Society for Geriatrics and Gerontology (Member of the Board)
Society for Internal Medicine of Vienna and Lower Austria
Austrian Society for Rheumatology
Austrian Society for Cytometry
Medical Society of Vienna
Affiliation with the Ludwig Boltzmann Institute for Aging Research, Vienna
page 104 of 168
Sources of funding in last 5 years (2000-2005) Only FWF and equivalent projects
Period
Organization
Short Title
2007-2009
Jubilumsfonds der
sterreichischen
Nationalbank Projekt
# 12544
Vergleichsstudie von Hftknochen von

Mnnern mit Schenkelhaslfrakturen bzw.
Hftarthrosen
47
2002-2004
Medizinischwissenschaftlicher
Fonds des
Brgermeisters der
Bundeshauptstadt
Wien, Projekt # 2240
Die Wirkung von Bone morphogenetic

protein-5 auf die Generation von
Osteoklasten in Knochenmarkskulturen.
26
2002-2004
Hochschuljubilumsst The role of lymphocyte subpopulations

in osteoclast generation in murine bone
iftung der Stadt Wien,
marrow cultures.
Projekt # H1166/2003
2001
2006
FWF
Forschungsprojekt
P16060-B05 (Coaplicant)
Extended studies on the modulation of

the ageing processes in the rat by
physical exercise and food restriction
2001
Medizinischwissenschaftlicher
Fonds des
Brgermeisters der
Bundeshauptstadt
Wien
Die Bedeutung des Vitamin D-Rezeptors

fr die Zytokinproduktion von TLymphozyten
2000-2001
Jubilumsfonds der
sterreichischen
Nationalbank
The relationship of cytokines, sex

steroids and bone turnover in aging men
and women.
204
36

Name
Title of thesis
Period (expected) Acad. Title
Ing. Susanne Brosch
Die
Wirkung
von 1999-2001
Bisphosphonaten auf die
Osteoklastogenese und das
Immunsystem
MD
Maria Winzer
The
effects
phytoestrogens
on
MD
of 2003-2006
the
page 105 of 168
generation of osteoclasts
Mag. Pharm. Brigitte Metaanalysis
Behal
spontaneous
osteoporosis
of
course
the 2005-2007
of
Dr. scient. med.
Mag.rer.nat. Daniela Bone

metabolism
Stupphann
ankylosing spondylitis
in 2006-2007
Dr. scient. med.
Dr. med. univ. Janina Microarchitecture of bone in 2007-2008

Patsch
osteoporotic men: Relation
with
osteoblastic
gene
expression patterns and
treatment effects
Dr. scient. med.
Dipl.
Ing.
(FH) Molecular mechanisms of 2006-2008
Martina Rauner
osteoblast
differentiation:
Relevance
to
senile
osteoporosis
Dr. scient. med.
Publications
99 original publications and 28 reviews in peer reviewed scientific journals, 9 book
chapters, >100 invited lectures,
Peer reviewed manuscripts 2000-2005 (original research and reviews)
Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M (2000) Surface markers and
transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 35: 213 224
Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F,
Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral
density and biochemical parameters of bone metabolism in female patients with systemic
lupus erythematosus. Ann Rheum Dis 59: 308 310
Pietschmann P, Stckl J, Draxler S, Majdic O, Knapp W (2000) Functional and
phenotypic characterization of dendritic cells generated in human plasma supplemented
medium. Scand J Immunol 51: 377 383
Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P (2001) Phenotypic
characteristics of human monocytes undergoing transendothelial migration. Arthritis Res
3: 127 - 132
Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder R,
Peterlik M (2001) Bone turnover markers and sex hormones in men with idiopathic
osteoporosis. Eur J Clin Invest 31: 444 451
page 106 of 168
Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E,

Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral
blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp
Gerontol 36: 1749-1759
Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S,
Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002). Ankylosing
spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but
differ with regard to bone formation. J Rheumatol 29: 1430 1436
Lernbass I, Wutzl A, Grisar J, Schett G, Redlich K, Spitzauer S, Grampp S, Imhof H,
Peterlik M, Pietschmann P (2002) Quantitative ultrasound in the assessment of bone
status of patients suffering from rheumatic diseases. Skeletal Radiol 31: 270 276
Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Biegelmayer C, Pacher
R, Maurer G, Fialka-Moser V, Pietschmann P (2003) Pathogenesis of bone loss in heart
transplant candidates and recipients. J Heart Lung Transpl 22: 843 850
Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M, Woloszczuk W,
Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by
human peripheral blood mononuclear cells and markers of bone metabolism. Exp
Gerontol 38: 1119 1127
Kerschan-Schindl K, Mitterbauer M, Freder W, Kudlacek S, Grampp S, Biegelmayer C,
Fialka-Moser V, Pietschmann P, Kahls P (2004) Post- transplant complications Bone
metabolism in patients more than five years after bone marrow transplantation. Bone
Marrow Transplantation 34:491-496
Sipos W, Willheim M, Hofbauer G, Pietschmann P (2005) Evaluation of the suitability of
monoclonal antibodies for flow cytometric intracellular cytokine detection in peripheral
blood lymphocytes. J Vet Med A 52: 55-60
Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P (2005) Serum
levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40: 532
535
Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Hartl R, Exel B,
Dobretsberger M, Pietschmann P (2005) Characterization of the cytokine pattern of
porcine bone marrow-derived cells treated with 1,25(OH)2D3. J Vet Med A52: 382-387
Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F,
Peterlik M, Pietschmann P (2006) Bone morphogenetic proteins 5 and 6 stimulate
osteoclast generation. J Biomed Mater Res A 77 (1): 75-83
Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H,
Grimm G, Lind P, Pietschmann P (2006) Receptor activator of nuclear factor B ligand
and osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36: 566-573
Brosch S, Shehata M, Hofbauer G, Peterlik M, Pietschmann P (2006) Alendronate
stimulates expression of functional surface molecules ICAM-1, HLA-DR and B7-2 on
page 107 of 168
human monocytes. Osteol 15: 188-196

Rauner M, Winzer M, Stupphann D, Krenbek D, Pietschmann P (2007) RANKL and
OPG gene expression in bone marrow stromal cells and calvarial osteoblasts in mouse
and rat. Osteol 16: 19-28
Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K,
Lorenc R, Pietschmann P, Silverman S, Felsenberg D, Vandormael K, Daifotis A,
Lombardi A (2000) Alendronate treatment of osteoporosis in men. N Engl J Med 343:
604 610
Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G (2001) A comparison
of quantitative computed tomography and dual X-ray absorptiometry for evaluation of
bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37: 1247
1252
Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C,
Kato S, Cross HS (2001) Characterization of a vitamin D receptor knockout mouse as a
model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429-1435
Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Trk B,
Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett
G (2002) Tumor necrosis factor -mediated joint destruction is inhibited by targeting
osteoclasts with osteoprotegerin. Arthritis Rheum 46: 785 792
Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003) Serum
levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681
686
Sipos W, Duvigneau CJ, Pietschmann P, Willheim M, Hller K, Hartl RT, Wahl K,
Steinborn R, Gemeiner M, Schmoll F (2003) Parameters of humoral and cellular
immunity following vaccination of pigs with a European modified-live strain of porcine
reproductive and respiratory syndrome virus (PRRSV), Viral Immunol 16: 335 346
Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu
Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of
non-traumatic fracture. JAMA 291: 1108 1113
Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F,
Frisch H, Geyer G, Hrl WH, Mayer G, Luger A (2004) Effects of 12 months of
recombinant growth hormone therapy on parameters of bone metabolism and bone
mineral density in patients on chronic hemodialysis. J Nephrol 17: 87 94
Sipos W, Duvigneau JC, Willheim M, Schilcher F, Hartl RT, Hofbauer G, Exel B,
Pietschmann P, Schmoll F (2004) Systemic cytokine profile in feeder pigs suffering from
natural postweaning multisystemic wasting syndrome (PMWS) as determined by
semiquantitative RT-PCR and flow cytometric intracellular cytokine detection. Vet
Immunol Immunopathol 99: 63 71
page 108 of 168
Grisar J, Aringer M, Kller MD, Stummvoll GH, Eselbck D, Zwlfer B, Steiner CW,
Zierhut B, Wagner L, Pietschmann P, Smolen JS (2004) Leflunomide inhibits
transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 63:
1632-1637
Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P, Thomas R
(2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis
Res Ther 7: R230-40
Karanikas G, Schtz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak
R, Willheim M (2005) Relation of anti-TPO antibody titre and T-lymphocyte cytokine
production patterns in Hashimotos thyroiditis. Clin Endocrinol 63: 191 196
Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions of 1,25dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T
lymphocytes. J Allergy Clin Immunol 116: 683 689
Sipos W, Duvigneau JC, Pietschmann P, Schilcher F, Hofbauer G, Hartl RT, Schmoll F
(2005) Porcine dermatitis and nephropathy syndrome (PDNS) is associated with a
systemic cytokine expression profile indicative of proinflammation and a Th1 bias. Vet
Immunol Immunopathol, A52: 382-387
Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S, Strele A,
Obermayer-Pietsch B (2005) Molecularly-defined malabsorption, milk consumption and
anthropometric differences in adult males. Q J Med 98: 857-863
Fischer P, Gruenblatt E, Pietschmann P, Tragl KH (2006) Serotonin Transporter
Polymorphism and LDL-Cholesterol. Mol Psychiatry 11 (8): 707-709
Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R,
Baumann A. (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer
patients. Wien Klin Wochenschr 118 (15-16): 473-478
Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P, Kudlacek
S, Obermayer-Pietsch B (2007) Calcium supply, bone mineral density and genetically
defined lactose maldigestion in a cohort of elderly men. J Endocrinol Invest 30 (1): 46-51
Reviews:
Kudlacek S, Willvonseder R, Stohlawetz P, Hahn P, Pietschmann P (2000) Immunology
and aging. The aging male 3: 137 142
Resch H, Gollob E, Kudlacek S, Pietschmann P (2001) Die Osteoporose beim Mann.
Wien Med Wschr 151: 457-463
Pietschmann
P
(2001)
Geschlechtsunterschiede
bei
Gelenkserkrankungen:
pathophysiologische Grundlagen. Wien Med Wschr 151: 573-575
page 109 of 168
Mitringer A, Pietschmann P (2002) Osteoporose bei prmenopausalen Frauen. Wien Med

Wschr 152: 586 - 590
Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentsen
Therapie der postmenopausalen Osteoporose. Wien Med Wschr 152: 596 - 612
Brosch S, Redlich K, Pietschmann P. (2003) Pathogenese der Osteoporose bei
chronischer Polyarthritis. Acta Med Austriaca 30: 1 5
Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender specific aspects. Wien
Med Wschr 154/17-18: 411- 415
Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy
Immunol 143: 31-48
Patsch J, Muschitz C, Resch H, Pietschmann P (2007) Of mice and men: pathophysiology
of male osteoporosis. JMHG 4(1): 87-93
page 110 of 168
Gerhard PRAGER
Dept. of Surgery, Med. Univ. of Vienna
gerhard.prager@meduniwien.ac.at
Influence of bariatric surgery on gastrointestinal hormones

Abstract
In the last decades there has been a dramatic increase in the incidence of morbid obesity in the
western world. Bariatric surgery is the most effective current treatment of morbid obesity.
Different surgical approaches (restrictive, malabsorptive, gastric pacing) are nowadays
applied to achieve permanent weight loss. Although bariatric surgery provides excellent
results concerning weight loss and improvement of comorbidities its exact mode of action is
still not completely understood. Several recently discovered gastrointestinal peptide hormones
play an important role in the regulation of hunger and satiety. Only little is known about the
regulation of these hormones after different bariatric procedures. Based on that knowledge we
plan to determine the levels of different gastrointestinal (GI) hormones (ghrelin, glucagon-like
peptide (GLP) 1, GLP 2, gastric inhibitory polypeptide (GIP), apelin, etc.) before and after
bariatric surgery (gastric banding, gastric bypass, gastric stimulation) to improve and optimize
our understanding of current procedures and gain further insight in the regulation of hunger
and satiety. Determination of GI hormones is done in cooperation with the lab facilities of
Dept. Internal Medicine III.
Thesis Subjects
GI hormones play a key role in satiety-hunger control. Bariatric surgery has significant impact
on the levels of different GI hormones.

More than 100 patients per year operated. Blood samples from the surgical department.
Analysis and determination in cooperation with Dept. Internal Medicine III. All required
equipment available.
page 111 of 168
Curriculum Vitae
Gerhard PRAGER
Address: Clinical Division of General Surgery, Department of Surgery, Medical University of
Vienna, Waehringer Grtel 18-20, A-1090 Vienna, Austria;
Email gerhard.prager@meduniwien.ac.att
Born 11th July 1967 in Vienna; Austrian citizen; married with DI Silvia Prager ne Ertl;
architect), 1 daughter, 1 son
Graduation Doctor of Medicine, 08th July 1992
1st October 1992 31st Mai 1993 Military service (military anesthetist)
1st December 1993 13th April 1997 and 1st October 1997 28th February 1998
Resident, Hospital Mistelbach, Dept of Surgery (Chief: Univ. Prof. Dr. E. Schima)
14th April 1997 30th September 1997 Guest surgeon, Surgical Endocrinology, Univ. Prof.
Dr. B. Niederle, at the Clinical Division of General Sugery (Chief: o. Univ. Prof. Dr. R.
Jakesz), University Clinics for Surgery, Vienna
Since 1st March 1998 Resident at the Clinical Division of General Surgery, University
Clinics for Surgery, Vienna
30th April 1999 Certificate in Surgery of the Austrian Medical Association
April 2003 Appointment Consultant at the University Clinics for Surgery
23rd March 2004 Habilitation at the Medical University of Vienna (Univ. Doz.)
April 2004 Chief Working Group Bariatric Surgery at the Clinical Division of General
Surgery, Dept of Surgery
April 2005 Chief Working Group Minimal Invasive Surgery at the Clinical Division of
General Surgery, Dept of Surgery
page 112 of 168
List of Publications (since 2000)

First Author
4 Prager, G. Czerny, Ch. Kurtaran, A. Passler, Ch. Scheuba, Ch. Bieglmayer, Ch. Niederle,
B.: Minimally invasive open parathyroidectomy in an endemic goiter area. ARCH SURG
136, 810 - 816 (2001)
5 Prager, G. Heinz-Peer, G. Passler, Ch. Kaczirek, K. Schindl, M. Scheuba, Ch. Niederle,
B.: Surgical strategy in adrenal masses. EUR J RADIOL 41, 70-77 (2002)
6 Prager, G. Kalaschek, A. Kaczirek, K. Passler, Ch. Scheuba, Ch. Sonneck, G. Niederle,
B.: Parathyroidectomy improves concentration and retentiveness in patients with primary
hyperparathyroidism. SURGERY 132, 930 - 936 (2002)
7 Prager, G. Heinz-Peer, G. Passler, Ch. Kaczirek, K. Schindl, M. Scheuba, Ch.
Vierhapper, H. Niederle, B.: Can dynamic Gadolinium-enhanced magnet resonance
imaging with chemical shift studies predict the status of adrenal masses?. WORLD J
SURG 26, 958 - 964 (2002)
8 Prager, G. Czerny, C. Ofluoglu, S. Kurtaran, A. Passler, C. Kaczirek, K. Scheuba, C.
Niederle, B.: Impact of localization studies on feasibility of minimally invasive
parathyroidectomy in an endemic goiter region. J AM COLL SURG 196, 541-548 (2003)
9 Prager, G. Heinz-Peer, G. Passler, Ch. Kaczirek, K. Scheuba, Ch. Niederle, B.:
Applicability of laparoscopic adrenalectomy in 150 consecutive patients - a prospective
study. Arch Surg, 2004. 139(1): 46-9
Coauthor and Senior Author
13 Zacherl, J. Scheuba, Ch. Prager, G. Zacherl, M. Jakesz, R. Niederle, B.: Wie
kostengnstig ist die laparoskopische Adrenalektomie wirklich?. MINIMAL INVASIVE
CHIRURGIE 9, 79 - 84 (2000)
14 Neunteufl, Th. Heher, S. Prager, G. Katzenschlager, R. Abela, C. Niederle, B. Stefenelli,
Th.: Effects of sucessful parathyroidectomy on altered arterial reactivity in patients with
hypercalcemia: results of a 3-year follow-up study. CLIN ENDOCRINOL 53, 229 - 232
(2000)
15 Niederle, B. Prager, G. Scheuba, Ch. Passler, Ch. Schindl, M.: Minimal invasive
chirurgische Endokrinologie. ACTA CHIR AUSTRIACA 32, [Suppl165] 39 - 46 (2000)
16 Passler, Ch. Avanessian, R. Kaczirek, K. Prager, G. Scheuba, Ch. Schindl, M. Niederle,
B.: Schilddrsenchirurgie im Alter. ACTA CHIR AUSTRIACA 33, 288-293 (2001)
17 Hnigschnabl, S. Gallo, S. Niederle, B. Prager, G. Kaserer, K. Lechner, G. Heinz-Peer,
G.: How accurate is MR imaging in characterisation of adrenal masses: update of a longterm study . EUR J RADIOL 41, 113-122 (2002)
18 Kaczirek, K., Prager, G., Schindl, M., Kaserer, K., Gessl, A., Vierhapper, H., Niederle,
B.: Multiple endocrine neoplasia 1- current recommendations for diagnosis and
treatment. WIEN KLIN WOCHENSCHR 114, 258-266 (2002)
19 Zettinig, G. Prager, G. Kurtaran, A. Kaserer, K. Czerny, Ch. Dudczak, R. Niederle, B.:
Stellenwert
eines
strukturierten
Befundschemas
zur
Interpretation
der
Nebenschilddrsenszintigraphie bei primrem Hyperparathyreoidismus. ACTA MED
AUSTRIACA 29, 68 - 71 (2002)
page 113 of 168
20 Zettinig, G. Kurtaran, A. Prager, G. Kaserer, K. Dudczak, R. Niederle, B.: "Suppressed"

double adenoma - a rare pitfall in minimally invasive parathyroidectomy. HORMONE
RES 57, 57 -60 (2002)
21 Schindl, M. Kaczirek, K. Passler, Ch. Kaserer, K. Prager, G. Scheuba, Raderer, M.
Niederle, B.: Treatment of small intestinal neuroendocrine tumos: Is an extended
multimodal approach justified?. WORLD J SURG 26, 976 - 984 (2002)
22 Bieglmayer, C. Prager, G. Niederle, B.: Kinetic analyses of parathyroid hormone
clearence as measured by three rapid immunoassays during parythyroidectomy. CLIN
CHEM 48, 1731-1738 (2002)
23 Hoda, M. R. Rasoul-Rockenschaub, S. Felberbauer, F. X. Prager, G. Szeles, J. C. Dadgar,
N. Wenzl, E.: Pregnancy and labor after adjustable gastric banding for therapy of morbid
obesity. WIEN KLIN WOCHENSCHR 114, 781-784 (2002)
24 Passler, Ch. Avanessian, R. Kaczirek, K. Prager, G. Scheuba, Ch. Niederle, B.: Thyroid
surgery in the geriatric patient. ARCH SURG 137, 1243 - 1248 (2002)
25 Passler, C. Prager, G. Scheuba, C. Kaserer, K. Zettinig, G. Niederle, B.: Application of
staging systems for differentiated thyroid carcinoma in an endemic goiter region with
iodin substitution. ANN SURG 237, 227-234 (2003)
26 Saeger, W. Fassnacht, M. Chita, R. Prager, G. Nies, C. Lorenz, K. Bhrlehner, E. Simon,
D. Niederle, B. Beuschlein, F. Allolio, B. Reincke, M.: High diagnostic accuracy of
adrenal core biopsy: Results of the German and Austrian adrenal network multicenter
trial in 220 consecutive patients. HUMAN PATHOL 34, 180-186 (2003)
27 Kaczirek, K. Soleiman, A. Schindl, M. Passler, Ch. Scheuba, C. Prager, G. Kaserer, K.
Niederle, B.: Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism.
EUR J CLIN INVEST 33, 488-492 (2003)
28 Niederle, B. Prager, G.: Advanced endoscopic adrenal surgery-new developments. EUR
SURG 35, 71-75 (2003)
29 Rauhofer, U. Prager, G. Hoermann, M. Auer, H. Kaserer, H. Niederle, B.: Cystic
echninococcosis of the thyroid gland in children and adults. THYROID 13, 497-502,
(2003)
30 Passler, C. Prager, G. Scheuba, C. Niederle, BE. Kaserer, K. Zettinig, G. Niederle, B.:
Follicular variant of papillary thyroid carcinoma - a long term follow up. Arch Surg,
2003. 138(12): 1362-6.
31 Stift, A. Prager, G. Selzer, E. Widder, J. Kandioler, D. Friedl, J. Teleky, B. Herbst, F.
Wrba, F. Bergmann, M.: The early response of p53-dependant proteins during
radiotherapy in human rectal carcinoma and in adjacent normal tissue. Int J Oncol, 2003.
23(5): 1269-75.
32 Bohdjalian, A. Langer, F. Reza Hoda, M. A. Felberbauer, F. Silberhumer, G. Zacherl, J.
Schindler, K. Luger, A. Ludvik, B. Prager, G.: Surgical treatment of obesity. Wien Med
Wochenschr, 2004. 154(13-14): 329-33.
33 Kaczirek, K. Schindl, M. Weinhausel, A. Scheuba, C. Passler, C. Prager, G. Raderer, M.
Hamilton, G. Mittlbock, M. Siegl, V. Pfragner, R. Niederle, B.: Cytotoxic activity of
camptothecin and paclitaxel in newly established continuous human medullary thyroid
carcinoma cell lines. J Clin Endocrinol Metab, 2004. 89(5): 2397-401.
34 Passler, C. Scheuba, C. Prager, G. Kaczirek, K. Kaserer, K. Zettinig, G. Niederle, B.:
Prognostic factors of papillary and follicular thyroid cancer: differences in an iodinereplete endemic goiter region. Endocr Relat Cancer, 2004. 11(1): 131-9.
page 114 of 168
35 Schindler, K. Prager, G. Ballaban, T. Kretschmer, S. Riener, R. Buranyi, B. Maier, C.

Luger, A. Ludvik, B.: Impact of laparoscopic adjustable gastric banding on plasma
ghrelin, eating behaviour and body weight. Eur J Clin Invest, 2004. 34(8): 549-54.
36 Stadler, A. Schima, W. Prager, G. Homolka, P. Heinz, G. Saini, S. Eisenhuber, E.
Niederle, B.: CT density measurements for characterization of adrenal tumors ex vivo:
variability among three CT scanners. AJR Am J Roentgenol, 2004. 182(3): 671-5.
37 Widhalm, K. Dietrich, S. Prager, G.: Adjustable gastric banding surgery in morbidly
obese adolescents: experiences with eight patients. Int J Obes Relat Metab Disord, 2004.
28 Suppl 3: S42-5.
38 Fleischmann, E. Kurz, A. Niedermayr, M. Schebesta, K. Kimberger, O. Sessler, D. I.
Kabon, B. Prager, G.: Tissue oxygenation in obese and non-obese patients during
laparoscopy. Obes Surg, 2005. 15(6): 813-9.
39 Kaczirek, K. Riss, P. Wunderer, G. Prager, G. Asari, R. Scheuba, C. Bieglmayer, C.
Niederle, B.: Quick PTH assay cannot predict incomplete parathyroidectomy in patients
with renal hyperparathyroidism. Surgery, 2005. 137(4): 431-5.
40 Langer, F. B. Wenzl, E. Prager, G. Salat, A. Miholic, J. Mang, T. Zacherl, J.:
Management of postoperative esophageal leaks with the Polyflex self-expanding covered
plastic stent. Ann Thorac Surg, 2005. 79(2): 398-403; discussion 404.
41 Langer, F. B. Reza Hoda, M. A. Bohdjalian, A. Felberbauer, F. X. Zacherl, J. Wenzl, E.
Schindler, K. Luger, A. Ludvik, B. Prager, G.: Sleeve gastrectomy and gastric banding:
effects on plasma ghrelin levels. Obes Surg, 2005. 15(7): 1024-9.
42 Langer, F. B. A. Bohdjalian, A. Felberbauer, F. X. Fleischmann, E. Reza Hoda, M.
Ludvik, B. Zacherl, J. Jakesz, R. Prager, G.: Does Gastric Dilation Limit the Success of
Sleeve Gastrectomy as a Sole Operation for Morbid Obesity?. Obes Surg, 2006. 16: 166171
43 Langer, F. B. A. Bohdjalian, A. Hoda, A Silberhumer, G Felberbauer, F. X. RasoulRockenschaub, S Zacherl, J. Wenzl, E Prager, G.: Early Results of Laparoscopic
Adjustable GastricBanding using the new Low Pressure Soft Gastric Band. EUR SURG
2004. 36: 345-349
44 Silberhumer, G Miller, K. Krivanek, S. Widhalm, K. Pump, A. Prager, G.: Laparoscopic
adjustable Gastric Banding in Adolescents: The Austrian Experience. Obes Surg, 2006.
16: 1062-1067
45 Haider, D. Schindler, K. Schaller, G. Prager, G. Wolzt, M. Ludvik, B.: Increased Plasma
Visfatin Concentrations in Morbidly Obese Subjects are reduced after Gastric Banding. J
Clin Endocrinol Metab, 2006. 91: 1578-1581.
46 Bohdjalian, A. Prager, G. Aviv, R. Policker, S. Schindler, K. Kretschmer, S. Riener, R.
Zacherl, J. Ludvik, B.: One-year experience with Tantalus: a new surgical approach to
treat morbid obesity. Obes Surg, 2006. 16(5): 627-634
47 Kaczirek, K. Prager, G. Riss, P. Wunderer, G. Asari, R. Scheuba, Ch. Bieglmayer, Ch.
Niederle, B.: Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone
monitoring in renal hyperparathyroidism. Arch Surg 2006. 141: 129-134
48 Bieglmayer, C. Kaczirek, K. Prager, G. Niederle, B.: Parathyroid Hormone Monitoring
during Total Parathyroidectomy for Renal Hyperparathyroidism: Pilot Study of the
Impact of Renal Function and Assay Specificity. Clin Chem 2006. 52: 1112-1119
49 Haider, D.G. Mittermayer, F. Schaller, G. Artwohl, F. Baumgartner-Parzer, S.M. Prager,
G. Roden, M. Wolzt, M.: Free fatty acids normalize a rosiglitazone-induced visfatin
release. Am J Physiol Endocrinol Metab 2006
page 115 of 168
Michael RODEN
1st Med. Dept. & Landsteiner-Institute, Hanusch Hospital
michael.roden@meduniwien.ac.at
Pathogenesis of insulin resistance, obesity and diabetes in humans

Abstract
Obesity and type 2 diabetes are becoming the most important health problems all over the
world. Although treatment and prevention can be effective the underlying causes defining
success or failure of lifestyle intervention are still not well understood. We have previously
contributed to the current hypothesis that increased lipid availability is mainly responsible for
insulin resistance in obesity and type 2 diabetes. Now, we focus our research on the
mechanisms underlying these defects in lipid metabolism, particularly on the role of
mitochondrial energy metabolism by noninvasive measurement of ATP synthesis. We test the
efficacy of various forms of intervention (diet, exercise and antidiabetic drugs) in patient
groups with different genetic risk to develop diabetes mellitus. Further, we analyze changes in
hormone secretion in those patients as well as in morbidly obese before and after severe
weight loss.
Thesis Subjects
Effects of exercise on mitochondrial function
Assessment of early defects in energy metabolism in the development of fatty liver disease
Effects of different dietary composition on insulin action

Clinical metabolic lab, stable isotope dilution techniques to assess whole body glucose and
lipid metabolism, noninvasive measurement of intracellular lipids and glucose metabolites as
well as quantification of tissue specific metabolic fluxes using magnetic resonance
spectroscopy, tissue biopsies
page 116 of 168
Curriculum Vitae
Michael RODEN
1.Medical Department, Hanusch Hospital, Heinrich Collin Strasse 30, A-1140 Vienna,
Austria; Phone +43 1 91021 85011; Fax +43 1 91021 85019;
Email michael.roden@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
11.02.1961
Vienna, Austria
Austria
Education
2004
Certificate of Achievement, Continuing Research
1997
1994
1993
1986
Education Credit Program (CREC) in compliance with

NIH, Case Western Reserve University, Cleveland, OH
Specialist in Endocrnology and Metabolism
Certificate in Emergency Medicine
Graduation as Medical Doctor (Dr.med.)
Career History
2005 present
2003 present
1997
1994-1995
1994
1988 2003
1986-1988
1982-1984
1979 and 1986
Director of the Karl-Landsteiner-Institute for

Endocrinology and Metabolism; Vienna
Head of the I. Medical Department, Hanusch Hospital,
Vienna
Associate Professor of Medicine, University of Vienna
Max-Kade Fellowship, Division of Endocrinology,
Department of Internal Medicine, Yale University, New
Haven, CT, USA
Venia docendiin Internal Medicine, Univ. Vienna
University Assistant , Division of Endocrinology
Metabolism, Department of Internal Medicine I, then III,
(Medical) University of Vienna, Austria
University Assistant, Pharmacological Institute, University
of Vienna
Instructor, Anatomical Institute, University of Vienna
Regular Military Service
page 117 of 168
1996-present
2000-2007
2000-2007
1996-2002
1997-present
1995
EU Liason Person, Council Member, Advisory Board

Member of the Annual Meeting,
Past-President, President, Vice-President and Councillor,
Austrian Diabetes Association (DG)
Councilor, Treasurer, First Secretary, Federation of
International Danube Symposia (FID)
Vice-President, Honorary Secretary-Treasurer, Councilor,
European Society for Clinical Investigation (ESCI)
Editorial Boards
Assistant Editor Diabetologia (-2003)
Associate Editor Eur. J. Clin. Invest. (present)
Associate Editor Diabetic Medicine (present)
Editorial Board Am. J. Physiol. (present)
Management Training for Leadership in Medicine,
University of Vienna and University of Salzburg
Awards
2006
2004
2002
2001
1999
1996
1994
1992
ESCI (formerly Mack-Foster) Award for Excellence in

Clinical Sciences, European Society for Clinical
Investigation
International Novartis Award for Innovative Patient
Oriented Research - Young Investigator, Europe-USA
Novartis (formerly Sandoz) Award for Chemistry, Biology
and Medicine, Austria
Ferdinand-Bertram Award, German Diabetes Association
Kardinal-Innitzer Award, Austria
Joseph-Skoda-Research Award, Austrian Society of
Internal Medicine
Hoechst Award, Faculty of Medicine, University of Vienna
Theodor Krner Award
Austria Research Award, City of Vienna by the Mayor of
the City of Vienna
Friedrich Wewalka Memorial Award by the Austrian
Society for Gastroenterology and Hepatology
Memberships
Diabetes Associations: USA, Europe, Germany, Austria
Endocrinology / Obesity: USA, Germany, Austria
European Society for Clinical Investigation
page 118 of 168

Period
2006
present
2005
present
2002
present
2002-2004
Organization
Juvenile Diabetes
Research Foundation
International (JDRF),
New York, NY
Austrian National
Bank
Short Title
K/yr
Noninvasive measurement of hepatic
glycogen synthesis kinetics in type 1
diabetics
Vergleich der Effekte von Kraft-Ausdauer

(REsistance )- mit aeroben
Konditionstrainings (COnditioning) Training
- RECO Studie
Austrian
Science Metabolic regulation in human skeletal
Fund (FWF)
muscle
Effects of lipids on cellular metabolism
European Foundation Metabolic effects of long-term suppression of
for the Study of lipolysis
Diabetes (EFSD)

Name
Title of thesis
Period (expected)
Acad.Title
Martin Krssak
(Mitbetreuuer, ormalund
Naturwissenschaftl.
Fakultt, 2000)
Applications of 1H-NMR
methods in the experimental
liver transplantation
2000
Dr. rer.
nat.
Harald Stingl
Die Bedeutung freier Fettsuren

fr die Regulation der
hepatischen Glukoneogenese des
Menschen
2000
MD
Elisabeth Bernroide
Hepatischer
Glykogenstoffwechsel bei
Patienten mit Diabetes mellitus
Typ 1
2000
DM
Daniel Weghuber
Effekte freier Fettsuren auf

muskulren Glukosetransport /
phosphorylierung und den
intramyozellulren Lipidgehalt
beim Menschen
2001
MD
page 119 of 168
Name
Title of thesis
Period (expected)
Acad.Title
Christian Anderwald
Die residuale Insulinresistenz

von Leber und Muskel bei
Diabetes mellitus Typ 2
2002
MD
Attila Breh
Regulation des postprandialen

Leberglykogenstoffwechsels bei
Typ-2 Diabetes
2003
MD
Rainer Englisch
Effects of insulin-like growth

factor I on basal and stimulated
glucose fluxes in rat liver
2004
Dr. rer.
nat. techn.
Goran Mitkovski
(Mitbetreuer)
Nutrient dependent regulation of

signal transduction in human
skeletal muscle
2006
MD
Christian Toth
The role of mitochondiral

dysfunction in muscle insulin
resistance of type 2 diabetes
mellitus
2007
MD
Michaela Farukuoye
Ernhrungsintervention bei
Gesunden und Nachkommen
von Typ-2 Diabetikern
2005 - (2007)
Dr. scient
med.
Romana Stark
Automated applications of high

resolution magnetic resonance
spectroscopic imaging (MRSI)
in metabolic studies
2005 - (2007)
Dr. scient
med.
Michaela Kacerovsky
Noninvasive measurement of
liver glycogen kinetics in type 1
diabetes
2006 - (2009)
PhD
Publications
More than 100 original papers in peer reviewed journals
More than 30 reviews in peer reviewed journals
More than 90 invited lectures
Only original and published papers (since 2000)
1. Krssak M, Falk Petersen K, Bergeron R, Price T, Laurent D, Rothman DL, Roden M,
Shulman GI (2000) Intramuscular glycogen and intramyocellular lipid utilization
during prolonged exercise and recovery in man: a 13C and 1H nuclear magnetic
resonance spectroscopy study. J Clin Endocrinol Metab 85:748-754
page 120 of 168
2. Stulnig T, Berger M, Roden M, Stingl H, Raederstorff D, Waldhusl W (2000)

Inhibition of T lymphocyte signaling by elevated serum concentrations of unsaturated
free fatty acids. FASEB J 14:939-947
3. Roden M, Stingl H, Chandramouli V, Schumann WC, Hofer A, Landau BR, Nowotny
P, Waldhusl W, Shulman GI (2000) Effects of free fatty acid elevation on
postabsorptive endogenous glucose production and gluconeogenesis in man. Diabetes
49:401-407
4. Frnsinn C, Brunmair B, Neschen S, Roden M, Waldhusl W (2000) Troglitazone
directly inhibits CO2 production from glucose and palmitate in isolated rat skeletal
muscle. J Pharmacol Exp Ther 293:487-493
5. Roden M, Ludwig C, Nowotny P, Schneider B, Roden A, Waldhusl W (2000)
Relative hypoleptinemia in type 1 and type 2 diabetes mellitus. Int J Obesity 24:976981
6. Schatzl G, Reiter WJ, Thrridl T, Waldmller J, Roden M, Sregi S, Madersbacher S
(2000) Endocrine patterns in patients with benign and malignant prostatic diseases.
Prostate 44:219-224
7. Krebs M, Stingl H, Nowotny P, Weghuber D, Bischof M, Waldhusl W, Roden M
(2000) Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem 46:950-954
8. Englisch R, Wurzinger R, Frnsinn C, Schneider B, Frisch H, Waldhusl W, Graf J,
Roden M (2000) Effects of insulin-like growth factor I on basal and stimulated glucose
fluxes in rat liver. Biochem J 351:39-45
9. Brunmair B, Neschen S, Furtmller R, Roden M, Waldhusl W, Frnsinn C (2000)
Metabolic response to anisoosmolarity of rat skeletal muscle in vitro. Horm Metab Res
32:251-255
10. Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhusl W,
Roden M (2000) Diagnostic efficacy of plasma free metanephrines for the detection of
pheochromocytoma. Arch Intern Med 160:2959-2963
11. Bischof MG, Ludwig C, Hofer A, Kletter K, Krebs M, Stingl H, Nowotny P,
Waldhusl W, Roden M (2000) Hormonal and metabolic counterregulation during and
after high dose insulin induced hypoglycemia in diabetes mellitus type 2. Horm Metab
Res 32:417-423
12. Roden M, Anderwald C, Frnsinn C, Waldhusl W, Lohninger A (2000) Effects of
short-term leptin exposure on triglyceride deposition in rat liver. Hepatology 32:10451049
13. Polak K, Schmetterer L, Luksch A, Gruber S, Polska E, Peternell V, Bayerle-Eder M,
Wolzt M, Krebs M, Roden M (2001) Free fatty acids/triglycerides increase ocular and
subcutaneous blood flow. Am J Physiol 280:R56-R61
14. Bischof MG, Krssak M, Krebs M, Bernroider E, Stingl, H, Waldhusl W, Roden M
(2001) Intensive insulin therapy does not normalise all defects of hepatic carbohydrate
metabolism in type 1 diabetes mellitus. Diabetes 50:392-398
15. Stingl H, Krssak M, Krebs M, Bischof M, Nowotny P, Frnsinn C, Shulman GI,
Waldhusl W, Roden M (2001) Lipid-dependent control of hepatic glycogen stores in
healthy man. Diabetologia 44:48-54
16. Krampl E, Kametas N, Cacho Zegarra AM, Roden M, Nicolaides KH (2001) Maternal
blood glucose at high altitude. Brit J Obstet Gynaec 108:254-257
17. Krampl E, Kametas N, Nowotny P, Roden M, Nicolaides KH (2001) Glucose
metabolism in pregnancy at high altitude. Diabetes Care 24:817-822
18. Krebs M, Krssak M, Weghuber D, Nowotny P, Gruber S, Mlynarik V, Bischof M,
Stingl H, Frnsinn C, Waldhusl W, Roden M (2001) Free fatty acids inhibit glucosestimulated increases of intramuscular glucose-6-phosphate concentrations in man. J
page 121 of 168
Clin Endocrinol Metab 86:2153-2160

19. Roden M, Raffesberg W, Raber W, Bernroider E, Niederle B, Waldhusl W, Gasic S
(2001) Quantification of unconjugated metanephrines in human plasma without
interference with acetaminophen. Clin Chem 47:1061-1067
20. Wurzinger R, Englisch R, Roka S, Langer R, Gajdzik L, Roden M, Graf J (2001)
Intracellular calcium in the isolated rat liver: correlation to glucose release, K+ balance
and bile flow. Cell Calcium 30:403-412 (doi:10.1054/ceca.2001.0248)
21. Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhusl W, Frnsinn C
(2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is
independent of PPAR-mediated changes in gene expression. Diabetes 50:2309-2315
22. Starcuk Jr Z, Starcuk Z, Mlynarik V, Roden M, Horky J, Moser E (2001) Low power
water suppression by hyperbolic secant pulses with controlled offsets and delays
(WASHCODE). J Magn Reson 152:168-178
23. Szles JC, Csap B, Klarhfer M, Balssy C, Hoda R, Berg A, Roden M, Polterauer P,
Waldhusl W, Moser E (2001) In vivo magnetic resonance micro-imaging of the
human toe at 3 tesla. Magn Reson Imaging 19:1235-1238
24. Bischof MG, Bernroider E, Ludwig C, Kurzemann S, Kletter K, Waldhusl W, Roden
M: (2001) Hypoglycemia counterregulation during near physiologic insulin therapy.
Horm Res 56:151-158
25. Frnsinn C, Nowotny P, Brunmair B, Gras F, Roden M, Waldhusl W, Vierhapper H
(2002) Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Endocrinology 143:327
26. Bayerle-Eder M, Fuchsjger-Mayrl G, Sieder A, Polska E, Roden M, Stulnig T,
Bischof M, Waldhusl W, Schmetterer L, Wolzt M (2002) Effect of pravastatin on
responsiveness to N-monomethyl-L-arginine in patients with hypercholesterolaemia.
Atherosclerosis 160:177-184
27. Bischof MG, Bernroider E, Krssak M, Krebs M, Stingl H, Nowotny P, Yu C, Shulman
GI, Waldhusl W, Roden M (2002) Hepatic glycogen metabolism in type 1 diabetes
mellitus after long-term near normoglycemia. Diabetes 51:49-54
28. Krebs M, Krssak M, Bernroider E, Anderwald C, Brehm A, Meyerspeer M, Nowotny
P, Roth E, Waldhusl W, Roden M (2002) Mechanism of amino acid-induced skeletal
muscle insulin resistance in humans. Diabetes 51:599-605
29. Artwohl M, Roden M, Hlzenbein T, Freudenthaler A, Waldhusl W, BaumgartnerParzer S (2002) Modulation by leptin of proliferation and apoptosis in vascular
endothelial cells. Int J Obesity 26:577-580
30. Schmidt A, Pleiner J, Schaller G, Roden M, Dallinger S, Mayer G, Schmetterer L,
Wolzt M (2002) Renal hemodynamic effects of somatostatin are not related to
inhibition of endogenous insulin release. Kidney Int 61:1788-1793
31. Pleiner J, Schaller G, Mittermayer F, Bayerle-Eder M, Roden M, Wolzt M (2002)
FFA-induced endothelial dysfunction can be corrected by Vitamin C. J Clin
Endocrinol Metab 87:2913-2917
32. Anderwald C, Mller G, Koca G, Frnsinn C, Waldhusl W, Roden M (2002) Leptindependent inhibition of hepatic gluconeogenesis is modulated by insulin receptor
substrate-2. Mol Endocrinol 16:1612-1628
33. Fuchsjger-Mayrl G, Kautzky-Willer A, Kiss B, Rainer G, Findl O, Wagner O, Roden
M, Pleiner J, Wolzt M, Schmetterer L (2002) Ocular hyperperfusion following onset of
intensified insulin therapy is inversely correlated with plasma endothelin-1 in type 1
diabetes. Diabetologia 45:883-890
34. Anderwald C, Koca G, Frnsinn C, Waldhusl W, Roden M (2002) Inhibition of
glucose production and stimulation of bile flow by R(+)--lipolic acid in rat liver.
page 122 of 168
Liver 22:356-362
35. Anderwald C, Bernroider E, Krssak M, Stingl H, Brehm A, Bischof MG, Roden M,
Waldhusl W (2002) Effects of insulin treatment in type 2 diabetic patients on
intracellular lipid content in liver and skeletal muscle. Diabetes 51:3025-3032
36. Stingl H, Schnedl WJ, Krssak M, Bernroider E, Bischof MG, Lahousen T, Pacini G,
Roden M (2002) Reduction of hepatic glycogen synthesis and breakdown in patients
with agenesis of the dorsal pancreas. J Clin Endocrinol Metab 87:4678-4685
37. Stingl H, Raffesberg W, Nowotny P, Waldhusl W, Roden M (2002) Reduction of
plasma leptin concentrations by arginine but not lipid infusion in humans. Obes Res
10:1111-1119
38. Herkner H, Klein N, Joukhadar C, Lackner E, Langenberger H, Frossard M,
Bieglmayer, Wagner O, Roden M, Mller M (2003) Transcapillary insulin transfer in
human skeletal muscle. Europ J Clin Invest 33:141-146
39. Kautzky-Willer A, Krssak M, Winzer C, Pacini G, Tura A, Serdat F, Wagner OF,
Brabant G, Horn R, Stingl H, Waldhusl W, Roden M (2003) Increased
intramyocellular lipid concentrations identify impaired glucose and energy metabolism
in women with prior gestational diabetes. Diabetes 52:244-251
40. Artwohl M, Graier WF, Roden M, Waldhusl W, Bischof M, Freudenthaler A,
Baumgartner-Parzer SM (2003) Glycated low-density lipoprotein modulates apoptosis
and proliferation in vascular endothelial cells. Diabetes 52:1240-1247
41. Gras F, Brunmair B, Roden M, Waldhusl W, Frnsinn C (2003) Differences in
troglitazone action on glucose metabolism in freshly isolated versus long-term
incubated rat skeletal muscle. Brit J Pharmacol 138:1140-1146
42. Raber W, Raffesberg W, Waldhusl W, Gasic S, Roden M (2003) Exercise induces
excessive normetanephrine responses in hypertensive diabetic patients. Europ J Clin
Invest 33:480-487
43. Krebs M, Brehm A, Krssak M, Anderwald M, Bernroider M, Nowotny P, Roth E,
Chandramouli V, Landau BR, Waldhusl W, Roden M (2003) Direct and indirect
effects of amino acids on hepatic glucose metabolism in humans. Diabetologia 46:917925
44. Anderwald C, Brabant G, Bernroider E, Horn R, Brehm A, Waldhusl W, Roden M
(2003) Insulin-dependent modulation of plasma ghrelin and leptin concentrations is
less pronounced in type 2 diabetic patients. Diabetes 52:1792-1798
45. Krebs M, Polak K, Vales A, Geiger M, Schmetterer L, Wagner OF, Waldhusl W,
Binder BR, Roden M (2003) Increased plasma levels of plasminogen activator
inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in
man. Thromb Haemost 90:422-428
46. Kunert O, Stingl H, Rosian E, Krk M, Bernroider E, Seebacher W, Zangger K,
Staehr P, Chandramouli V, Landau BR, Nowotny P, Waldhusl W, Haslinger E,
Roden M (2003) Measurement of fractional whole-body gluconeogenesis in humans
from blood samples using 2H nuclear magnetic resonance spectroscopy. Diabetes
52:2475-2482
47. Artwohl M, Roden M, Waldhusl W, Freudenthaler A, Baumgartner-Parzer SM (2004)
Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular
endothelial cells. FASEB J 18:146-148
48. Bischof MG, Brehm A, Bernroider E, Krssak M, Mlynarik V, Bauer E, Madl C,
Waldhusl W, Roden M (2004) Brain energy metabolism during hypoglycemia in
healthy and type 1 diabetic humans. Diabetologia 47:648-651
49. Krssak M, Mlynarik V, Meyerspeer M, Moser E, Roden M (2004) 1H NMR relaxation
times of skeletal muscle metabolites at 3 Tesla. Magn Reson Mater Phy 16:155-159
page 123 of 168
50. Brunmayr B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E,

Nohl H, Waldhusl W, Frnsinn C (2004) Thiazolidinediones, like metformin, inhibit
respiratory complex I: a common mechanisms contributing to their antidiabetic
actions? Diabetes 53:1052-1059
51. Hills SA, Blakau B, Coppack SW, Dekker JM, Mari A, Natali A, Walker M,
Ferrannini E, on behalf of the EGIR-RISC Study Group ( Roden M) (2004) The
EGIR-RISC STUDY (The European group for the study of insulin resistance:
relationship between insulin sensitivity and cardiovascular disease risk): I.
Methodology and Objectives. Diabetologia 547:566-570
52. Hanusch-Enserer U, Cauza E, Brabant G, Dunky A, Rosen A, Pacini G, Tchler H,
Prager R, Roden M (2004) Plasma ghrelin in obesity before and after weight loss after
laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 89:3352-3358
53. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pacini G,
Funahashi T, Kautzky-Willer A (2004) Plasma adiponectin, insulin sensitivity and
subclinical inflammation in women with prior gestational diabetes. Diabetes Care
27:1721-1727
54. Brunmayr B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Waldhusl W,
Frnsinn C (2004) Fenofibrate impairs rat mitochondrial function by inhibition of
respiratory complex I. J Pharmacol Exp Ther (PMID 15166256)
55. Bayerle-Eder M, Polska E, Kopf A, Roden M, Waldhusl W, Pleiner H, Wipler B,
Wolzt M, Schmetterer L (2004) Free fatty acids exert a greater effect on ocular and
skin blood flow than triglycerides in healthy subjects. Europ J Clin Invest 34:519-529
56. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M (2004) Relationship of plasma
lipoprotein ratios and insulin resistance in obesity. Clin Chem 50:2316-2322
57. Krssak M, Brehm A, Bernroider E, Anderwald C, Dalla Man C, Nowotny P, Cobelli
C, Shulman GI, Waldhusl W, Roden M (2004) Postprandial hepatic glycogen
metabolism in type 2 diabetes. Diabetes 53:3048-3056
58. Brabant G, Nave H, Horn R, Anderwald C. Mller G, Roden M (2004) In vivo and in
vitro evidence for a hepatic modulation of the leptin signal in rats. Europ J Clin Invest
34:831-837
59. Bayerle-Eder M, Pleiner J, Mittermayer F, Schaller G, Roden M, Waldhusl W,
Bieglmayer C, Wolzt M (2004) Effect of systemic vitamin C on free fatty acid-induced
lipid peroxidation. Diabetes Metab 30:433-439
60. Artwohl M, Frnsinn C, Waldhusl W, Hlzenbein T, Rainer G, Freudenthaler A,
Roden M, Baumgartner-Parzer S (2005) Thiazolidendiones inhibit proliferation of
micro- and macrovascular cells by a PPAR-independent mechanism. Diabetologia
48:586-594
61. Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm MJ, Widel M, Tan M
(2005) Pioglitazone elicits long-term improvements in insulin sensitivity and lipids in
patients with type 2 diabetes: comparisons with gliclazide-based regimen.
Diabetologia 48:553-560
62. Brabant G, Mller G, Horn R, Roden M, Nave H (2005) Hepatic leptin signalling in
obesity. FASEB J 19:1048-1050
63. Bernroider E, Brehm A, Krssak M, Anderwald C, Trajanoski Z, Cline G, Shulman GI,
Roden M (2005) The role of intramyocellular lipids during hypoglycemia in patients
with intensively treated type 1 diabetes. J Clin Endocrinol Metab 90:5559-5565
64. Roden M, Laakso M, Johns D, Widel M, Urquhart R, Richardson C, Mariz S, Tan MH
(2005) Long-term effects of pioglitazone and metformin on insulin sensitivity in
patients with type 2 diabetes. Diabetic Med 22:1101-1106
65. Lechleitner M, Roden M, Haehling E, Mller M (2005) Insulin glargine in
page 124 of 168
combination with oral antidiabetic drugs as a cost equivalent alternative to

conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wschr 117:593-598
66. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P,
Waldhusl W, Marette A, Roden M (2005) Overactivation of the S6 kinase 1 a cause
of human insulin resistance duirng increased amino acid availability. Diabetes
54:2674-2684
67. Meyerspeer M, Krssak M, Kemp GJ, Roden M, Moser E (2005) Dynamic Interleaved
1
H/31P STEAM MRS at 3 Tesla using a pneumatic force-controlled plantar flexion
exercise rig. MAGMA 18:257-262
68. Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhusl W, Roden M (2006)
Increased lipid availability impairs insulin stimulated ATP synthesis in human skeletal
muscle. Diabetes 55:136-140
69. Stingl H, Chandramouli V, Brehm A, Nowotny P, Waldhusl W, Landau BR, Roden
M (2006) Changes in glycogen cycling during a glucose load in healthy humans.
Diabetologia http://dx.doi.org/10.1007/s00125-005-0099-x
page 125 of 168
Erich ROTH
Surgical Research Laboratory, Surgical University Clinic
erich.roth@meduniwien.ac.at
Metabolism and Clinical Nutrition in Critically Ill Patients

Abstract
Clinical nutrition is of high importance for the outcome of critically ill patients. Recently it
was shown that certain macronutrients have an immunomodulating capacity. Therefore
immunonutrition contains several potentially immunomodulating agents such as glutamine,
arginine, omega-3 fatty acids, and nucleotides. In general, results with these agents
demonstrate a reduction in rate of infectious complications, reduction in the number of days
in hospital, but no effect on mortality. Our research unit was mainly interested to investigate
the effect of glutamine on metabolism and immunoreactivity. The amino acid glutamine (Gln)
plays a central role in nitrogen transport within the body and is a fuel for rapidly dividing
cells, such as in the gut and the immune system. The plasma Gln levels decline during critical
illness and therefore these cells suffer from Gln-starvation under these conditions. Glnstarvation leads to energy depletion, which is associated with a reduced responsiveness to
exogenous stimuli. In addition, Gln-starving cells show a reduced expression of the 70 kDa
heat shock protein, which is an important factor for cell survival and contain a reduced level
of the antioxidant glutathione. Recent findings show that the extracellular Gln level affects the
susceptibility of cells to different apoptosis triggers: while Gln-starving cells are more
sensitive to Fas-ligand mediated apoptosis they are desensitized against the cytotoxic effects
of TNF-alpha. In addition, we are interested in the investigation of the molecular mechanisms
of Gln-sensing and the role of AMP-activated protein kinase, the cellular redox state,
osmosignaling, regulation of translation, and amino acyl tRNA synthetases.
Moreover, there is increasing evidence that oxidative stress plays an important role during
development and progression of inflammatory diseases. Recent publications have shown that
an oxidized cytosolic environment amplifies activation of nuclear factor kappa B (NFB),
which plays a critical role during inflammatory processes by activating many genes encoding
for proinflammatory cytokines and immunoregulatory mediators. The cytosolic redox state of
a cell depends on the equilibrium between oxidative and antioxidative substances. One of the
most important intracellular antioxidative defense systems against oxidative stress is the
tripeptide glutathione (GSH), which is oxidized to glutathione disulfide (GSSG) while it
scavenges free radicals. As during inflammatory diseases reduced levels of GSH and/or
increased levels of free radicals are detected, recent therapies against inflammatory diseases
focus on antioxidant administration to diminish oxidative stress and thereby arrest
inflammatory processes. Therefore we are interested in investigating new substances with
antioxidative capacities especially of natural polyphenols such as cachexins, curcumine,
alpha-lipoic acid, which has become already of particular clinical interest.
Thesis Subjects
Immunomodulating nutrients - mode of action and clinical relevance
Influence of natural antioxidants on the redox potential
Inflammatory models: Critically ill patients, endotoxic mouse model, cell cultures models.
HPLC Lab, immunomonitoring by FACS, ELISA techniques, Western plot, proteomic
analysis, genomic analysis
page 126 of 168
Curriculum Vitae
Erich ROTH
Surgical Research Laboratory, Department of Surgery, Medical University of Vienna,
Waehringer Guertel 18-20, A-1090 Vienna, Austria; Phone +43 1 40400 6949; Fax +43 1
40400 6782; Email: erich.roth@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
17.08.1946
Trofaiach, Austria
Austria
Education
1977 present
Specialist for Nutritional and Meatbolic Research
2000 2006
1973-1976
1967-1973
1957 1966
Study of Social- and Cultural Anthropology, University of

Vienna
PhD degree in Natural Science at the University of
Agronomics of Vienna. Doctoral thesis work at the Vienna
Sandoz-Research Institute (now: Novartis Research
Institute) on Enterotoxines of Escherichia coli:
Determination of single Parameters for the Production of
Vaccine
Combined studies of Microbiology and Biochemistry at the
University of Agronomics of Vienna, University of Vienna,
Technical University of Vienna
secondary school in Leoben, Styria, Austria
Career History
1993 present
1977
Associate Professor at the Department of Surgery, Surgical

Research Laboratory, Medical University of Vienna.
Administrative director of the Surgical Research
Laboratory
Conferment of the title Associate Professor
venia docendi for Medical Biochemistry
Research State at the St. Eric Hospital Stocholml
1976-1977
1973
Biochemical Adviser for the Kontron company, Vienna

Graduation: Engineer of Microbiology and Biochemistry,
1994
1993
1986
page 127 of 168
Diplomawork: Autoinhibitory and Autostimulating

Substances of Aspergillus orycae
1966-1967
1993 1994
regular Military Service

temporary University Assistant at the Clinical Division of
Endocrinology & Metabolism, Univ. of Vienna
1998- 2003
2003
2000
Awards
2006
President of the Austrian Society for clinical Nutrition

Organizer of the International Congress on Nutrtion
Congress President of the International Nutrition Congress,
Hofburg, Vienna
Honorary Cuthbertson Lecture of the European Society of

Enteral, Parenteral Nutrition and Metabolism, Istanbul,
Turkey
Conferment of the Konrad Lang Award of AKE/DAKE in
Heidelberg for: fundamental investigations on the
metabolism of amino acids and proteins of critically ill
patients
Several research awards in Austria
1985
1986-2005
Editorial Board
Clinical Nutrition
Journal Parenteral Enteral Nutrition
Nutrition
Current Opinion in Clinical Nutrition and Metabolic Care
European Journal of Nutrition
Aktuelle Ernhrungsmedizin
Journal fr Ernhrungsmedizin
Period
Organization
Short Title
2007 - 2003
Fresenius Kabi
Deutschland
Influence of substances with antioxidative

capacity on the cellular redox potential
150
2000 2003
Novartis Nutrition
Austria/International
Glycine as an immunomodulator
148
2002
Abbot Laboratory
Immune enhancing effects of FOS

page 128 of 168
40
2000 2001
BASF
Immunmodilation by Liponic acid and

Glutamine
72

Name
Title of thesis
Period (expected)
Nicole Manhart
Modulation of intestinal immune 1998 2000
Dr.rer. nat.
response by protein malnutrition

and amino acids
techn.
Alexander
Catecholamine induced
Gornikiewicz
immunomodulation in sepsis
Carmen Ludwig
P53 Status and response to
1998-2000
Influence of nutritive
1999-2002
Importance of individual gene
2002-2004
Polyunsaturated fatty acids
2002-2005
Genetic tumor profiling using
2003-2005
Influence of hepatic growth

factor on wound healing and
tumor growth
page 129 of 168
Dr.rer.nat.
techn.
2002-2005
the p53 tumor suppressor gene

as diagnostic and predictive
marker
Anja Bernhardt
Dr.rer.nat.
techn
enhance arsenic trioxidemediated cytotocity in tumor

cells by increasing oxidative
stress
Sonja Kappel
Dr.rer.nat.
techn
profiles and mismatch repair

genes in colorectal cancer
biology
Melanie Baumgartner
Dr.rer.nat.
techn
antioxidants on the cellular

redox potential under
inflammatory conditions
Brigitte Wolf
Dr.
rer.nat.tech
n
neoadjuvant therapy in breast

cancer patients
Barbara Wessner
Acad.Title
Dr.rer.nat.
Techn.
2007-
Dr.med.sci
.
Publications
170 peer reviewed publications and reviews, in scientific journals,
over 100 plenary, invited or guest lectures on national or international congresses, workshops,
and symposia in the field of clincial nutrition and metabolism
Original Publications since 2000
119. Zauner C., Schneewei B., Kranz A., Madl C., Ratheiser K., Kramer L., Roth E.,
Schneider B., Lenz K. Resting energy expenditure in short-term starvation is increased
as a result of an increase in serum norepinephrine. Am.J.Clin.Nutr. 71:1511-1515
(2000)
120. Gornikiewicz A., Sautner T., Brostjan C., Schmierer B., Fgger R., Roth E., Mhlbacher
F., Bergmann M. Catecholamines up-regulate lipopolysaccharide-induced IL-6
production in human microvascular endothelial cells. FASEB J. 14:1093-1100 (2000)
121. Oehler R., Weingartmann G., Manhart N., Salzer U., Meissner M., Schlegel W., Spittler
A., Bergmann M., Kandioler D., Oismller C., Struse H.M. Roth E. Polytrauma induces
increased expression of pyruvate kinase in neutrophils. Blood 95: 1086-1092 (2000)
122. Oehler R., Schmierer B., Zellner M., Prohaska R., Roth E. Endothelial cells
downregulate expression of the 70 kDa Heat shock protein during hypoxia. Biochemical
and Biophysical Research Communications 274:542-547 (2000)
123. Manhart N., Vierlinger K., Akomeah R., Bergmeister H., Spittler A., Roth E. Influence
of enteral diets supplemented with key nutrients on lymphocyte subpopulations in
Peyers patches of endotoxin-boostered mice. Clinical Nutrition 19:265-269 (2000)
124. Manhart N., Vierlinger K., Habel O., Bergmeister H., Gtzinger P., Sautner T., Spittler
A., Boltz-Nitulescu G., Marian B., Roth E. Lipopolysaccaride causes atrophy of Peyers
patches and an increased expresssion of CD28 and B7 costimulatory ligands. Shock 14:
478-483 (2000)
125. Manhart N., Vierlinger K., Bergmeister H., Boltz-Nitulescu G., Spittler A., Roth E.
Influence of short-term protein malnutrition of mice on the phenotype and costimulatory
signals of lymphocytes from spleen and Peyers patches. Nutrition 16:197-201 (2000)
126. Gebhard B., Gnant M., Schtz G., Roka S., Weigel G., Kandioler D., Taucher S.,
Grnberger T., Roth E., Jakesz R., Spittler A. Different transendothelial migration
behaviour pattern of blood monocytes derived from patients with benign and malignant
diseases of the breast. Anticancer Research 20:4599-4604 (2000)
127. Spittler A., Razenberger M., Kupper H., Kaul M., Hackl W., Boltz-Nitulescu G., Fgger
R., Roth E. Relationship between interleukin-6 plasma concentration in patients with
sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production.
Clinical Infectious Diseases 31:1338-42 (2000)
128. Manhart N., Vierlinger K., Spittler A., Bergmeister H., Sautner T., Roth E. Oral feeding
with glutamine prevents lymphocyte and glutathione depletion of Peyers patches in
endotoxemic mice. Annals of Surgery 234:92-97 (2001)
129. Spittler A., Sautner T., Gorniekiewicz A., Manhart N., Oehler R., Bergmann M., Fgger
R., Roth E. Postoperative glycyl-glutamine infusion reduces immunosuppression: partial
prevention of the surgery -induced decreases in HLA-DR expression on monocytes.
Clinical Nutrition 20:37-42 (2001)
130. Krebs M., Krssak M., Bernroider E., Anderwald C., Brehm A., Meyerspeer M., Nowotny
P., Roth E., Waldhusl W., Roden M. Mechanism of amino acid-induced skeletal
muscle insulin resistance in humans. Diabetes 51:599-605 (2002)
131. Roth E., Oehler R., Manhart N., Exner R., Wessner B., Strasser E., Spittler A. Regulative
potential of glutamine-relation to glutathione metabolism. Nutrition 18:217-221 (2002)
132. Zellner M., Hergovics N., Roth E., Jilma B., Spittler A., Oehler R. Human monocyte
page 130 of 168
stimulation by experimental whole body hyperthermia. Wien.Klin.Wochenschr.

114/3:102-107 (2002)
133. Oehler R., Pusch E., Dungel P. Zellner M., Eliasen M.M., Brabec M., Roth E. Glutamine
depletion impairs cellular stress response in human leucocytes. British Journal of
Nutrition 87:S17-S21 (2002)
134. Wekerle Th., Blaha P., Asari R., Schmid M., Kiss Ch., Roth E., Mhlbacher F. Tolerance
induction through mixed chimerism. Eur.Surg. 34:131-135 (2002)
135. Exner R., Weingartmann G., Eliasen M.M., Gerner Ch., Spittler A., Roth E., Oehler R.
Glutamine deficiency renders human monocytic cells more susceptible to specific
apoptosis triggers. Surgery 131:75-80 (2002)
136. Manhart N., Akomeah R., Bergmeister H., Spittler A., Ploner M., Roth E. Administration
of proteolytic enzymes bromelain and trypsin diminish the number of CD4+ cells and
the interferon- response in Peyers patches and spleen in endotoxemic balb/c mice.
Cellular Immunology 215:113-119 (2002)
137. Bauer E., Gendo A., Madl C., Garo F., Roth E., Kramer L. Effects of sorbent suspension
dialysis on plasma amino acid levels in cirrhotic patients with refractory hepatic
encephalopthy . The International Journal of Artificial Organs 25:923-928 (2002)
138. Exner R., Tamandl D., Goetzinger P., Mittlboeck M., Fuegger R., Sautner T.,
Spittler A., Roth E. Perioperative GLY-GLN infusion diminishes the surgery-induced
period of immunosuppression. Annals of Surgery 237:110-115 (2003)
139. Lassnig A., Punz A., Barker R., Keznickl P., Manhart N., Roth E., Hiesmayr M.
Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative
stress: a double-blinded, randomized, controlled study. British Journal of Anaesthesia
90:148-154 (2003)
140. Blaha P., Bigenzahn S., Koporc Z., Schmid M., Langer F., Selzer E., Bergmeister H.,
Wrba F., Kurtz J., Kiss Ch., Roth E., Muehlbacher F., Sykes M., Wekerle T. The
influence of immunosuppressive drugs on tolerance induction through bone marrow
transplantation with costimulation blockade. Blood 101:2886-2893 (2003)
141. Oehler R., Roth E.Regulative capacity of glutamine. Current Opinion in Clinical
Nutrition and Metabolic Care 6:277-282 (2003)
142. Manhart N., Spittler A., Bergmeister H., Mittlbck M., Roth E. Influence of
fructooligosaccharides on Peyers patch lymphocyte numbers in healthy and
endotoxemic mice. Nutrition 19:657-660 (2003)
145. Spittler A., Roth E. Is monocyte HLA-DR expression predictive for clinical outcome in
sepsis ? Intensive Care Medicine (2003)
146. Sturlan S., Baumgartner M., Roth E., Bachleitner-Hofmann T. Docosahexaenoic acid
enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.
Blood 101:4990-4997 (2003)
147. Wessner B., Strasser E.-M. Spittler A., Roth E. Effect of single and combined supply of
glutamine, glycine, N-acetylcysteine, and R,S- -lipoic acid on glutathione content of
myelomonocytic cells. Clinical Nutrition 22:515-522 (2003)
148. Nanobashvili J., Neumayer C., Fgl A., Punz A., Blumer R., Prager M., Mittlbck M.,
Gruber H., Polterauer P., Roth E., Malinski T., Huk I. Ischemia/reperfusion injury of
skeletal muscle: Plasma taurine as a measure of tissue damage. Surgery 133:91-100
(2003)
149. Roth E., Zellner M., Wessner B., Strasser E., Manhart N., Oehler R., Spittler A. Glycine
An inert amino acid comes alive. Nutrition 19:817-818 (2003)
150. Tamandl D., Bahrami M., Wessner B., Weigel G., Ploder M., Frst W., Roth E., BoltzNitulescu G., Spittler A. Modulation of toll-like receptor 4 expression on human
monocytes by tumor necrosis factor and interleukin-6: tumor necrosis factor evokes
page 131 of 168
lipopolysaccharide
hyporesponsiveness,
whereas
interleukin-6
enhances
lipopolysaccharide activity. Shock 20:224-229 (2003)
151. Krebs M., Brehm A., Krssak M., Anderwald C., Bernroider E., Nowotny P., Roth E.,
Chandramouli V., Landau B.R., Waldhusl W., Roden M. Direct and indirect effects of
amino acids on hepatic glucose metabolism in humans. Diabetologia 46:917-925 (2003)
152. Bergmann M., Gornikiewicz A., Tamandl D., Exner R., Roth E., Fgger R., Gtzinger
P., Sautner T. Continuous therapeutic epinephrine but not norepinephrine prolongs
splanchnic IL-6 production in porcine endotoxic shock. Shock 20:575-581 (2003)
153. Varga P., Griffiths R., Chiolero R., Nitenber G., Leverve X, Pertkiewicz M., Roth E.,
Wernerman J., Pichard C., Preiser J.-C. Is parenteral nutrition guilty? Intensive Care
Med 29:1861-1864 (2003)
154. Roth E., Manhart N., Wessner B. Assessing the antioxidative status in critically ill
patients. Current Opinion in Clinical Nutrition and Metabolic Care 7:161-168 (2004)
155. Hallwirth U., Pomberger G., Pollak A., Roth E., Spittler A. Monocyte switch in
neonates: high phagocytic capacity and low HLA-DR expression in VLBWI are
inverted during gestational aging. Pediatr Allergy Immunol 15:513-516 (2004)
156. Baumgartner M., Sturlan S., Roth E., Wessner B., Bachleitner-Hofmann T. Enhancement
of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxideresistant solid tumor cells. Int J Cancer 112:707-712 (2004)
157. Roth E., Manhart N. Einfluss der Mangelernhrung auf die Immunittslage.
Mangelernhrung, S. 94-97. In: Ernhrungs- und Infusionstherapie Standards fr
Klinik, Intensivstation und Ambulanz. Hg.: Hartig W., Biesalski H.K., Druml W., Frst
P., Weimann A. Thieme-Verlag (2004)
158. Oehler R., Roth E. Glutamine metabolism. In: Metabolic and therapeutic aspects of
amino acids in clinical nutrition. Hg.: Cynober L.A. CRC Press (2004)
159. Roth E., Kudsk KA. Immunonutrition: Back to Science. J Par Ent Nutr 28:278 (2004)
160. Pollheimer J., Zellner M., Eliasen M.M., Roth E., Oehler R. Increased susceptibility of
glutamine-depleted monocytes to fever-range hyperthermia. Ann Surg 241:349-355
(2005)
161. Zellner M., Winkler W., Hayden H., Diestinger M., Eliasen M., Gesslbauer B., Miller I.,
Chang M., Kungl A., Roth E., Oehler R. Quantitative validation of different protein
precipitation methods in proteome analysis of blood platelets. Electrophoresis 26:248191 (2005)
162. Roth E., Wessner B. L-arginine: an amino acid with multiple effects. Wien Klin
Wochenschr 117:666-72, 2005
163. Strasser E.-M., Wessner B., Manhart N., Roth E. The relationship between the
antioxidative, anti-inflammatory effects of curcumin and cellular glutathione content in
myelomonocytic cell. Biochemical Pharmacology 70:552-559, 2005
164. Roth E. L-Arginin-Gabe bei chirurgischen Patienten. Ist das gefhrlich? Schweizer
Zeitschrift fr Ernhrungsmedizin 3:12-15, 2005
165. Tremblay F., Krebs M., Dombrowski L., Brehm A., Bernroider E., Roth E., Nowotny P.,
Waldhausl W., Marette A., Roden M. Overactivation of S6 kinase as a cause of human
insulin resistance during increased amino acid availability. Diabetes 54:2674-84, 2005
166. Wessner B., Strasser EM., Manhart N., Roth E. Supply of R-alpha-Lipoic acid and
glutamine to casein-fed mice influences the number of B lymphocytes and tissue
glutathione levels during endotoxemia. Wien Klin Wochenschr. In press 2006
167. Kappel S., Kandioler D., Steininger R., Lngle F., Wrba F., Ploder M., Berlakovich G.,
Soliman T., hetz H., Rockenschaub S., Roth E., and Mhlbacher F. Genetic Detection of
Lymph Node Micrometastases: A Selection Criterion for Liver Transplantation in
Patients with Liver Metastases after Colorectal Cancer. Transplantation 81: 64-70, 2006
page 132 of 168
168. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J, Zugel U, Steinmeyer

A, Pollak A, Roth E, Boltz-Nitulescu G, Spittler A.Vitamin D3 down-regulates
monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated
molecular patterns. Eur J Immunol. 36:361-70, 2006
169. Eliasen MM, Brabec M, Gerner C, Pollheimer J, Auer H, Zellner M, Weingartmann G,
Garo F, Roth E, Oehler R.Reduced stress tolerance of glutamine-deprived human
monocytic cells is associated with selective down-regulation of Hsp70 by decreased
mRNA stability. J Mol Med. 84:147-58, 2006
170. Ploder M., Pelinka L., Schmuckenschlager C., Wessner B., Ankersmit HJ., Frst W.,
Redl H., Roth E., and Spittler A. Lipopolysaccharide- induced tumor necrosis factor
alpha production and not monocyte human leukocyte antigen-DR expression is
correlated with survival in septic trauma patients. Shock 25:1-7, 2006
page 133 of 168
Thomas M. STULNIG
thomas.stulnig@meduniwien.ac.at
Polyunsaturated fatty acids in morbid obesity

Abstract
Obesity is associated with a chronic state of subclinical inflammation that resides in adipose
tissue. This subclinical inflammation is associated with the development of metabolic
disorders such as insulin resistance and diabetes mellitus and cardiovascular complications.
Therefore, obesity-associated adipose tissue inflammation has become a novel aspect of the
pathophysiology of type 2 diabetes and its complications. Molecular mechanisms underlying
macrophage immigration and activation are currently investigated in order to discover novel
drug targets.
Polyunsaturated fatty acids (PUFAs), particularly those of the n-3 series, ameliorate
insulin resistance and development of diabetes mellitus type 2. Previous studies in our
laboratory revealed that feeding a diet rich in saturated and monounsaturated fatty acids to
obese diabetic mice leads to extensive adipose tissue infiltration with macrophages together
with increased expression with a number of inflammatory genes. Notably, macrophage
infiltration of adipose tissue in obese diabetic mice under high-fat diet could be totally
prevented by including marine n-3 PUFA in the diet. Moreover, adipocytes of animals on
high-fat diets showed signs of dedifferentiation by reduced expression of cell type-specific
genes and those involved in lipid metabolism that were also prevented by n-3 PUFA. Since
macrophage infiltration and activation selectively occurs in adipose tissue and only in obese
mice, adipocytes that are heavily loaded with lipids appear to provoke macrophage infiltration
by unknown mechanisms.
Starting from this knowledge from animal models, effects of n-3 PUFA on metabolic
regulation and adipose tissue inflammation are to be analyzed. Within a clinical study,
morbidly obese patients are to treated with n-3 PUFA or not immediately prior to a planned
bariatric operation. Within the thesis, metabolic control is studied before and at the end of the
treatment period. Moreover, samples from visceral and subcutaneous adipose tissue are taken
at the bariatric operation in order to study possible effects on adipose tissue inflammation.
Tissue specimens obtained during these clinically oriented investigations will facilitate studies
on the factors underlying n-3 PUFA effects in adipose tissue of morbidly obese patients.
These studies will not only allow translation of basic research into clinical application but also
training of students with various methods to investigate body composition, metabolic control
and nutrition in an increasingly prevalent population of patients.
Thesis Subjects
PUFA effects on metabolic control in morbidly obese patients
PUFA effects on adipose tissue inflammation in morbidly obese patients
Assessment of insulin sensitivity; dietary assessment and interventions; explant and primary
cell culture; analyses of cytokines by ELISA and bead assays; immunofluorescence analyses;
immunoblotting; FACS analysis; quantitative real-time RT-PCR; all required equipment is
available.
page 134 of 168
Curriculum Vitae
Thomas STULNIG
40400 4368; Fax +43 1 40400 7790; Email thomas.stulnig@meduniwien.ac.at
Personal Data
Date of Birth:
Place of Birth:
Nationality
31.05.1964
Burghausen, Obb., Germany
Austria
Education
2003 present
specialist in Endocrinology and Metabolism
1999
1991
1982 1990
1974 1982
Career History
2002 2005
2001 2002
2000 present
2000
1998 2003
1995 present
1994 1995
specialist in Internal Medicine

Educational Commission for Foreign Medical Graduates
(ECFMG) test passed
secondary school
principal Investigator of the CeMM Center of Molecular

Medicine of the Austrian Academy of Sciences (ID#20020)
Marie-Curie Individual Fellowship of the European
Commission at the Karolinska Insitute, Dept. of Medical
Nutrition at Novum Research Center, Huddinge, Sweden
with Prof. Jan-ke Gustafsson
Associate Professor at the Department of Internal Medicine
III, Medical University of Vienna. Clinical duties and
supervising physician at the inpatient and various
outpatient departments
venia docendi for Internal Medicine
Coapplicant in the Interdisciplinary Cooperation Project
Molecular Medicine at the University of Vienna
University Assistant at the Clinical Division of
Endocrinology Metabolism, Department of Internal
Medicine III, (Medical) University of Vienna, Austria
regular Military Service
page 135 of 168
1993 1994
1991 1993
1990 1991
1986 1989
2002 2003
2004 present
Awards
2005
2003
2003
2000
1995
1991
temporary University Assistant at the Clinical Division of

Endocrinology & Metabolism, Univ. of Vienna
University Assistant at the Institute for General and
Experimental Pathology, Univ. of Innsbruck
Research Assistant at the Institute for General and
Experimental Pathology, Univ. of Innsbruck
Doctoral Thesis at the Insitute for Medical Biology and
Genetics, Univ. of Innsbruck
Training Course for Medical Management at the University

of Salzburg
Section leader "Obesity and Lipid Disorders", Austrian
Society for Endocrinology and Metabolism
Novartis Prize 2004 for Medicine

Research Award of the Erste sterreichische Sparkasse in
cooperation with the Medical Association of Vienna
Josef-Skoda Research Award of the Austrian Association
of Internal Medicine (research grant)
Ludwig-Heilmeyer Medaille in Silver of the Association
for Progress in Internal Medicine
Johannes-Tuba-Prize of the Tyrolean Medical Association
Talentfrderungsprmie of the country Upper Austria
Memberships
Austrian Society for Allergology and Immunology
Austrian Society for Biochemistry and Molecular Biology
American Diabetes Association
page 136 of 168

Period
Organization
Short Title
2007
European Science
Foundation (EW06007)
Exploratory Workshop on Targeting

Obesity-driven Inflammation
14
2006 2009
Austrian Science
Cellular communication in health and
Fund (FWF) Doctoral disease (own share)
program (W1205B09)
129
2006 2008
FWF (P18776-B11)
The role of osteopontin in adipose tissue

inflammation
296
2003 2006
FWF (P16788-B13)
Polyunsaturated fatty acids and dendritic

cells
191
2003 2005
Austrian Society for Proteomic analysis of insulin signaling via

Internal Medicine,
adipocyte lipid rafts
Joseph-Skoda
Research Award 2003
2002 2005
CeMM (ID# 20020),

Austrian Academy of
Sciences
2001 2002
Marie-CurieThe biological role of nuclear oxysterol

Fellowship, European receptors LXRa and LXRb
Commission
1999 2003
FWF (P13507-B01)
Fatty acids as molecular modulators of

insulin sensitivity in adipocytes (own
share)
40
600
78
The role of lipid rafts for lymphocyte

activation
290

Name
Title of thesis
Period (expected)
Acad.Title
Maximilian Zeyda
Molecular mechanisms of T cell

inhibition by polyunsaturated
fatty acids
1998 2001
Dr. nat.
techn.
Ren Geyeregger
Impact of polyunsaturated fatty

acids on the formation of the
immunological synapse
2001 2005
Dr. rer.
nat.
page 137 of 168
Name
Title of thesis
Period (expected)
Jelena Todoric
Mechanisms of adipose tissue

3.2005 (6.2007)
macrophage infiltration and their
prevention by polyunsaturated
fatty acids
(PhD)
Florian Kiefer
Role of MCP-1 and osteopontin

in adipose tissue inflammation
(PhD)
5.2006 (2.2009)
Acad.Title
Publications
7 invited lectures,
Stulnig T.M., M. Berger, M. Roden, H. Stingl, D. Raederstorff, W. Waldhusl:. 2000.
Elevated serum free fatty acid concentrations inhibit T lymphocyte signaling. FASEB J
14:939-947.
Stulnig T.M., J. Huber, N. Leitinger, E.M. Imre, P.Angelisov, P. Nowotny, W. Waldhusl.
2001. Polyunsaturated eicosapentaenoic acid displaces proteins from membrane rafts by
altering raft lipid composition. J. Biol Chem. 276:37335-37340.
Zeyda M., T. Sigmund, G. Staffler, V. Horejs, W. Waldhusl, T.M. Stulnig. 2002. LAT
displacement from lipid rafts as molecular mechanism of T cell inhibition by
polyunsaturated fatty acids. J. Biol. Chem. 277: 28418-28423.
Stulnig T.M., U. Oppermann, K.R. Steffensen, G.U. Schuster, J.-. Gustafsson. 2002. Liver
X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and
activity. Diabetes 51:2426-2433.
Stulnig T.M., K.R. Steffensen, H. Gao, M. Reimers, K. Dahlman-Wright, G.U. Schuster, J.-.
Gustafsson. 2002. Novel roles of liver X receptors exposed by gene expression profiling in
liver and adipose tissue. Mol. Pharmacol. 62:1299-13095.
Zeyda M., A. Szekeres, M.D. Semann, R. Geyeregger, H. Stockinger, G.J. Zlabinger, W.
Waldhusl, T.M. Stulnig. 2003. Suppression of T Cell signaling by polyunsaturated fatty
acids: Selectivity in inhibition of mitogen-activated protein kinase and nuclear factor
acitivation. J. Immunol. 170:6033-6039.
Stulnig T.M. 2003. Immunomodulation by polyunsaturated fatty acids: mechanisms and
effects. Int. Arch. Allergy Immunol. 132:310-321. (Review)
Stulnig T.M., W. Waldhusl. 2004. 11beta-hydroxysteroid dehydrogenase Type 1 in obesity
and Type 2 diabetes. Diabetologia 47:1-11. (Review)
Stulnig T.M., M. Zeyda. 2004. Immunomodulation by polyunsaturated fatty acids: impact on
T cell signaling. Lipids 30:1171-1175. (Review)
Zeyda M., M.D. Semann, K.M. Stuhlmeier, G.J. Zlabinger, W. Waldhusl, T.M. Stulnig.
2005. Polyunsaturated fatty acids inhibit dendritic cell activation and function
independently of NF-kappaB activation. J. Biol. Chem. 280:14293-14301.
page 138 of 168
Geyeregger R., M. Zeyda, G. Zlabinger, W. Waldhusl, T.M. Stulnig. 2005. Polyunsaturated

fatty acid treatment of T cells alters formation of the immunological synapse. J. Leukoc.
Biol. 77:680-688.
Zeyda M., R. Geyeregger, B.M. Kirsch, K.M. Stuhlmeier, W.H. Hrl, G.J. Zlabinger, M.D.
Semann, T.M. Stulnig. 2005. Inhibition of human dendritic cell maturation and function
by the novel immunosuppressant FK778. Transplantation, 80:1105-1111 (2005).
Geyeregger R., Zeyda M., Stulnig T.M. 2005. Liver X receptors in cardiovascular and
metabolic disease. Cell. Mol. Life Sci. 63:524-539 (2006). (Review)
Zeyda M., Stulnig T.M. 2005. Lipid rafts & Co.: an integrated model of membrane
organization in T cell activation. Progr. Lipid Res., submitted for publication. (Review)
Lffler M., M. Bilban, M. Reimers, W. Waldhusl, T.M. Stulnig. 2006. Blood glucose
lowering nuclear receptor agonists do not normalize hepatic gene expression in db/db
mice. J. Pharmacol. Exp. Therap., 316:797-804.
Todoric J., M. Lffler, J. Huber, M. Bilban, M. Reimers, A. Kadl, M. Zeyda, W. Waldhusl,
T.M. Stulnig: Adipose tissue inflammation induced by high-fat diet in obese diabetic mice
is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49:2109-2119 (2006).
Zeyda M., T.M. Stulnig: Lipid rafts & Co.: an integrated model of membrane organization in
T cell activation. Progr. Lipid Res. 45:187-202 (2006). (Review)
Huber J., M. Lffler, M. Bilban, M. Reimers, A. Kadl, J. Todoric, N. Leitinger, W.
Waldhusl, T.M. Stulnig: Prevention of high-fat diet-induced adipose tissue remodeling in
obese diabetic mice by polyunsaturated fatty acids. Int. J. Obes. 31:1004-1013 (2007).
Geyeregger R., M. Zeyda, W. Bauer, E Kriehuber, M.D. Semann, G.J. Zlabinger, D. Maurer,
T.M. Stulnig: Liver X receptors regulate dendritic cell phenotype and function through
blocked induction of the actin bundling protein fascin. Blood 109:4288-4295 (2007).
Zeyda M., D. Farmer, O. Aszmann, M. Speiser, G. Zlabinger, T.M. Stulnig: Human adipose
tissue macrophages are of an anti-inflammatory phenotype but capable of excessive proinflammatory mediator production. Int. J. Obes., in press (2007).
Schmaldienst S., S. Banyai, T.M. Stulnig, G. Heinz, M. Jansen, W.H. Hrl, K. Derfler. 2000.
Prospective randomised cross-over comparison of three LDL-apheresis systems in statin
pretreated patients with familial hypercholesterolemia. Atherosclerosis 151:493-399.
Van Laethem V., X. Liang, F. Andris, J. Urbain, M. Vandenbranden, J.-M.Ruysschaert,
M.D. Resh, T.M. Stulnig, O. Leo. 2003. Glucocorticoids alter the lipid and protein
composition of membrane rafts of a murine T cell hybridoma. J. Immunol. 170:2932-2939.
Semann M.D., M. Zeyda, C. Diakos, A. Szekeres, G.A. Bmig, P. Kelemen, O. Parolini, H.
Stockinger, E. Prieschl, T. Stulnig, T. Baumruker, G.J. Zlabinger. 2003. Pharmacological
targeting of JAK3 impairs early T cell receptor (TCR)-triggered cellular activation.
Transplantation 75:1864-1872.
Sanzone S., M. Zeyda, M.D. Semann, M. Soncini, W. Holter, G. Fritsch, W. Knapp, F.
Candotti, T.M. Stulnig, O. Parolini. 2003. SAP deficiency causes imbalanced early signal
transduction and blocks downstream activation in T cells from XLP patients. J. Biol.
Chem. 278:29593-29599.
Steffensen K.R., M. Nilsson, G.U. Schuster, T.M. Stulnig, K. Dahlmann-Wright, J.-.
page 139 of 168
Gustafsson. 2003. Gene expression profiling in adipose tissue indicates different

transcriptional mechanisms of liver X receptors alpha and beta, respectively. Biochem.
Biophys. Res. Commun. 310:589-593.
Staffler G., A. Szekeres, G.J. Schtz, M.D. Semann, E. Prager, M. Zeyda, K. Drbal, I.
Hilgert, G.J. Zlabinger, T.M. Stulnig, H. Schindler, V. Horejs, H. Stockinger. 2003.
Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts.
J. Immunol171:1707-1714.
Seo J.B. H.M. Moon, W.S. Kim, Y.S. Lee, H.W. Jeong, E.J. Yoo, J. Ham, H. Kang, M.-G.
Park, K.R. Steffensen, T.M. Stulnig, J.-. Gustafsson, S.D. Park, J.B. Kim. 2004.
Activated liver X receptors stimulate adipocyte differentiation through induction of
PPARgamma expression. Mol. Cell. Biol. 24: 3430-3444.
Jaksits S., W. Bauer, E. Kriehuber, M. Zeyda, T.M. Stulnig, G. Stingl, E. Fiebiger, D. Maurer.
2004. Lipid raft-associated GTPase signaling controls morphology and CD8+ T cell
stimulatory capacity of human dendritic cells. J. Immunol. 173: 1628-1639.
Corton J.C., U. Apte, S.P. Anderson, P. Limaye, L, Yoon, J. Latendresse, C. Dunn, J.X.
Everitt, K.A. Voss, C. Swanson, C. Kimbrough, J.S. Wong, S.S. Gill, R. Chandraratna,
M.K. Kwak, T.W. Kensler, T.M. Stulnig, K.R. Steffensen, J.-. Gustafsson, H.M.
Mehendale. 2004. Mimetics of caloric restriction include agonists of lipid-activated
nuclear receptors. J. Biol. Chem. 270: 46204-46212.
Steffensen K.R., S.Y. Neo, T.M. Stulnig, V.B. Vega, S.S. Rahman, G.U. Schuster, J.-.
Gustafsson, E.T. Liu. 2004. Genome-wide expression profiling: a panel of mouse tissues
discloses novel biological functions of LXRs in adrenal. J. Mol. Endocrinol. 33:609-622.
Anderson S.P., C. Dunn, A. Laughter, L. Yoon, C. Swanson, T.M. Stulnig, K.R. Steffensen,
R.A.S. Chandraratna, J.-. Gustafsson, J.C. Corton. 2004. Overlapping transcriptional
programs regulated by peroxisome proliferator-activated receptor alpha, retinoid X
receptor and liver X receptor in the mouse liver. Mol. Pharm. 66:1440-1452.
Semann M.D., M. Zeyda, T.M. Stulnig, G.A. Bhmic, T. Wekerle, W.H. Hrl, G.J.
Zlabinger. 2004. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for
allogeneic transplantation. Transplant. Int. 17:481-489. (Review)
Semann M.D., T. Weichhart, M. Zeyda, G. Staffler, K. Stuhlmeier, Y. Sobanov, T.M.
Stulnig, W.H. Hrl, G.J. Zlabinger. 2005. Tamm-Horsfall glycoprotein links innate
immune cell activation with adaptive immunity via a TLR4-dependent mechanism. J.
Clin. Invest. 115:468-475.
Kirsch B., M. Zeyda, K. Stuhlmeier, J. Grisar, J. Smolen, B. Watschinger, T.M. Stulnig. W.H.
Hrl, G.J. Zlabinger, M.D. Semann. 2005. The active metabolite of leflunomide A77
1726 potently interferes with dendritic cell maturation via inhibition of NFkappaB
signaling. Arthritis Res. Ther. 7:R694-R703.
Zeyda M., M, Poglitsch, R. Geyeregger, J. Smolen, G.J. Zlabinger, W.H. Hrl, W. Waldhusl,
T.M. Stulnig, M.D. Semann. 2005. The active leflunomide metabolite teriflunomide
disrupts the interaction of T cells with antigen-presenting cells: involvement of impaired
integrin activation and immunological synapse formation. Arthritis Rheum., 52:27302739.
Schuster G., L. Johansson, S. Kietz, T.M. Stulnig, P Parini, J.-. Gustafsson: Improved
metabolic control by depletion of liver X receptors in mice. Biochem. Biophys. Res.
Commun. 348:176-182 (2006).
Nilsson M., T.M. Stulnig, C.Y. Lin, A.L. Yeo, P. Nowotny, E.T. Liu, K.R. Steffensen: Liver
X receptors regulate adrenal steroidogenesis and hypothalamic-pituitary-adrenal feedback.
Mol. Endocrinol. 21:126-137 (2007).
page 140 of 168
Zeyda M., R. Geyeregger, M. Poglitsch, T. Weichhart, G.J. Zlabinger, S. Koyasu, W.H. Hrl,
T.M. Stulnig, B. Watschinger, M.D. Semann: Impairment of T cell interactions with
antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin
and NF-kappaB in immunological synapse formation. J. Leukoc. Biol. 81:319-327 (2007).
Haidinger M., R. Geyeregger, M. Poglitsch, T. Weichhart, M. Zeyda, B. Vodenik, T.M.
Stulnig, G.A. Bhmig, W.H. Walter, M.D. Semann: Anti-thymocyte globulin impairs T
cell/antigen-presenting cell interaction: disruption of immunological synapse and
conjugate formation. Transplantation, in press (2007).
page 141 of 168
Walter TSCHUGGUEL
Dept. Obstetrics and Gynecology
Endometriosis, a sequel of diseased eutopic endometrium

Abstract
Endometriosis is a common, benign, estrogen dependent, chronic gynecological disorder
associated with pelvic pain and infertility. It is characterized by the presence of uterine
endometrial tissue outside of the normal location (i.e. ectopic sites) mainly on the pelvic
peritoneum, but also on the ovaries and in the rectovaginal septum, and more rarely in the
pericardium, pleura, and even in the brain. The prevalence of pelvic endometriosis approaches
610% in the general female population in the reproductive age (Giudice and Kao, 2004). The
answer to the question how uterine endometrial tissue following retrograde menstruation is
able to migrate towards and to invade extrauterine sites is presently missing. However, it
implies the existence of a not yet described mechanism responsible for this process. Due to
recent findings that eutopic endometrium of endometriosis patients, in contrast to
endometrium of healthy patients, contains the enzyme aromatase (also known as CYP19)
(Noble et al., 1996; Kitawaki et al., 1997; Wolfler et al. 2005), we speculate aromatase
expression is a major hallmark of this disease.
Understanding the links between aromatase expression, abnormal cell migration and invasion
may give us the additional possibility to speculate on other facets of endometriosis, e.g., how
ectopic lesions survive apoptosis, but do not become metastatic. Furthermore, such
investigations could disclose novel early eutopic markers of endometriosis that can help to
identify the disease out of menstrual discharge, which makes uninformative, invasive
procedures, i.e. laparoscopy or laparotomy unnecessary.
Thesis Subjects
Does the eutopic endometrium of endometriosis vs. healthy patients contain a fully developed
principle making endometrial cells able to proliferate, migrate and translocate towards ectopic
sites?
Primary endometrial cell culture, Western blotting, Raf-1 kinase assay,
immunohistochemistry, immunofluorescence, RT-PCR and Real-Time RT-PCR, FACS
analysis, migration assay, transfection of cells, all required equipment available.
page 142 of 168
CURRICULUM VITAE
Walter TSCHUGGUEL
Medical University of Vienna, Department of Obstetrics & Gynecology, Division of
Gynecological Endocrinology & Reproductive Medicine, A-1090 Vienna/Austria,
Waehringer Guertel 18-20 +43 1 40400 7828, +43 676 924 2 924; FAX +43 1 40400 7842
Personal Data
Date of Birth:
02-06-1966
Place of Birth:
Vienna, Austria
Nationality:
Austria
Education
1972 - 1976
Primary School, Vienna, Austria
1976 - 1984
High School, Vienna, Austria, Matura
1984 - 1990
Medical School, University of Vienna, Austria, MD degree
Career History
1986 - 1990
Academic Tutor, Institute of Anatomy, University of Vienna
1991
Resident, Department of Urology, University of Vienna School

of Medicine
1992
Military Service in the Austrian Armed Force
1992 - 1993
Coordinator for Liver and Kidney
Transplantation at the Department of Surgery, University of Vienna

1993-1996
Rotation Internship, Departments of Surgery and Internal

Medicine, Krankenhaus Floridsdorf, Vienna, Austria
1996
General Physicians degree
1992 - 1996
Postdoc, Department of General & Experimental Pathology,

Division of Cellular Pathology, University of Vienna
1996 - 2000
Resident, Department of Obstetrics and Gynecology, University

of Vienna School of Medicine
2000 - Present
Fellow, Department of Obstetrics and Gynecology, Division of

Gynecological Endocrinology & Reproductive Medicine,
University of Vienna School of Medicine
page 143 of 168
2000
Habilitation (Universittsdozent), Associate Professor,

Department of Obstetrics and Gynecology, Division of
University of Vienna School of Medicine
2003
Chief Officer for Education and Training of Residents at the

Department of Obstetrics and Gynecology, Division of
Medical University of Vienna
2005
Education in the program Klinischer Studienleiter, part I,

collaboration between the Medical University of Vienna and the
Vienna school of Clinical Research (VSCR)
Awards
1998 International Organon Award for Assisted Reproduction
2002 Wyeths Presidents Presenter Award of the Society for Gynecologic Investigation
(SGI), Toronta, Canada, USD $ 1000. - to Mentee Dr. Felix Stonek
(SGI), Los Angeles, CA, USD $ 1000. - to Mentee Dr. Monika Wlfler
(SGI), Toronta, Canada, USD $ 1000. - to Mentee Mag. Cristina Rubiolo
Memberships
Austrian Society of Gynecology and Obstetrics (OEGGG)
Society for the Study of Reproduction (SSR)
Society for Gynecological Investigation (SGI, Full Member)
Reviewing Activities
British Journal of Cancer (since 1999)
Molecular Human Reproduction (since 2000)
Human Reproduction (since 2000)
Breast Cancer Research and Treatment (since 2001)
page 144 of 168
Molecular Endocrinology (since 2004)

Lancet (since 2005)

Period
Organization
Short Title
1998
Jubilee Fund of the

Austrian National
Bank
Inducible Nitric Oxide Synthase (iNOS)

Induction in Human Endometrium
18
2000
Jubilee Fund of the

Austrian National
Bank
Inducible Nitric Oxide Synthase (iNOS) as

a Regulator of Apoptosis and
Collagenolysis in Cultured Steroidhormone treated Endometrial Stromal Cells
22
2007 2009
Austrian Science
Fund (P19327-B02)
Endometriosis, a Sequel of Diseased

Eutopic Endometrium
328

Name
Title of thesis
Period (expected)
Acad.Title
Gudrun Brunnmayr
The Psychiatric Co-morbidity
2004 2005
MD
2004 2006
MD
(DSM-IV) between Chronic

Pelvic Pain Patients (CPP) and
Chronic Polysymptomatic
Patients is equal
Joanna Pong
Comparison of the Methylation

Status of the CpG-island
neighboring Exon 1 of the
Aromatase Gene in Human
Myomas and their adjacent
Myometria by using
Methylation-specific PCR
Publications
1. Wolfler MM, Facchinetti F, Venturini P, Huber A, Helmer H, Husslein P, Tschugguel
W. Induction of labor at term using isosorbide mononitrate simultaneously with
dinoprostone compared to dinoprostone treatment alone: a randomized, controlled trial
. (2006). Am J Obstet Gynecol; 195, 1617-22.
page 145 of 168
2. Dietrich W, Haitel A, Holzer G, Huber JC, Kolbus A, Tschugguel W. Estrogen

receptor-beta is the predominant estrogen receptor subtype in normal human synovia.
(2006). J Soc Gynecol Investig. 13, 512-7.
3. Demyanets S, Pfaffenberger S, Kaun C, Rega G, Speidl WS, Kastl SP, Weiss TW,
Hohensinner PJ, Dietrich W, Tschugguel W, Bochkov VN, Awad EM, Maurer G,
Huber K, Wojta J. The estrogen metabolite 17beta-dihydroequilenin counteracts
interleukin-1alpha induced expression of inflammatory mediators in human
endothelial cells in vitro via NF-kappaB pathway. (2006). Thromb Haemost. 95, 10716.
4. Wolfler, M.M., Nagele, F., Kolbus, A., Seidl, S., Schneider, B., Huber, J.C,
Tschugguel W. A predictive model for endometriosis. (2005). Hum Reprod; 20 (6):
1702-08.
5. Eppel, W., Facchinetti, F., Schleussner, E., Piccinini, F., Pizzi, C., Gruber, D.M.,
Schneider, B., Tschugguel, W. Second trimester abortion using isosorbide mononitrate
in addition to gemeprost compared with gemeprost alone: a double-blind randomized,
placebo-controlled multicenter trial. (2005). Am J Obstet Gynecol, 192, 856-61.
6. Fuchsjager-Mayrl, G., Nepp, J., Schneeberger, C., Sator, M., Dietrich, W., Wedrich,
A., Huber,
7. J., Tschugguel, W. Identification of estrogen and progesterone receptor mRNA
expression in the conjunctiva of premenopausal women. (2004). Invest Ophthalmol
Vis Sci, 43, 2841-4.
8. Stonek, F., Dietrich, W., Schneeberger, C., Vycudilik, W., Tschugguel, W.
Quantitative determination of carbon monoxide in cell culture supernatants by
spectrophotometric analysis. (2004). J Biochem Biophys Methods, 58, 49-58.
9. Tschugguel, W., Berga, S.L. Treatment of functional hypothalamic amenorrhea with
hypnotherapy. (2003). Fertil Steril, 80, 982-5.
10. Tschugguel, W., Dietrich, W., Zhegu, Z., Stonek, F., Kolbus, A., Huber, J.C.
Differential regulation of proteasome-dependent estrogen receptor alpha and beta
turnover in cultured human uterine artery endothelial cells. (2003). J Clin Endocrinol
Metab, 88, 2281-7.
11. Gruber, C.J., Tschugguel, W., Schneeberger, C., Huber, J.C. Production and actions of
estrogens. (2002). N Engl J Med, 346, 340-52.
12. Singer, C.F., Kronsteiner, N., Marton, E., Walter, I., Kubista, M., Czerwenka, K.,
Schreiber, M., Tschugguel, W., Wieser, F., Kubista, E. IL-1alpha gene expression in
page 146 of 168
human endometrial cancer is independent of ovarian steroid receptor expression.

(2002). Eur J Cancer, 38 Suppl 6, S76-7.
13. Singer, C.F., Kronsteiner, N., Marton, E., Walter, I., Kubista, M., Czerwenka, K.,
Schreiber, M., Tschugguel, W., Wieser, F., Kubista, E. Interleukin-1 system and sex
steroid receptor gene expression in human endometrial cancer. (2002). Gynecol Oncol,
85, 423-30.
14. Wieser, F., Schneeberger, C., Hudelist, G., Singer, C., Kurz, C., Nagele, F., Gruber,
C., Huber, J.C., Tschugguel, W. Endometrial nuclear receptor co-factors SRC-1 and
N-CoR are increased in human endometrium during menstruation. (2002). Mol Hum
Reprod, 8, 644-50.
15. Tschugguel, W., Stonek, F., Zhegu, Z., Dietrich, W., Schneeberger, C., Stimpfl, T.,
Waldhoer, T., Vycudilik, W., Huber, J.C.
Estrogen increases endothelial carbon
monoxide, heme oxygenase 2, and carbon monoxide-derived cGMP by a receptormediated system. (2001). J Clin Endocrinol Metab, 86, 3833-9.
16. Stonek, F., Tschugguel, W., Huber, J.C., Schneeberger, C. Calculated background
elimination in quantifying nitric-oxide synthase enzyme activity. (2001). J Biochem
Biophys Methods, 50, 29-32.
17. Wieser, F., Hosmann, J., Tschugguel, W., Czerwenka, K., Sedivy, R., Huber, J.C.
Progesterone increases the number of Langerhans cells in human vaginal epithelium.
(2001). Fertil Steril, 75, 1234-5.
page 147 of 168
Nicole UNGER-MANHART
Dept. Surgery, Research Labaratories
nicole.unger-manhart@meduniwien.ac.at
Influence of green tea extract on immunological and redox parameters

during endotoxemia
Abstract
Both clinical and experimental studies have shown that intestinal dysfunction and failure of
the gut barrier function are involved in the development of distant organ injury under septic
conditions. Generally the portal venous route is considered as the primary route of
translocating bacteria and the liver has become one of the most intensively studied organs
during septic conditions. On the other hand it has been proposed that translocation to the
mesenteric lymph and subsequent lung injury plays a role in the onset of multiorgan failure.
With respect to gut dysfunction during sepsis the intestinal immune system has gained
particular interest. Previous studies in our laboratory revealed that endotoxemia induces an
atrophy of Peyers patch (PP) lymphocytes, which is associated with a decrease in PP
glutathione content. We showed that PP lymphocytes react very sensitively to different
dietary interventions and that diets rich in immune modulatory substances are able to diminish
PP atrophy and glutathione depletion. From this data we assumed that not only inflammation
but also oxidative stress plays an important role.
Recently it has been shown that green tea extract (GTE) exerts antioxidative as well as antiinflammatory effects. These effects are attributed to the high flavonoid content of green tea.
The main flavonoids in green extract are epigallocatechingallat, epicatechin, gallocatechin,
and catechin. Several experimental studies show that catechins inhibit cellular signaling of the
NF-kB pathway thereby reducing the production of pro-inflammatory mediators. This turns
GTE into an interesting dietary additive during endotoxemia. In contrast to the described
antioxidative effects of GTE, recent studies reveal a potent prooxidative potential of this
extract. Therefore we want to evaluate the pro/anti-oxidative and anti-inflammatory effects of
GTE under endotoxemic conditions.
In a current project the effect of GTE on inflammatory as well as on oxidative parameters is
to be investigated during murine endotoxemia. In particular, the most effective concentration
of GTE and the most appropriate feeding time has to be evaluated. We focus on the main
inductive site of the intestinal immune system, the PP lymphocytes, and the remote organs
lung and liver. Methods to evaluate pro- or anti-oxidative effects on PP lymphocytes as well
as on lung and liver tissues have to be established. Furthermore, anti-inflammatory properties
of GTE are to be investigated on molecular level.
Thesis Subjects

Mouse model of endotoxemia, dietary intervention, cell isolation from tissues, primary
culture, FACS analysis, ELISA, real-time PCR, western blot, HPLC
page 148 of 168
CURRICULUM VITAE
Unger-Manhart Nicole
Division of Surgery, Department of surgical research laboratories, Medical University of
Vienna, Waehringer Guertel 18, A-1090 Vienna, Austria;
Phone + 43 1 40400 6959, Fax +43 1 40400 6782;
E-mail: Nicole.Unger-Manhart@meduniwien.ac.at
Personal data:
Date of birth:
26.04.1970
Place of Birth:
Vienna
Nationality:
Austria
Education:
2004-present
Assistant professor since 2004
2000
Doctor rerum naturalium technicarum

University of agricultural sciences, Institute of applied microbiology,
Vienna
1997
Master of science (April 1997); University of Vienna, Department of

Surgical Research, Vienna
1991-1997
Study of Nutritional Science, University of Vienna, Institute of

Nutritional Science, Vienna
Career History:
2002 present
University of Vienna, Department of Surgical Research

Modulation of the mucosal immunsystem by antioxidative nutrients
Islet cell transplantation
Collaborations and support of clinical studies
Training of ungraduated students
2001 2002
University of Bonn, Department of Nutritional Science

University assisent
page 149 of 168
Training of ungraduated students in basics of nutrition (performance of

lectures, seminars and practical training)
Collaboration and support of physicians in accomplishing clinical
nutritional studies
1997 2000

Ph.D. student:
Set-up of a mouse model to investigate mucosal and systemic immune
response
Application of methods to investigate immune response (ELISA, flow
cytometry, real time PCR)
Support of diploma theses
Support of clinical studies
1998
University of Memphis Tennessee, Department of Traumatology

Research training
Training of experimental parenteral administration of nutrients and
pharmaceuticals to mice
1996 -1997

Undergraduate student
Establishment of a flow cytometrical method to measure the respiratory
burst of immune cells
Performance of cell culture
Awards:
2000
Best original article published in Clinical Nutrition during the year

2000
2000
Travel fellowship for the ESPEN congress
1999
Travel fellowship for the ESPEN congress
Membership
Arbeitsgemeinschaft fr klinische Ernhrung
Laboratory training (February 1996) in the routine laboratory of the hospital Wr.
Neustadt, Austria
page 150 of 168
Seminar on nutrition assessment, planning and communication in developing countries

(February 1996 March 1996) University of Giessen, Institute of Nutritional Science,
Germany
Laboratory training (July 1995 - August 1995) in the laboratory of the health
insurance organisation Vienna, Wr. Gebietskrankenkasse, Vienna, Austria
Laboratory training (August 1994) in the laboratory of the health insurance

organisation Vienna, Wr. Gebietskrankenkasse, Vienna, Austria
Practical training (July 1994) in the dietitian group of the hospital Rudolfstiftung,
Vienna, Austria
secretary (July 1993) Semperit technical products GmbH, Wimpassing, Austria
executive officer (May 1992 September 1992) Wichem med. LaserSysteme GmbH, Vienna, Austria
executive officer (October 1990 June 1991) Wichem International GmbH, Vienna,
Austria
Publications:
11 and 9 peer reviewed publications and reviews, resp., in scientific journals, 15 invited
lectures
Orginal Manuscripts:
The relationship between the anti-inflammatory effects of Curcumin and cellular glutathione
content in myelomonocytic cells Strasser EM., Wessner B., Manhart N., Roth E.
Biochem.Pahrmacol 15: (70):552-559 2005
Influcence of fructooligosaccharides on Peyers patch lymphocyte numbers in healthy and
endotoxemic mice. Manhart N., Spittler A., Bergmeister H., Mittlbock M., Roth E. Nutrition
2003, 19(7-8):657-660
Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a
double-blinded, randomized, controlled study. A.Lassnigg, A. Punz, R.Barker, P. Keznickl,
N.Manhart, E.Roth and M.Hiesmayr Br J Anaesth 90:148-154; 2003
Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyers
patches in endotoxemic mice. N.Manhart, K.Vierlinger, A.Spittler, H.Bergmeister,
T.Sautner, E.Roth Ann Surg 234:92-97; 2001
Postoperative glycyl-glutamine infusion reduces immunosuppression: partial prevention of
the surgery induced decrease in HLA-DR expression of monocytes A.Spittler, T.Sautner,
A.Gornikiewicz, N.Manhart, R.hler, M.Bergmann, R.Fgger, E.Roth Clin Nutr 20:37-42;
2001
page 151 of 168
Lipopolysaccharide causes atrophy of Peyers patches and an increased expression of CD28

and B7 costimulatory ligands N.Manhart, K.Vierlinger, O.Habel, H.Bergmeister,
P.Gtzinger, T.Sautner, A.Spittler, G.Botz-Nitulescu, B.Marian, E.Roth Shock 14:478-483;
2000
Influence of enteral diets supplemented with key nutrients on lymphocyte subpopulations in
Peyers patches of endotoxin-boostered mice N.Manhart, K.Vierlinger, R.Akomeah,
H.Bergmeister, A.Spittler, E.Roth Clin Nutr 19:265-269; 2000
Influence of short-term protein malnutrition of mice on the phenotype and costimulatory
signals of lymphocytes from spleen and Peyers patches N.Manhart, K.Vierlinger,
H.Bergmeister, G.Boltz-Nitulescu, A.Spittler, E.Roth Nutrition 16:197-201; 2000
Polytrauma induces increased expression of pyruvate kinase in neutrophils. R.hler,
G.Weingartmann, N.Manhart, U.Salzer, M.Meissner, W.Schlegel, A.Spittler, M.Bergmann,
D.Kandioler, C.Oismller, H.Struse, E.Roth. Blood 95:1086-1092; 2000
Reviews:
Assessing the antioxidative status in critically ill patients Roth E, Manhart N, Wessner B.
Curr Opin Clin Nutr Metab Care. 2004; 7:161-8
Glycine--an inert amino acid comes alive Roth E, Zellner M, Wessner B, Strasser E,
Manhart N, Oehler R, Spittler A Nutrition. 2003 Sep;19(9):817-8.
Nutritive amino acids effective modulators of the immune response
Manhart N., Stehle P. Forum Nutr 56:151-154 2003
Regulative potential of glutamine relation to glutathione metabolism. E.Roth, R.Oehler,
N.Manhart, R.Exner, B.Wessner, E.Strasser, A.Spittler Nutrition 18:217-21;2002
Nutritive amino acids effective modulators of the immune response
N. Manhart, P. Stehle Forum of Nutrition, book series Karger, Basel, Switzerland, submitted
October 2001
Therapeutic potential of glutathione R.Exner, B.Wessner, N.Manhart, E.Roth
Wien Klin Woschenschr 112/14:610-616; 2000
page 152 of 168
Heinrich VIERHAPPER
Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III
heinrich.vierhapper@meduniwien.ac.at
Curriculum Vitae
Date and place of birth: April 29, 1951; Ernstbrunn, Austria
Nationality: Austrian
Civil status: married, to Maria Sofia Puelma-Lugones
Studies:
1. Primary school in Ernstbrunn, Austria (1956-1960).
2. Realgymnasium der Theresianischen Akademie,Vienna, Austria (1960 - 1968)
3. University of Vienna Medical School, ViennaAustria (1968 - 1974); M.D.: March,
1974.
Training in Internal Medicine:

I. Medizinische Universittsklinik,
University of Vienna Medical School (1974-1980).
Training in Laboratory Medicine:

I. Medizinische Universittsklinik and Institute of Clinical Chemistry
University of Vienna Medical School (1980-1985).
Scientific work:
Since 1976, predominantly in the field of Endocrinology;
at the Division of Clinical Endocrinology and Diabetes mellitus; I. Med. Univ.-Klinik
University of Vienna Medical School.
page 153 of 168
Ludwig WAGNER
Dept. Internal Medicine III,
Mechanism of action of mutated RUVBL1/TIP49a versions in

neuroendocrine tumorigenesis
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms, which arise from
the system of neuroendocrine cells. In general, oncogenesis is caused by an imbalance
between cell death and cell proliferation. A reduced rate of cells undergoing apoptosis is the
reason for the development of NETs. Three genes (bcl-2, c-myc, p53) are mainly involved in
deregulation of the homeostasis between cell proliferation and apoptosis observed in NETs.
TIP49a, a DNA-helicase, is a newly identified interaction partner of c-myc and -cathenin. Its
name originates from the property to play a role in the RNA-polymerase II holoenzyme
complex. Due to its homology to the bacterial protein RuvB, it was also termed RUVBL1.
Remarkable presence of this predominantly intranuclear protein in cytoplasm was one of our
previous interesting findings. Immunofluorescence microscopy using the recently developed
anti-RUVBL1/TIP49a mAb IB3 demonstrated that in apoptotic cells the characteristic
staining was lost. Using these immunoreagents we found that RUVBL1/TIP49a can interact
with microtubules during mitosis of U937 cells. The correct formation of the mitotic spindle
is a central point for mitotic rates and cell proliferation.
These data and tumor-specific overexpression as well as results from other authors
demonstrated that the molecule might play an important role in carcinogenesis. We performed
Southern analysis, using DNA from various NET samples. These exhibited a characteristic
band pattern, which was comparable to genomic DNA obtained from leukocytes. Strikingly,
the RFLP derived from one carcinoid tumor differed from the other analyzed NETs. This
patient had been diagnosed with a carcinoid tumor and, having already metastasis, he died
shortly after surgery due to rapid tumor growth. The deranged findings in the Southern blot
motivated us to investigate the protein-morphology in this tumor. Immunoblots comparing
this tumor with other NETs presenting with normal RUVBL1/TIP49a RFLP patterns,
identified a truncated version of this protein. Therefore, we aim at identifying the mutated
sequence of RUVBL1/TIP49a in the tumor and to continue to perform RFLP analyses in a
larger number of tumors. In addition, malignancy associated mutations were identified in
adult leukemias.
Thesis Subjects
Biological relevance of identified tumor-specific mutations within the RUVBL1/TIP49a gene
in tumorigenesis.
RLFP, tumor DNA analysis, long range PCR, cDNA cloning, cellular overexpression of
mutants, cell cycle analysis, expression analysis, protein analysis (immunoblot, 2D-gel and
proteomics),
page 154 of 168
Curriculum Vitae
Ludwig Wagner
Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 1820, A-1090 Vienna, Austria; Phone +43 1 40400 4319; Fax +43 1 40400 7790; Email
Personal Data
Date of Birth:
Place of Birth:
Nationality
16.04.1955
Waidhofen/Ybbs, N., Austria
Austria
Education
1997 present
Ass. Professor of Internal Medicien
1989
1977-1982
1975 1977
1967 1975
specialist in Internal Medicine

studies in Medicine
studies of Human Human Sciences
secondary school
Career History
1982-85
Training at the Department of Medicine I in order to

specialize in Internal Medicine (Head Prof. Deutsch),
University of Vienna.
1986-87
Postgraduate training at the University College Hospital

London (immunohematological laboratory: Head: Prof.
Goldstone)
1987-92
Clinical and part time research work at the Department of

Medicine I, University of Vienna.
1993
Postgraduate training at the Harvard Medical School in

the Laboratory of Infectious Disease, Massachusetts
General Hospital East.
1994-95
Research at the laboratory of the Department of Medicine

III, Div. of Clinical Endocrinology & Metabolism (Head:
page 155 of 168
o.Prof. Waldhusl). University of Vienna.

1996-97
Research at the Infectious Disease Laboratory,

Massachusetts General Hospital East, Harvard Medical
School, Boston.
1997-2000
Part-time research and clinical work at the Department of

Medicine III, University of Viennna (Head o.Prof.
Waldhusl)
1998 and 1999
During the summer months, research at the Infectious

Disease Laboratory, Massachusetts General Hospital East,
Harvard Medical School, Boston
2000
September-December: Research at National Center of

Biotechnology, Campus Cantoblanco, Madrid
2001-
Part-time research at the Research Laboratory and clinical

work at the Department of Medicine III, University of
Viennna (Head o.Prof. Walter Hrl)
Awards and Fellowship

Research fellowship from the Austrian Ministery of Science 1986-1987
Research fellowship of the Max Kade foundation 1993
Biochemie-Research award for Thyroid disease 2002
Memberships
European Society for Calcium binding Proteins
Period
Organization
2001 2003 Akademie der

Wissenschaften: Doc
Stipendium
2002
Short Title
Phnotypische und Genotypische
Klassifizierung neuroendokriner Neoplasien
BiochemieForschungspreis fr
Schilddrsenpage 156 of 168
K/yr
21
erkrankungen
Collaborative research agreement between University of Vienna and Biosite:
Neurobiochemical Marker proteins indicative for brain microembolism. 2003-2005
Collaborative research agreement between Medical University of Vienna and Biosite:
Development of a tumor marker device specific for brain tumors and evaluation of
neuropathological markers in multiple sclerosis and peripheral polyneuropathy. 2005-2007
Name
Title of thesis
Period (expected)
Acad.Title
Barbara Zierhut
Phnotypische und genotypische
2003
MD
2004
PhD
2004
PhD
2007
PhD
Klassifizierung neuroendokriner
Neoplasien
Teodora Daneva
The involvement of calcium

binding proteins,
DREAM/Calsenilin and
Secretagogin in pancreatic beta
cell function
Tibor Altenberger
Aberrant gene expression

patterns in pituitary tumors
Ivelina Mineva
Differential expression of
alphaB-crystallin and Hsp27-1 in
anplastic thyroid carcinomas
because of tumor-specific
alphaB-crystallin gene silencing
(Univ. Sofia)
Anastasiya Nabokikh
Genes influencing insulinoma
pending
growth
Aysegul Ilhan
Molecular cloning and renal
pending
expression analysis of the

C20orf3 gene product
Publications
57 peer reviewed publications in scientific journals.
30) Wagner L. , O. Oliyarnyk, W. Gartner, P. Nowotny, M. Groeger, K. Kaserer, W.
Waldhusl, and MS. Pasternack. Cloning and Expression of Secretagogin, a Novel
Neuroendocrine- and Pancreatic Islet of Langerhans-specific Ca2+-binding Protein. J Biol
Chem 2000 275: 24740-24751
page 157 of 168
31) B. Lamkhioued, EA. Garcia-Zepeda, S. Abi-Younes, H. Nakamura, S. Jedrzkiewicz, L.

Wagner, PM. Renzi, Z. Allakhverdi, C. Lilly, Q. Hamid, and AD. Luster. Monocyte
Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma.
Induction in Epithelial Cells and Monocuclear Cells by Proinflammatory Cytokins. Am J
Resp Crit Care Med 2000 162: 723-732
32) Artwohl M, Hoelzenbein T, Wagner L, Freudenthaler A, Waldhaeusl W, BaumgartnerParzer. Levamisole induced apoptosis in cultured vascular endothelial cells. Br J
Pharmacol 2000 131: 1577-1583
33) E. Templ, G. Mostbeck, L. Wagner and M. Weissel. Reversibility of Retroperitoneal
Fibrosis after Successful Treatment of Colon Cancer. Acta med Austriaca 2000 27: 168170
34) D. Zhang, M. Pasternack, P. Beresford, L. Wagner, A. Greenberg, J. Lieberman.
Induction of rapid histon degradation by the cytotoxic T lymphocyte protease granzyme A.
J Biol Chem 2001 276: 3683-3690
35) W. Gartner, W. Lang, F. Leutmetzer, H. Domanovits. W. Waldhaeusl, L. Wagner.
Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand
Ca2+-binding Protein. Cerebral Cortex 2001 11:1161-1169.
36) Brunmair, B., F. Gras, S. Neschen, M. Roden, L. Wagner, W. Waldhusl, C. Frnsinn.
Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent
of peroxisome proliferator-activated receptor- gamma-mediated changes in gene
expression. Diabetes, 2001. 50(10): 2309-15.
37) Sauty, A., RA. Colvin, L. Wagner, S. Rochart, F. Spertini, AD. Luster. CXCR3
internalization following T cell-endothelial cell contact: preferential role of IFN-inducible
T cell alpha chemoattractant (CXCL11). J Immunol, 2001. 167(12): 7084-93.
38) Meier, C., D. Rzler, L. Wagner, G. Grabner, G. Khler, A. Luger. Evidence for specific
glucocorticoid binding sites on the cell membrane by fluorescence correlation
spectroscopy. Single Mol. 2002.3: 211-216.
39) Gartner, W., J. Rossbacher, B. Zierhut, T. Daneva, W. Base, M. Weissel, W. Waldhusl,
M.S. Pasternack, L.Wagner. The ATP-dependent Helicase RUVBL1/TIP49a associates
with tubulin during mitosis. Cell Motility and Cytoskel. 2003.56:79-93.
40) Zierhut, B., Mechtler, K., Gartner, W., Daneva, T., Base, W., Weissel, M., Niederle, B.,
and Wagner, L. Heat shock protein 70 (Hsp70) subtype expression in neuroendocrine
tissue and identification of a neuroendocrine tumour-specific Hsp70 truncation. Endocr
Relat Cancer. 2004. 11: 377-389.
41) Grisar J, Aringer M, Koller MD, Stummvoll GH, Eselbock D, Zwolfer B, Steiner CW,
page 158 of 168
Zierhut B, Wagner L, Pietschmann P, Smolen JS. Leflunomide inhibits transendothelial

migration
of peripheral blood. Cell Ann Rheum Dis. 2004 Dec;63(12):1632-7.
42) Barbara Zierhut, Teodora Daneva, Wolfgang Gartner, Barbara Brunnmaier, Tord
Berggrd, L Wagner. Setagin and secretagogin-R22: Posttranscriptional modification
products of the secretagogin gene (SCGN). Biochem Biophys Res Commun (2005)
329:1193-1199.
43) Brunmair B., F. Gras, L. Wagner, M. Artwohl, B. Zierhut, W. Waldhusl, C. Frnsinn.
Expression of uncoupling protein-3 mRNA in rat skeletal muscle is acutely stimulated by
thiazolidinediones: an exercise-like effect? . Diabetologia (2004) 47: 1611-1614.
44) T. Altenberger, M. Bilban, M. Auer, E. Knosp, S. Wolfsberger, W. Gartner, I. Mineva, C.
Zielinski, L. Wagner, and A. Luger. Identification of DLK1 variants in pituitary- and
neuroendocrine tumors, Biochem Biophys Res Commun 340 (2006) 995-1005.
45) S. M. Baumgartner-Parzer, R. Lang, L. Wagner, G. Heinze, B. Niederle, K. Kaserer, W.
Waldhausl, and H. Vierhapper. Polymorphisms in exon 13 and intron 14 of the RET
protooncogene: genetic modifiers of medullary thyroid carcinoma?, J Clin Endocrinol
Metab 90 (2005) 6232-6236.
46) W. Gartner, I. Mineva, T. Daneva, S. Baumgartner-Parzer, B. Niederle, H. Vierhapper, M.
Weissel, and L. Wagner. A newly identified RET proto-oncogene polymorphism is found
in a high number of endocrine tumor patients, Hum Genet 117 (2005) 143-153.
47) D. Haubenberger, R. E. Bittner, S. Rauch-Shorny, F. Zimprich, C. Mannhalter, L. Wagner,
I. Mineva, K. Vass, E. Auff, and A. Zimprich. Inclusion body myopathy and Paget disease
is linked to a novel mutation in the VCP gene, Neurology 65 (2005) 1304-1305.
48) I. Mineva, W. Gartner, P. Hauser, A. Kainz, M. Loffler, G. Wolf, R. Oberbauer, M.
Weissel, and L. Wagner. Differential expression of alphaB-crystallin and Hsp27-1 in
anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB)
silencing, Cell Stress Chaperones 10 (2005) 171-184.
49) H. Vierhapper, S. Rondot, E. Schulze, L. Wagner, S. Hanslik, B. Niederle, C. Bieglmayer,
K. Kaserer, and S. Baumgartner-Parzer. Primary hyperparathyroidism as the leading
symptom in a patient with a Y791F RET mutation, Thyroid 15 (2005) 1303-1308.
50) K. Birkenkamp-Demtroder, L. Wagner, F. Brandt Sorensen, L. Bording Astrup, W.
Gartner, H. Scherubl, B. Heine, P. Christiansen, and T. F. Orntoft. Secretagogin is a novel
marker for neuroendocrine differentiation, Neuroendocrinology 82 (2005) 121-138.
51) W. Gartner, F. Koc, A. Nabokikh, T. Daneva, B. Niederle, A. Luger, and L. Wagner.
Long-term in vitro growth of human insulin-secreting insulinoma cells,
Neuroendocrinology 83 (2006) 123-130.
page 159 of 168
52) K. Adolf, L. Wagner, A. Bergh, P. Stattin, P. Ottosen, M. Borre, K. BirkenkampDemtroder, T. F. Orntoft, and N. Torring. Secretagogin is a new neuroendocrine marker in
the human prostate, Prostate (2007) in press.
53) J. Attems, M. Quass, W. Gartner, A. Nabokikh, L. Wagner, S. Steurer, S. Arbes, F.
Lintner, and K. Jellinger. Immunoreactivity of calcium binding protein secretagogin in the
human hippocampus is restricted to pyramidal neurons, Exp Gerontol 42 (2007) 215-222.
54) A. Rogstam, S. Linse, A. Lindqvist, P. James, L. Wagner, and T. Berggard. Binding of
calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin, Biochem J 401
(2007) 353-363.
55) I. Pipp, L. Wagner, K. Rssler, H. Budka, M. Preusser. Secretagogin expression in tumors
of the human brain and ist coverings, APMIS 2007 in press
56) A. Nabokikh, A. Ilhan, M. Bilban, W. Gartner, G. Vila, B. Niederle, JH. Nielsen, O.
Wagner, W. Base, A. Luger, L. Wager, Reduced TGF-1 expression and its target genes in
human insulinomas. Experimental and Clinical Endocrinology & Diabetes 2007 in press
57) W. Gartner, G. Vila, T. Daneva, A. Nabokikh, F. Koc-Saral, A. Ilhan, O. Majdic, A.
Luger, L. Wagner, New functioanl aspects of the neuroendocrine marker secretagogin
based on the characterization of ist rat homolog. Am J Physiol Endocrinol Metab 2007 in
press
page 160 of 168
Kurt M. WIDHALM
Div.of Clin Nutrition and Metabolism, Dept of Pediatrics, Med.Univ Vienna
Early detection and treatment of children and adolescents affected with

familial hypercholesterolemia (FH)
Abstract (area of research, most recent results; <3000 characters)
Thesis Subjects
Association between genotype and phenotype in families affected with FH
Effect of ApoE pattern on the effect of diet on serum lipoproteins in children with FH
Dose effect of soy proteins and isoflavons
Clinical characteristics of Apo-B-100-Defect
Postprandial Hypertriglyceridemia in parents with familial comb. Hyperlipidemia
Effekt of w-3 fatty acids in infants and children with homozygous LPL-deficiency
Intima Media thickness in young children with homozygous familial hypercholesterolemia
undergoing LDL-apheresis

Outpatient clinic for lipid and lipoprotein disorders
Dietary intervention for affected subjects.
Lipoprotein research laboratory including ultracentrifuge, isoelectric, focusing,
electrophoresis etc.
Cooperations to detect LDL-receptor gene mutations
Unit for clinical drug trials
page 161 of 168
CURRICULUM VITAE
Kurt WIDHALM, Dr.med.
Professor for Clinical Nutrition, Head, Div. Nutrition and Metabolism, dept. of Pediatrics,
Med.Univ. of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria, Phone: +43-1404002337 or 3232, Fax: +43-1-40400 2338 or 3194, E-Mail:
Personal Data
Date of Birth :
02.02.1946
Place of Birth:
Linz, Austria
Nationality:
Austria
Education:
1964: Graduated at Academic Gymnasium Linz, with honors;

Jan.1971: Dr.med.univ., Univ.Vienna Nov.1977: Board Certification:
Pediatrics ("Facharzt fr Kinderheilkunde")
Jan.1998: Board Certification: Clinical Chemistry ("Facharzt fr
medizinische und chemische Labordiagnostik")
Brief Chronology
of Employment:
Feb.1971-May 1973: Dept.of Physiology, Univ. Vienna

1973-1992: Dept.of Pediatrics, Univ.Vienna
1992-1994: Director and Head of Internal Dept. Mautner Markhof
Childrens Hospital Vienna
1994-: Dept. of Pediatrics, Med. Univ. of Vienna
Career History:
Since 1974: Head of Outpatient Clinic for Obesity, Feb.1978: Senior

Lecturer in Pediatrics Lipid Disorders and Nutrition Conseling
1980: Assoc.Prof.of Pediatrics
July 1986: Professor for Pediatrics
1987: Head of the "Academy of Clinical Nutrition" of the Austrian
Nutrition Society and of the Physicians Board of Vienna
1.1.1988-1992: Director of the Austrian Screening Program for Inborn
Errors of Metabolism (incl.Treatment Program), located on
the Dept. of Pediatrics, Univ.Vienna
page 162 of 168
15.10.1992: Director and Head of Internal Department of the Mautner

Markhof Children's Hospital, Vienna
1994: Professor for Clinical Chemistry
1995: Professor for Pediatrics, Dept. for Pediatrics, Univ.Vienna
1997: President Austrian Academy for Medical Nutrition
2003: Full Professor for Clinical Nutrition and Head of Dept.
Nutrition and Metabolism
Foreign studies:
May/June 1975: Clin. Institute for Research on Myocardial Infarction,

Med.Clinics, Univ. Heidelberg, Germany.
Oct.1977: Lipid Res.Clinics, Dept.Pediatrics, Johns Hopkins Univ.,
Baltimore, Md. (Prof.Dr. P.O.Kwiterovich)
May 1982: Invited Tour Speaker, Amer.Ass.Clin. Chem.
Oct.1983: The Cleveland Clinic Foundation, Dept.of Biochemistry,
Section Lipids, Nutrition and Metabolic Dis.
Oct.1985: Children's Hospital Melbourne
Oct./Nov.1988: University Riberao Preto, Sao Paulo, Brasil
Jan.1992: Inst.for Genetic Diseases, Academy of Science, Moscow
Military Service:
July/August 1976
Committees and
Boards:
Secretary of the Austrian Society for Pediatrics (1982-86)

Council Member and Vice President (1992-96) of the Austrian Society
for Nutrition (1990-2000)
President Austrian Medical Academy of Nutrition (since 1997)
President of the Austrian Lipid Society (until 1994)
Member of the Health Council of the City of Vienna (1991-1999)
President of the Federation of European Societies of Nutrition (FENS)
1995-99
President European Childhood Obesity Group (since 2003)
Editorial Scientific
Boards:
Aktuelle Ernhrungsmedizin (G.Thieme, Stuttgart)

page 163 of 168
Nutrition Research (Pergamon Press)

Klinische Pdiatrie (F.Enke-Verlag)
J.Amer.Coll.Nutrition
Int.Pediatrics
Editor: J. fr Ernhrungsmedizin (Wien)
Publications: (Alan R.Liss, New York) K.Widhalm, H.K. Naito

(Books)
(Eds.): Detection and Treatment of Lipid and Lipoprotein Disorders of

Childhood 1985 (Progress in Clin. and Biol. Res.Vol.88)
K.Widhalm, H.K. Naito (Eds.): Recent Aspect of Diagnosis and
Treatment of Lipoprotein Disorders 1988 (Progress in Clin. and
Biol.Res.Vol. 255)
Apolipoproteins in Lipid Disorders, Springer, Wien, New York-1991
Ernhrungsmedizin, Verlag d. sterr. rztekammer, Wien, 2000, 2006
Kinderernhrung, Verlag d. sterr. rztekammer, Wien, 2002
350 scientific papers, most of them in International Journals
Reviewer:
Pediatric Research, Pediatrics, Annals of Nutrition and Metabolism,

European Journal of Pediatrics,J. Nutrition, Metabolism and
Cardiovascular Diseases, Journal of Pediatric
Gastroenterology and Nutrition, Gene Therapy,
J.Inher.Metab.Dis., Int.J.Obesity etc.

Period
Organization
Short Title
2005 2008
EU (partner Project
no. 007034)
HELENA Healthy Lifestyle in Europe by

Nutrition in Adolescence
2007
Medpace
Randomized Double-Blind PlaceboControlled Efficacy and Safety Study of

Colesevelam HCI Administered to
Pediatric patients with Heterozygous
Familial Hypercholesterolemia on a Stable
of Statins or Treatment Naive to LipidLowering Therapy
page 164 of 168
2007
Aesca
Klin. Prfung von Ezemibide/ Simvastatin

bei Kindern und Jugendlichen mit
familirer Hypercholesterinmie
2003 2006
Fresenius, Graz
Ernhrungszustand/Malnutrition bei
hospitalisierten Patienten
2005
Alpro Foundation,
Brssel
Effekt von Sojaprotein bei Kinder und

Jugendlichen mit familirer
Hypercholesterinmie
2005
Numico Int.,
Wageningen, The
Netherlands
Glucosestoffwechsel bei bergewichtigen

Jugendlichen
2005
Rudolf Mach
CLA Studie
2005
Abbott
Anwendungsbeobachtung der Wirkung von

Sibutramine bei morbid adipsen
Jugendlichen
2004
EU (QULRT-200000716)
QULRT Quality of life in chronically ill

children
2004
Agrana, BM, FG
(Projetknummer
323/III/48)
PRESTO Prevention Study of Obesity
2004
Nhrstoffakademie
Salzburg
Mikronhrstoffe in sterreich
2004
ARC Seibersdorf
Altersabhngigkeit HF
Strahlungsabsorption
finished
Nestl
Familial Hypercholesterolemia

Name
Title of thesis
Period (expected)
Acad.Title
Irene Mann
Homozygote, familire
Hypercholesterinmie: Klinik,
Diagnose und Therapie an Hand
von drei pdiatrischen Fllen
2006
Dr.
Michaela Kiss
Glucosetoleranz bei morbid

obesen Patienten
2006
Dr.
Marie-Therese HeineGeldern
Malnutrition: Ernhrungszustand
von ambulanten Patienten
2005
Dr.
page 165 of 168
Name
Title of thesis
Period (expected)
Acad.Title
Christina Denninger
Mgliche Assoziation zwischen

unterschiedlichen Mutationen
des LDLR - Gens u. des
Gesamtcholesterins bzw. LDL Cholesterins
2005
Dr.
Philipp Kahl
Anwendungsbeobachtung der
Wirkung von Sibutramine bei
morbid adipsen Jubendlichen
2005
Dr.
Iris Ciba
Nonalcoholic Fatty Liver

Disease und deren Korrelation
mit Insulinresistenz bei adipsen
Kindern und Jugendlichen
2005
Dr.
Barbara ller
Das Polycystische
Ovarialsyndrom und die nichtalkoholischen
Fettlebererkrankungen im
Kindes- und Jugendalter
2005
Dr.
Eva Rettenbacher
Mutationsanalyse des
Melanocortin-4-Rezeptorgens
bei extrem adipsen Kindern
und Jugendlichen (Univ.
Marburg, Germany)
2004
Dr.
Bettina Bandur
Bericht ber in sterreich

durchgefhrte Untersuchungen
zur Versorgung der Bevlkerung
mit Vitaminen und
Spurenelementen
2004
Dr.
Christian Denzer
Adipostias im Kindes- und

Jugendalter: Profil einer
universitren
Adipositasambulanz
2003
Dr.
page 166 of 168
Name
Title of thesis
Period (expected)
Acad.Title
Andrea Preisinger
Pediatric Obesity A review of

literature and 3,5-year-follow-up
of an outpatient weight reduction
program in obese children and
adolesents
2002
Dr.
Publications
Widhalm K., Schnegger K., Huemer C., Auterieth A.: Does the BMI reflect body fat in
obese children and adolescents? A study using the TOBEC method. Int.J.Obesity 25, 279-285
(2001), IF 3,199
Eisenklbl J., Katasurya M., Widhalm K.: Underestimation of body fat mass percentage
measured by bioelectrical bioimpedance. Eur.J.Clin.Nutrition 55, 423-429 (2001) IF 1,668
Boeck A., Zeitlhofer J., Widhalm K.: Visual evoked potential changes in asymptomatic
children with biotinidase deficiency: Wien.Klin.Wschr. 113: 527-530 (2001) IF 0,588
Widhalm K.: Adipositas. State of the Art. sterr. rztezeitung 6, 34-38 (2001)
Dirisamer A., Widhalm K.: Homocysteine in children and adolescents from families with
premature cardiovascular disease. Abstr. Ped.Res. 49, 257A (2001), IF 2,661
Widhalm K. Miranda da Cruz B., de Sonneville LMJ.: Information processing characteristics
and uridine treatment in children with classical galactosemia. Nutr.Research 22, 257-270
(2002) IF 0,716 Standard, Original
Gulesserian T., Widhalm K.: Effect of a rapeseed oil substituted diet on serum lipids and
lipoproteins in children and adolescents with familial hypercholesterolemia.
J.Amer.Coll.Nutr. 21: 103-108 (2002) IF 1,546 Standard, Original
Widhalm K.: Diagnosis and treatment of hyperlipoproteinemias in children and adolescents.
In: Pediatric Endocrinology; F. Lifshitz, Ed., 859-64 M. Dekker, New York (2002) Review
Hofmann U., Dirisamer A., Heher S., Kostner K., Widhalm K., Neunteufel Th.: Relation of
peripheral flow-mediated Vasodilatation and coronary artery calcium in young patients with
heterozygous familial hypercholesterolemia. Am.J.Cardiol. 90, 70-73 (2002) IF 2,762 Top
Original
Widhalm K., Schwabl R.: Nutrient intakes of children and adolescents with morbid obesity
In: Study on Obesity and functional foods in Europe; EU-Cost Action 918, 396-401 (2002)
K.Bauer, et al.K.Widhalm: Cholesterin 2. ACCC 2002, Konsensus-Statement CliniCum,
Sonderausgabe Oktober 2002
page 167 of 168
Dirisamer A., Widhalm K.: Lipoprotein (a) as a potent risk indicator for early cardiovascular
disease. Acta Paediatr. 91:1313-17 (2002), IF 1,315
Dirisamer A., Hachemian N., Bucek R. A., Wolf F., Reiter M., Widhalm K.: The effect of
low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation.
Eur J Pediatr. 162: 421-425 (2003) IF 1,22
Widhalm K., Reithofer E.: Effect of Two Diets in Children and Adolescents with Familial
Hypercholesterolemia: Soy-Protein Diet Versus Low Saturated Fat Diet. Nutrition and
Biochemistry of Phospholipids. 16: 171-174, 563-564 (2003)
Denzer C., Reithofer E., Wabitsch M., Widhalm K.: The outcome of childhood obesity
management depends highly upon patient compliance. Eur. J. Pediat. 163:99-104 (2004)
Dirisamer A., Reiter M., Bucek R.A., Widhalm K.: Plasma homocysteine concentration in
children of families with proven myocardial infarction before the age of 55 years. Acta Paed.
93:1-2 (2004)
Dietrich S, Widhalm K: A multidisciplinary Therapy Program for Morbidly Obese Children
and Teenagers: Results After 7 Months. Int. Pediatrics 19:83-89 (2004)
Flodmark CE, Lissau I, Moreno L, Pietrobelli A, Widhalm K: New Insights into the Field of
Children and Adolescents Obesity: The European Perspective. Int. J. Obesity 28:1189-1196
(2004)
Widhalm K, Dietrich S, Prager G: Adjustable Gastric Banding Surgery in morbidly obese
Adolescents: Experiences with 8 patients; Int. J. Obesity 28:42-45 (2004)
Widhalm K, Weghuber D: Treatment of Children and Adolescents with Familial and
Polygenic Hypercholesterolemia with Classical and Soy Substituted Diet in: Koen
Descheemaeker, Ignace Debruyne (Hrsg.) Soy & Health 2004 Clinical Evidence Dietetic
Applications 41-47 (2005)
Pietrobelli A, Flodmark CE, Lissau I, Moreno LA, Widhalm K:From birth to adolescence:
Vienna 2005 European Childhood Obesity Group International Workshop. Int J Obesity
29:S1-S6 (2005)
Widhalm K, Fussenegger D: Actions and programs of European countries to combat obesity
in children and adolescents: a survey. Int J Obesity 29:S130-S135 (2005)
page 168 of 168

n790 Endocrinology PDF

Uploaded by

Copyright:

Available Formats

n790 Endocrinology PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

n790 Endocrinology PDF

Uploaded by

Copyright:

Available Formats

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

CLINICAL ENDOCRINOLOGY, METABOLISM AND NUTRITION

General Description and Aims

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

Sabina Baumgartner-Parzer, Christian

Congenital adrenal hyperplasia

Modern methods of clinical laboratory analysis

In vivo studies on hepatic glycogen metabolism

Stable isotope techniques-basics and applications

Clinical Nutrition and Infusion Therapy 1

Molecular methods in research and diagnostics of

Basics for working with experimental animals

Physiology and pathophysiology of growth

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

Physiology of the hypothalamic-pituitary regulation

Physiology of nutrition and pathophysiology of

Protein catabolism, post-aggression phase,

Lipid metabolism and hyperlipidemia

Pathophysiology of estrogen-dependent diseases

D-A-CH Reference values for food intake

Genes relevant in endocrine tumorigenesis

Familial hypercholesterolemia in childhood and

Multiple Endocrine Neoplasia 2

Interpretation of endocrinological lab results

Hypoglycemia counterregulation in type 1 diabetes

Analytical techniques for quantification of small molecules O. Bodamer

Molecular methods in research and diagnostics of

From cell culture to the whole organism: experimental

Basic scientific aspects of growth

Stresshyperglycemia, nutritive intervention in hospitalized

Pregnancy in patients with type 1 and type 2 diabetes

Direct and indirect effects of nutrients on glucose

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

New developments in the regulation of appetite and body

Physiology of nutrition and pathophysiology of vitamins

Pathogenesis and treatment of osteoporosis

Protein catabolism, post-aggression phase,

Dyslipidemias and polyunsaturated fatty acids

Polyphenols: anitoxidants and signalling molecules?

The beta cell and insulin transcription

Principles and evidence for a preventive nutrition

SE Journal Club "Endocrinology and Metabolism

Sabina Baumgartner-Parzer, Christian

Compulsory Optional Courses

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

SE Thesis Seminar "Endocrinology and

Sabina Baumgartner-Parzer, Christian

SE Practical Seminar "Endocrinology and

Sabina Baumgartner-Parzer, Christian

N790 Program "Clinical Endocrinology, Metabolism and Nutrition"

Baumgartner-Parzer, Unger-Manhart, Roth

cell culture, cell lines

Stulnig, Luger, Wagner, Bodamer, UngerManhart

cell culture, perfusion model

cell culture, primary

Stulnig, Baumgartner-Parzer, Pietschmann,

FACS - dynamic measurements (calcium etc.)